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ABSTRACT    
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Doctor of Philosophy  
ACQUIRED ABNOMALITIES OF CHROMOSOME 21 IN ACUTE 
LYMPHOBLASTIC LEUKAEMIA 
by Hazel M Robinson 
The intrachromosomal amplification of chromosome 21 (iAMP21) was identified 
as a novel and prognositically important acquired chromosomal abnormality in 
childhood acute lymphoblastic leukaemia (ALL). It is defined by multiple copies 
of the RUNX1 gene, as seen by fluorescence in situ hybridisation (FISH), localised 
to a single abnormal duplicated chromosome 21 [dup(21)]. The morphological 
form of this chromosome is highly variable between patients and currently the 
only reliable method of detection is FISH with probes to RUNX1. Studies of 48 
iAMP21 patients using detailed FISH techniques and array-based comparative 
genomic hybridisation highlighted an extensive region of chromosome 21 
involvement. A minimum common region of amplification, between 33.19 and 
39.80Mb, including RUNX1 was identified, together with a minimum common 
region of deletion, between 46.54 and 46.92Mb, in 100% and 77% of patients, 
respectively. This study established that there were unique patterns of imbalance, 
with evidence of deletions, inversions and amplification, displayed on the 
dup(21),  between individual patients. This provided evidence of an abnormality 
that may have arisen from a breakage-fusion-bridge mechanism, possibly initiated 
by loss of a telomere. Results indicated that iAMP21 represents a distinct genetic 
subgroup of childhood ALL and is not secondary to a cryptic abnormality of 
chromosome 21. Two possible variant cases were identified both involving 
chromosome 15. The abnormality can be distinguished from other numerical 
abnormalities of chromosome 21 by exploiting the unique pattern of gain, 
amplification and deletion seen in these patients. This allowed for the 
development of diagnostic tests based on copy number using either FISH or 
multiplex ligation dependent probe amplification (MLPA), both of which 
successfully identified iAMP21 patients. 
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Chapter One – Introduction 
 
 Introduction 
 
1 Introduction 
1.1  Cancer is an acquired genetic disorder  
    Recurrent chromosomal abnormalities are one of the hallmarks of 
malignancy. The detailed analysis of these abnormalities and their molecular 
characterisation has provided significant information regarding the biology of 
neoplastic disorders and frequently their clinical outcome. As a consequence, it is 
generally accepted that at the cellular level cancer is an acquired genetic disorder 
(Mitelman et al, 2007). The biology of cancer cells, in relation to the functions of 
cell division, differentiation, proliferation and apoptosis is similar to that of their 
normal counterparts. However, interference in the regulation of these functions 
leads to an altered phenotype resulting in malignancy. Thus it follows, that it is 
the disruption of the genes that control these regulatory pathways, which is 
crucial to the development of cancer.  
  There are two main types of gene involved in the development of a 
malignancy - active proto-oncogenes (oncogenes) and inactive tumour 
suppressor genes (Pierotti et al, 2003). The activation of proto-oncogenes usually 
occurs via one of three main mechanisms: mutation, amplification and/or 
chromosomal rearrangement such as translocation. The resulting oncogenes then 
play a direct role in the development of cancer due to their functional 
characteristics as either growth factors, growth factor receptors, signal 
transducers, transcription factors or regulators of apoptosis (Pierotti et al, 2003).  
  The normal role of tumour suppressor genes is to inhibit cell growth and 
differentiation when the conditions for division and proliferation are changed. 
Thus, their inactivation, promotes cell proliferation and differentiation of 
“damaged” cells. The inactivation of tumour suppressor genes usually occurs as 
a result of mutation and/or deletion (Pierotti et al, 2003). A further class of cancer 
  18Introduction 
genes also exists, known as DNA repair genes, whose function is to recognise 
aberrations in the DNA repair pathways (Wood et al, 2005). Unlike tumour 
suppressor and oncogenes the activation of these genes results in an increased 
rate of mutations in proto-oncogenes and tumour suppressors.  
  The majority of malignancies occur as a result of the acquisition of several 
mutations, which arise in a sequential manner rather than a single event. Studies 
of haematological malignancies have shown that tumours arise from a single 
ancestor cell and are thus, clonal in nature. Following an initial genetic event, the 
cell may attain a slight growth advantage. Progeny of this cell then acquire 
further mutations, which provide them with a selective advantage. By the 
continuation of this process the abnormal clone expands, in a multi-step fashion, 
until it eventually results in overt clinical disease (Figure 1.1). As the acquired 
mutations are random, it follows that some will be deleterious to the cell 
resulting in loss of that particular subclone. Within a tumour cell population 
many different subclones, all of which are derived from a single ancestral cell 
will exist. Evan and Vousden (2001) proposed that a minimum number of critical 
events are required to drive uncontrolled expansion and invasion. They 
hypothesised that these minimal requirements involve deregulation in cell 
proliferation and suppression of apoptosis. 
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Figure 1.1 Schematic diagram showing the development of cancer driven by 
the accumulation of genetic aberrations. Adapted from Evans (2001).  
 
1.2  Haematopoiesis 
  Normal adult peripheral blood contains a substantial number of highly 
specialized cells, all of which are generated via haematopoiesis, in the bone 
marrow from a common pluripotent progenitor cell, known as the 
haematopoietic stem cell (HSC). These cells have the most important function 
within the haematopoietic system, as they are responsible for the life long 
production of all circulating blood cells. It has been estimated that for every one 
stem cell there are 20 million nucleated cells in adult bone marrow (Hoffbrand & 
Pettit, 1993).  
  During haematopoiesis, HSC undergo cell division to produce two 
daughter cells, one of which retains its stem cell properties, and so maintains the 
stem cell pool, whilst the other undergoes a step wise process of division and 
differentiation to produce mature haematopoietic cells (Hoffbrand et al, 2005). 
Those cells committed to differentiation go on to divide and mature into cells 
  20Introduction 
from one of two main lineages: myeloid and lymphoid (Figure 1.2). Lineage 
specification is achieved by precise activation of individual genes controlling 
differentiation. External factors bring about alterations to specific growth factors. 
These in turn initiate changes to transcription factors resulting in the activation 
of the genes controlling differentiation and proliferation.  
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Figure 1.2 Diagrammatic representation of haematopoiesis. Pluripotent stem 
cell in the bone marrow gives rise via cell division and differentiation to 
circulating peripheral blood cells. Immature cells remain in the bone marrow 
environment whilst mature cells are passed into the blood. 
 
  The process of maturation consists of a number of stages and, as the stem 
cells differentiate into progenitor cells, they lose the ability to self renew, until 
finally, as mature haematopoietic cells, they have a limited life span. This 
process, which involves the rapid production of mature circulating blood cells, is 
controlled by the constant need to replace those cells undergoing apoptosis. 
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Disruption of those genes involved in the regulation of haematopoiesis results in 
the development of leukaemia (Byrne & Russell, 2005). 
1.3  Leukaemia 
  Leukaemia is defined as a neoplastic disorder, characterised by the 
uncontrolled proliferation of malignant haematopoietic cells, usually leucocytes. 
The disease can originate from any cell, blocked at a particular stage of 
development, including primitive cells with a multilineage potential, as well as 
more mature cells. The resulting abnormal cells exhibit a number of features 
common to all cancers: 
 
  Clonal generation from a single precursor cell  
  Unchecked growth, frequently of immature cells 
  Evasion of programmed cell death 
 
  There are two main clinical forms of leukaemia: acute and chronic. Acute 
leukaemia is characterized by the rapid growth and accumulation of malignant 
cells, typically undifferentiated immature cells, which if left untreated will lead 
to death within weeks or months (Bain, 1999). Chronic leukaemia, which may be 
asymptomatic for a number of years, is distinguished by the slow accumulation 
of cells frequently involving more mature cell types and, if left untreated, may 
lead to death within months or years (Bain, 1999). It is possible to further classify 
these two groups into myeloid and lymphoid lineages depending on the 
progenitor cell of their origin. 
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Large, generally homogeneous blasts with finely 
stippled chromatin, round nuclei, prominent 
nucleoli and moderate basophilic cytoplasm with 
vacuolization
L3
Large heterogeneous blasts with moderately  
abundant cytoplasm, irregularly shaped nuclei, 
variable chromatin, and prominent nucleoli.
L2
Small blasts with scanty cytoplasm, smooth-variable 
indented nuclear outline, condensed chromatin, and  
discrete nucleoli.
L1
Diagnostic criteria Blast 
appearance
FAB category
Large, generally homogeneous blasts with finely 
stippled chromatin, round nuclei, prominent 
nucleoli and moderate basophilic cytoplasm with 
vacuolization
L3
Large heterogeneous blasts with moderately  
abundant cytoplasm, irregularly shaped nuclei, 
variable chromatin, and prominent nucleoli.
L2
Small blasts with scanty cytoplasm, smooth-variable 
indented nuclear outline, condensed chromatin, and  
discrete nucleoli.
L1
Diagnostic criteria Blast 
appearance
FAB category
 
 
Table 1.1 French-American-British (FAB) classification of acute lymphoblastic 
leukaemia. 
 
  In adults, acute myeloid leukaemia (AML) is the most frequently 
occurring acute subtype with an incidence of approximately 10 in 100,000. 
Almost 1,950 new cases are diagnosed annually in the United Kingdom 
(Leukaemia Research, 2008a). In children, acute lymphoblastic leukaemia (ALL) 
is the most common acute subtype, accounting for 85% of all cases (Greaves, 
2002;Spector et al, 2006). It has an incidence of 4 in 100,000 and approximately 
400-450 new cases are diagnosed each year in the United Kingdom (Leukaemia 
Research, 2008b).  
1.4  Acute lymphoblastic leukaemia 
  ALL is a disease typically characterised, by the accumulation of immature 
abnormal lymphoid progenitor cells (lymphoblasts) in the bone marrow, which 
have abnormal proliferation and differentiation. It is a heterogeneous disease 
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which can be divided into a number of distinct biological and prognostic 
subtypes. The classification and accurate diagnosis of ALL involves a stepwise 
process, which has improved over the past 20 years with the development of 
new techniques. Originally it was classified solely using the French-American-
British (FAB) classification system (Bennett et al, 1976;Bennett et al, 1981). This 
scheme based on the simple morphological appearance of the blast cells, 
subdivides ALL into three main subgroups L1, L2 and L3 (Table 1.1). Due to the 
limited morphological variation between blast cells in ALL, the use of this 
classification system alone was restricted, as it included no correlation with 
specific immunophenotype or karyotype features which provided valuable 
prognostic information. Despite the limited variability in the appearance of 
leukaemic cells from one patient to another, there is significant variability in the 
underlying molecular pathology with a number of distinct subtypes of ALL now 
described (Downing & Mullighan, 2006). 
  ALL can develop from any lymphoid cell, blocked at a particular stage of 
development, including both primitive cells with a multilineage potential, as 
well as more mature cells. As reviewed by Downing and Mullighan (2006;2007), 
the differentiation of lymphoid progenitors into mature B cells is a tightly 
regulated process coordinated by a network of transcription factors and 
cytokines. The process is closely associated with the sequential rearrangement of 
immunoglobulin receptor genes. The initial rearrangement of the 
immunoglobulin heavy chain enables expression of the pre-B cell receptor 
required for survival of the B-cell precursors, whilst subsequent immunoglobulin 
light chain rearrangement permits expression of the mature B-cell receptors. At 
least seven transcription factors (PU.1, Ikaros, E2A, BCL11A, EBF, PAX5 and 
FOXP1) and two cytokines (FLT3 and IL-7R) are known to be involved 
(Figure1.3). 
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Figure 1.3 Transcription factors involved in the development of normal B cell 
lymphocytes. Large arrows denote the stage that each factor influences. Adapted 
from Downing and Mullighan (2006). 
 
  During haematopoiesis, as the cells differentiate and mature, the 
expression of their surface antigens alters, so making it possible to subdivide 
them into groups based on the stage of their development. Analysis of these 
immunological features led to the development of a comprehensive classification 
system using immunophenotyping (the process used to identify cells according 
to their cell lineage). The current World Health Organisation (WHO) 
classification of acute leukaemia (Harris et al, 1999;2001) identifies three main 
subtypes of ALL based on immunophenotype: precursor B-cell lymphoblastic 
leukaemia (BCP-ALL), precursor T lymphoblastic leukaemia (T-ALL), and 
mature B-cell leukaemia. Within BCP-ALL it is possible to further subdivide the 
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cases into three main divisions depending on the expression of their cluster of 
differentiation (CD) antigens (Table 1.2). 
 
  B- ALL  T- ALL 
Subgroup CD  Antigens  Subgroup  CD Antigens 
Pre-pre-
B-cell 
ALL 
CD19,CD79a,CD22 
CD10 - 
Pre-T-cell 
ALL 
CD1a, CD2, 
CD5, CD7, 
CD8, cCD3 
Common 
ALL 
CD10 (CALLA) 
 
  
Precursor 
B cell 
ALL 
Pre-B –
cell ALL 
Cytoplasmic IgM 
+ / – CD10 
  
 
Mature 
B-cell 
Cytoplasmic 
surface 
Ig λ or κ chains 
Mature T-
cell ALL 
Surface CD3 
(plus any other 
T-cell markers) 
 
Table 1.2 Basic immunological classification of acute lymphoblastic 
leukaemia. 
 
1.5  Acquired genetic aberrations in ALL 
  Since the discovery of the Philadelphia chromosome (Ph) by Nowell and 
Hungerford (1961), standard cytogenetic analysis has proved to be an essential 
tool in the identification of chromosomal changes in cancer, particularly 
leukaemia. A number of acquired chromosomal abnormalities arising from 
translocations, deletions, duplications and inversions have been identified which 
are often associated with deregulated gene expression. Over 50,000 cases of 
cancer with clonal cytogenetic abnormalities have been reported to the Mitelman 
Database of Chromosomal Abnormalities in Cancer, (2008) with approximately 
7000 being attributed to childhood and adult ALL (Johansson et al, 2004).  
  26Introduction 
  The development of sensitive molecular techniques, has improved the 
level of detection of these genetic aberrations, in addition to identifying novel 
alterations not visible cytogenetically. Characterisation of the genes involved has 
led to the definition of distinct genetic subgroups of prognostic significance, 
which have been adopted for risk stratification with regard to treatment.  
  Currently an abnormal karyotype is detected in more than 80% of 
childhood (Harrison, 2000) and 79% of adult ALL patients (Moorman et al, 
2007a). The chromosomal abnormalities may be either numerical or structural in 
nature, with many karyotypes containing both types of aberration.  
1.5.1 Numerical chromosomal abnormalities 
  Aneuploidy, defined as having more or less than the normal diploid 
number of chromosomes, is a significant feature of ALL. A high hyperdiploid 
karyotype, with 51-65 chromosomes, is found in approximately 30% of 
childhood and 5% of adult patients. It was the first to be associated with a good 
prognosis in childhood ALL (Secker-Walker et al, 1978), in which an event free 
survival of greater than 80% at five years has since been observed (Moorman et 
al, 2003). The chromosomal gains in the form of trisomies are restricted to certain 
chromosomes.  Chromosomes X, 4, 6, 10, 14, 17, 18 and 21 (frequently the gain of 
chromosome 21 is tetrasomic) were gained more often than expected (Moorman 
et al, 1996).  
  A second significant numerical abnormality in childhood ALL is 
hypodiploidy (Ho), where the modal number of chromosomes is ≤ 45 
chromosomes. It is rare, with an overall reported incidence of approximately 6% 
(Harrison et al, 2004). In the majority of reported cases patients have 45 
chromosomes (Raimondi et al, 2003;Harrison et al, 2004). 
  Overall, hypodiploidy has been linked to a poor prognosis (Heerema et al, 
1999a;Harrison et al, 2004;Raimondi et al, 2003). However, Harrison et al (2004) 
showed that it was possible to subdivide hypodiploidy into three distinct 
  27Introduction 
subgroups based on chromosome number, other cytogenetic features and clinical 
features: near-haploidy (23-29 chromosomes), low hypodiploidy (33-39 
chromosomes) and high hypodiploidy (42-45 chromosomes). Near–haploidy 
(which is restricted to childhood ALL) and low hypodiploidy have a poor overall 
survival in comparison to those cases with high hypodiploidy. Karyotypic 
analysis of the near-haploid group showed chromosomal gains onto the haploid 
chromosome set in common with high hyperdiploidy (X, Y, 14, 18 and 21). They 
showed rare structural abnormalities and a co-incident doubled hypodiploid 
clone. Doubling of the hypodiploid clone was also found in patients with low 
hypodiploidy.  
1.5.2  Structural chromosomal abnormalities 
  Structural chromosomal rearrangements occur in approximately 50% of 
childhood ALL (Harrison, 2000) patients. These rearrangements arise from 
translocations, deletions, duplications and inversions, resulting in the disruption 
of genes frequently encoding transcription factors. There are two main 
mechanisms in ALL which are responsible for activation of transcription factors:  
1.  Gene fusion, which occurs following the joining of discrete regions of two 
separate genes to form a novel fusion gene with oncogenic properties 
2.  Deregulation of intact transcription factor genes by juxtaposition with 
transcriptionally active promoter genes which are usually lineage specific 
1.5.2.1  The BCR-ABL1 fusion gene 
 The  BCR-ABL1 fusion gene is a characteristic example of the formation of 
a novel oncogene resulting from a translocation. This gene, usually located on 
the Ph (derived chromosome 22), arises from a reciprocal translocation between 
chromosomes 9 and 22 at breakpoints 9q34 and 22q11, respectively. The 
t(9;22)(q34;q11), results in the fusion of the 3’ segment of the tyrosine kinase 
ABL1 proto-oncogene to the 5’ segment of BCR on chromosome 22 (Figure 1.4). 
Although this rearrangement is the hallmark of chronic myeloid leukaemia 
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(CML), it occurs in 3-5% of children (Pui & Evans, 1998) and 25% of adults 
(Secker-Walker, 1997) with ALL. The incidence increases exponentially with age 
(Secker-Walker, 1997). It is associated with an extremely poor prognosis in adults 
(Secker-Walker, 1997) and children alike (Hann et al, 2001). In ALL, expression of 
the fusion gene results in two types of chimaeric mRNA. This is dependent upon 
the location of the breakpoint within the breakpoint cluster region (bcr) of the 
BCR gene. In two thirds of childhood patients, the breakpoint arises in BCR 
between exons e2’ and e2, known as the minor breakpoint cluster region (m-bcr). 
The translocation involving this breakpoint produces a p190 BCR-ABL protein 
(Deininger et al, 2000). In the remaining third of BCR-ABL1 positive ALL patients, 
the breakpoint occurs within a 5.8 kb region spanning BCR exons 12-16 (exons 
b1-b5), known as the major breakpoint cluster region (M-bcr). The translocation 
involving this breakpoint results in the production of a p210 BCR-ABL protein 
(Deininger et al, 2000). Studies in BCR-ABL1 transformed cells showed that there 
was increased activation in a number of signal transduction pathways, leading to 
increased proliferation, reduced growth-factor dependence and apoptosis, and 
an altered interaction with the  extracellular matrix (Deininger et al, 2005). These 
observations implied that the expression of BCR-ABL1 provides a survival 
advantage to leukaemic cells over the normal cells. The resultant fusion proteins 
have increased tyrosine kinase activity. These tyrosine kinase proteins are 
enzymes that catalyse the phosphorylation of the terminal phosphate from 
adenosine triphosphate (ATP) to tyrosine residues.  
  Targeting the activity of the tyrosine kinase BCR-ABL1 fusion protein has 
been effective in the development of the tyrosine kinase inhibitor, Imatinib®. This 
therapy is an effective treatment for chronic phase CML, with patients having an 
estimated overall survival of 89% at 60 months (Druker et al, 2006). In Ph positive 
ALL, initial haematological response to Imatinib® therapy was good, however 
development of relapse and subsequent disease progression were rapid 
(Ottmann et al, 2002). On the current UK treatment trials for ALL, virtually all 
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patients with a BCR-ABL1 fusion are treated on a high risk protocol, emphasising 
the importance of their accurate detection.  
 
 
 
Figure 1.4 Locations of the molecular breakpoints in the t(9;22) and the 
resulting mRNA structure. Adapted from Deininger et al (2000). 
 
1.5.2.2  The t(8;14)(q24;q32) translocation 
  The translocation, t(8;14)(q24;q32), is an example of a rearrangement 
resulting in the deregulation of intact transcription factor genes by juxtaposition 
to a transcriptionally active promoter gene. It was the first immunophenotype 
specific abnormality to be identified and is found in Burkitt’s lymphoma and 
mature B-cell or Burkitt’s type ALL (L3). It is highly specific for these disease 
subtypes, occurring in 85-90% of cases (Figure 1.5) (Hecht & Aster, 2000). The 
translocation has two variants, t(2;8)(p13;q24) and t(8;22)(q24;q11). In all three 
translocations the MYC oncogene, located at 8q24, is juxtaposed to either the 
immunoglobulin heavy chain (IGH) or one of the immunoglobulin light chain 
loci, kappa (IGK) or lambda (IGL), at 14q32, 2p11 and 22q11, respectively. 
Although the cytogenetic breakpoint on chromosome 8 is the same in all three 
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translocations, they differ at the molecular level. In the t(8;14), MYC breaks 5’ of 
the second exon, resulting in translocation of the entire coding sequence to 
chromosome 14. The orientation of the IGH and MYC on the derivative 
chromosome 14 is 5’ to 5’. In the two variant translocations, the breakpoint 
occurs 3’ of MYC, leaving the structure of MYC intact on the derivative 
chromosome 8. In these translocations the orientation of the IGK and IGL is 5’ to 
3’ (Harrison, 2001). In all three circumstances MYC is placed under the 
transcriptional influence of an immunoglobulin enhancer. This results in 
deregulation, increased transcription and overexpression of MYC, leading to 
increased cellular proliferation. This subtype of ALL (Burkitt’s type, mature B, 
L3) is particularly aggressive and its treatment differs from that of other forms of 
ALL, with patients responding well to short-term intensive treatment.  
 
 
 
Figure 1.5 Locations of the molecular breakpoints in the t(8;14) and the 
resulting mRNA structure. Adapted from Mitelman (2007). 
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1.5.2.3  Structural abnormalities specific to T-cell ALL 
  T-ALL is also associated with a number of specific genetic aberrations, 
which alter gene expression in a similar way to the t(8;14). Rearrangements of the 
T-cell receptor (TCR) genes result in their promoter/enhancer elements being 
placed adjacent to various oncogenes. This in turn leads to their deregulation and 
subsequent overexpression. The gene loci encoding the TCR ά and δ genes are 
located on the long arm of chromosome 14 at 14q11, whilst those encoding β and 
γ chains are located to chromosome 7 at 7q34 and 7p15, respectively. Cytogenetic 
analysis of T-ALL patients reveals recurrent translocations in 25-50% of patients 
(Graux et al, 2006). However a large proportion of patients have a normal 
karyotype with cryptic abnormalities which require more sophisticated 
molecular techniques for their detection (Ferrando & Look, 2003). 
1.5.3 Deletions  
  Deletions involving different chromosome arms are common 
abnormalities in ALL. Those involving the short arm of chromosomes 9 and 12 
and the long arm of chromosome 6 are among the most frequent recurrent 
abnormalities reported in ALL. There is some evidence that these deletions result 
in the loss of tumour suppressor genes. Deletion of the short arm of chromosome 
9 occurs in both T- and B-lineage ALL, with 80% of childhood T-ALL having a 
deletion of 9p compared to 20% in B-ALL. This deletion frequently involves the 
9p21~22 region, with loss of p16INKa (CDKN2A) and p15INKb (CDKN2B)  
(Heerema et al, 1999b;Andreasson et al, 2000;Harrison, 2000). These genes, 
members of the inhibitor of the cyclin-dependent kinase 4 (INK4) family, are an 
important class of tumour suppressors. Their main function is to act as negative 
regulators of cell cycle control by binding to and inhibiting cyclin-dependant 
kinase 4, thus preventing the phosphorylation of the retinoblastoma (Rb) protein. 
  Both homozygous and hemizygous deletions have been detected, with 
loss of material from the maternal chromosome being preferential (Morison et al, 
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2002). It has been suggested that loss of p16 and p15 expression may occur 
through methylation in the remaining allele in some patients (Chim et al, 2001). 
The prognostic significance of these deletions remains debatable with some 
reports indicating an association with a poor prognosis (Heerema et al, 1999b; 
Harrison, 2000) whilst other reports indicate no prognostic significance 
(Takeuchi et al, 1995). 
1.5.4 Amplification 
  Gene amplification, defined as the gain of additional copies of a gene, 
resulting from the duplication of a DNA segment (Myllykangas & Knuutila, 
2006) is another mechanism that can lead to the activation of a proto-oncogene. It 
frequently occurs in solid tumours but is rarely described in acute leukaemia. At 
the cytogenetic level, gene amplification is typically seen extrachromosomally as 
double minute chromosomes or intrachromosomally in the form of 
homogeneously staining regions (HSR). In T-ALL, the extrachromosomal 
amplification of the NUP214-ABL1 fusion in the form of episomes, has been 
reported at an incidence of ~2-5% (Barber et al, 2004;Graux et al, 2004). The 
intrachromosomal amplification of RUNX1 (see section 1.6.3) and MLL (Cuthbert 
et al, 2000) have also been reported as recurrent abnormalities in BCP-ALL, 
where they are associated with a poor prognosis. 
1.6  Abnormalities of chromosome 21 
  Abnormalities of chromosome 21 are frequently observed acquired 
genetic changes in ALL. Individuals with Down syndrome and constitutional 
trisomy 21 have a 10-20 fold increased risk of developing acute leukaemia of both 
myeloid and lymphoid origin. Acquired abnormalities of chromosome 21 can be 
either numerical or structural, which together account for > 50% of the acquired 
abnormalities detected in the abnormal karyotypes of ALL patients. Trisomy 21 
as a sole change has been reported in 1.8% of childhood ALL (Raimondi et al, 
1992), whilst extra copies are observed within hyperdiploid and hypodiploid 
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karyotypes. In hyperdiploid karyotypes gain of chromosome 21 is observed in all 
cases. The functional significance of a high hyperdiploid karyotype in ALL is not 
known. A study by Gruszka-Westwood et al (2004) used comparative expressed 
sequence hybridization to investigate if increased chromosome copy number in 
hyperdiploid ALL led to increased overexpression. They found a number of 
common regions of overexpression, including one on chromosome 21 at band 
q21, which they concluded was consistent with copy number gain. 
  Acquired structural rearrangements involving a number of breakpoints on 
chromosome 21 have been reported in ALL (Jeandidier et al, 2006), with the most 
frequent rearrangement being the translocation, t(12;21)(p13;q22) (section 1.6.2). 
This occurs at an incidence of approximately 25% in childhood ALL. Such 
findings clearly indicate that this chromosome plays a key role in the regulation 
of haematopoiesis. Detailed analysis of the abnormalities involving chromosome 
21 have provided insight into the importance of the RUNX1 gene in 
leukaemogenesis, which is known to be one of the most frequently targeted and 
rearranged genes in a variety of leukaemias (Mikhail et al, 2006). 
1.6.1  RUNX1 abnormalities  
 The  RUNX1 gene, located at 21q22, is one of the main regulators of 
definitive HSC formation. Niebuhr et al (2008) proposed that RUNX1 is a 
“gatekeeper”of the pathway responsible for maintaining haemopoietic cell 
numbers by regulating differentiation and proliferation. As reviewed by Mikhail 
(2005), it is one of the most frequently deregulated genes in leukaemia. It was 
originally identified by cloning the breakpoint of the translocation, 
t(8;21)(q22;q22), associated with AML (Miyoshi et al, 1991). It is a nuclear protein 
with two large functional domains, a proximal DNA-binding region, known as 
the Runt homology domain, and a distal transactivation domain. Together with 
its heterodimeric transcription co factor, core-binding factor (CBF-β), it functions 
as a transcription regulator of haematopoiesis by allowing for the assembly of a 
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number of transcriptional activation complexes. It can act as either an activator 
or repressor of transcription. This dual function is dependant on its interaction 
with a number of different lineage-specific transcription factors and co- 
regulators (Figure 1.6) 
 
 
Figure 1.6 The model of transcription activation and repression mediated by 
RUNX1. RUNX1, in association with its cofactor CBF-beta, has an enhanced 
binding affinity to the DNA sequence present in the regulatory region of genes. 
These sites are often adjacent to those of RUNX1-associated transcription factors 
including C/EBP-alpha, PU.1, MYB, ETS, LEF-1. RUNX1 can mediate transcription 
activation (A) or repression (B) by recruitment of non-DNA-binding 
transcription co-activators or co-repressor. Adapted from Mikhail (Mikhail et al, 
2006). 
 
  RUNX1 is rearranged through a variety of mechanisms including 
translocations, mutations and amplification, in a range of haematological 
disorders, providing evidence of its fundamental importance in haematopoiesis. 
A number of translocations involving RUNX1 have been found in different 
lineage specific subtypes of leukaemia. These include RUNX1-RUNX1T1 from 
t(8;21)(q22;q22), in AML (Miyoshi et al, 1991); ETV6-RUNX1 from 
t(12;21)(p13;q22) in ALL (Romana et al, 1994) and RUNX1-MDS1 from the  
t(3;21)(q26;q22) in myelodysplastic syndrome (MDS) and blast phase CML 
(Nucifora et al, 1993). The molecular consequence of these fusion genes is the 
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generation of fusion proteins that act as negative inhibitors of the normal RUNX1 
allele. 
  Acquired and inherited point mutations of RUNX1, have been detected in 
both AML and MDS (Osato et al, 1999;Roumier et al, 2003;Cameron & Neil, 
2004;Niebuhr et al, 2008;Owen et al, 2008;Mikhail et al, 2006). The majority of 
mutations occur in the Runt domain and result in the impairment of RUNX1 
through loss of DNA binding. Studies in RUNX1 +/- haploinsufficient mice have 
shown that haploinsufficiency resulted in a decrease in the number of HSC and a 
reduction in their capacity to expand and differentiate (Sun & Downing, 2004). 
This led to speculation that the function of RUNX1 is dose dependant and that 
haploinsufficiency may lead to leukaemia. Coupled with this mutations have 
been identified in familial platelet disorder. Such individuals have a 
predisposition to AML (Song et al, 1999;Owen et al, 2008).  
 Amplification  of  RUNX1 has also been reported as a potential mechanism 
of deregulation of this gene. In ALL amplification may occur from the gain of 
intact copies of chromosome 21 as seen in high hyperdiploidy, or through 
intrachromosomal amplification (section 1.6.3). 
1.6.2 ETV6-RUNX1 fusion gene 
  One of the most common translocations in childhood ALL is the 
t(12;21)(p12;q22). This cytogenetically cryptic translocation was first reported by 
Romana et al (1994) as a chance finding when investigating patients with 
deletions in the short arm of chromosome 12. It has subsequently been shown to 
result in the fusion of two transcription factor genes - ETV6 and RUNX1. The 
resulting chimeric fusion gene includes the 5’ portion of ETV6, a member of the 
ETS family of transcription factors and almost the entire coding region of RUNX1 
(Pui et al, 2004). The ETV6-RUNX1 fusion protein inhibits transcriptional activity 
by recruiting histone deacetylase, which induces the closure of the chromatin 
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structure leading to inhibition of transcription (Figure 1.7). The consequence of 
these changes is alteration in both the self- renewal and differentiation pathways.  
 
 
 
Figure 1.7 The ETV6-RUNX1 fusion. The ETV6-RUNX1 recruits histone 
deactylase, resulting in the closure of the chromatin structure and so inhibiting 
transcription. Adapted from Pui (2004). 
 
 The  ETV6-RUNX1 fusion alone is insufficient for the development of 
leukaemia. A number of studies have demonstrated that the fusion arises in 
utero ( Gale et al, 1997;Ford et al, 1998; Greaves et al, 2003). This is followed by a 
postnatal pre-leukaemia phase, which requires a further secondary genetic event 
in order to develop overt leukaemia (Greaves et al, 2003). Loss of the non 
rearranged ETV6 allele has been implicated as an important secondary event in 
transformation of the pre-leukaemic cells to leukaemia.  
  The t(12;21) translocation occurs almost solely in childhood BCP-ALL at 
an incidence of ~25% and a median age of 4 years (Mitelman et al, 2007). It has 
rarely been reported in adult ALL (Jabber Al-Obaidi et al, 2002),  and has only 
been described in a single case of T-ALL (Ma et al, 2001). It is generally associated 
with a favourable outcome (Rubnitz et al, 1997;Borkhardt et al, 1997;Romana et al, 
1995), however late relapse as well as the incidence of the fusion gene in 
diagnosis and relapse suggest that the ETV6-RUNX1 fusion may not be an 
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independent good–risk marker (Harbott et al, 1997). Further studies are required 
to fully characterise the genotype of those patients who relapse in order to 
determine the true prognostic significance of this rearrangement in relation to its 
associated genetic changes.  
1.6.3 Intrachromosomal amplification of chromosome 21 (iAMP21) 
  Gene amplification is a mechanism that may lead to altered gene 
expression. In 2003, two groups Harewood et al (2003) and Soulier et al (2003), 
defined a new molecular cytogenetic subgroup in ALL. The abnormality had an 
apparent amplification of the RUNX1 gene located to band 21q22, on a 
duplicated chromosome 21. It was described by both groups as the presence of 
multiple copies of apparently un-rearranged RUNX1 genes, which were detected 
using FISH. The signals appeared as clusters of ≥ 4- 5 signals in interphase cells. 
In metaphases ≥ 3-4 signals appeared in a ladder like fashion on a single marker 
chromosome, which was shown by chromosome painting to be composed 
entirely of chromosome 21 material (Figure 3.1). In both studies the RUNX1 copy 
number ranged from 4-≥ 10, in the majority of patients. Conventional cytogenetic 
analysis of those patients with an abnormal karyotype, found that one copy of a 
normal chromosome 21 was replaced by the marker/duplicated chromosome 
21[dup(21)]). However, both groups noted that the chromosomal morphology of 
the marker as determined by G-banded analysis was highly variable between 
patients. Harewood et al (2003) subdivided the dup(21) into five distinct 
morphological groups; small acrocentric (SA), large acrocentric (LA), large 
metacentric (M) resembling an isochromosome, sub-metacentric (SM) and ring 
(R) chromosomes (Table 1.3). 
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Table 1.3 Morphological forms and ISCN description of dup(21) as described 
by Harewood et al (2003). 
 
  The abnormality has been associated with distinctive clinical features. It 
occurs in childhood ALL, with a higher incidence in older children. The 
combined median age of patients from the two studies was 11 years (range 5-20 
years). This is outside the usual distribution for childhood ALL, which is 2-5 
years. The peripheral blood white cell count (WBC) at presentation was low 
(mean 6x109/l; range 1-19x109/l). All patients had a precursor B-cell 
immunophenotype, with distinct immunophenotypic features (Soulier et al, 
2003). Of note was that no other previously described, established recurrent 
genetic abnormalities were detected in association with dup(21), for example 
patients were all negative for ETV6-RUNX1 and BCR-ABL1 fusions, MLL 
rearrangements, high hyperdiploidy and near-haploidy (Harrison et al, 2005). 
  Although these two studies were the first to establish this aberration as an 
emerging subgroup in childhood ALL, sporadic cases had been previously 
reported. One of the first was described by Le Coniat and Berger in 1995 (1995). 
They reported a case of an 11 year girl with ALL whose G-banded analysis 
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showed the presence of an abnormal clone, in which there appeared to be a 
single copy of chromosome 21 and a marker: 46,XX,-21,+mar. Using FISH, they 
showed that the metacentric marker chromosome was composed entirely of 
chromosome 21 material, and involved the uneven amplification of a region of 
chromosome 21, at band 21q22. They proposed that the mechanism of formation 
may have been from a secondary breakage of a ring chromosome. From the 
literature reviewed by Harewood et al, Soulier et al and a more recent study by 
Perez- Vera et al (2008;2003;2003), a total number of 86 cases with RUNX1 
amplification have been identified. Comparison of all cases published to date in 
relation to karyotypes, age and WBC at presentation, established that these 
characteristics were consistent (Appendix 1). All patients had been identified 
using similar FISH techniques, with all having multiple copies of the RUNX1 
gene arranged on a dup(21) chromosome.  
  It was noted that in the initial studies follow up time was too short to 
draw any conclusions regarding the prognostic significance of this cytogenetic 
abnormality. However, a subsequent study by Robinson et al (2003), combining a 
further eight cases with the initial 20 described by Harwood et al (2003), showed 
that for children with this abnormality entered to the UK Medical Research 
Council (MRC) ALL97 treatment trial, relapse rate was high. This report also 
demonstrated that the estimated incidence was low at 1.5%. This finding was 
confirmed in a later report by Garcia-Casado et al (2006), who screened 110 
consecutive paediatric ALL cases and identified two with RUNX1 amplification.  
  Although previous studies had described this abnormality as “RUNX1 
amplification”, it was established that the involvement of chromosome 21 
extended beyond the RUNX1 gene. Consequently, this abnormality was renamed 
in order to more accurately reflect this, as the intrachromosomal amplification of 
chromosome 21 (iAMP21) (Strefford et al, 2006).   
  Following the initial observation that iAMP21 was associated with a low 
event-free survival, outcome data has since been closely monitored in these 
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patients. A recent report of those patients (Moorman et al, 2007b) identified with 
iAMP21, treated on the UKALL97 treatment protocol, has conclusively 
established that these patients had a significantly inferior event-free and reduced 
overall survival at 5 years compared with other ALL patients of 29% verses 78% 
and 71% versus 87%, respectively. Consequently, childhood patients entered to 
the current UK ALL 2003 treatment trial are being treated on the high risk arm 
(Moorman et al, 2007b). 
1.7  The morphological, immunological and cytogenetic (MIC) 
classification  system         
  The incidences of different chromosomal rearrangements vary, with some 
abnormalities being more common than others and some being associated with 
specific morphological or phenotypic subtypes. In 1981, the Third International 
Workshop on Chromosomes in Leukaemia demonstrated for the first time that 
cytogenetics had an impact on the biology, diagnosis and the prognosis of ALL 
(1981). Since that time, cytogenetic abnormalities have been further elucidated 
and their molecular and biological significance better understood. The impact of 
such genetic rearrangements and the development of improved cytogenetic 
techniques for their detection resulted in the development of a system of 
classification, which categorizes patients according to their acquired 
genetic/molecular aberrations. This system, the MIC classification, includes 
morphological, immunological and cytogenetic data (1986).  
  Further development of sophisticated molecular techniques including 
FISH and the polymerase chain reaction (PCR) has allowed the detection of 
genetic rearrangements at the molecular level. This resulted in an improved 
classification system being proposed that incorporated morphology, 
immunophenotype, cytogenetic and molecular analysis - MIC-M (Bain, 1998). 
Currently the WHO system (2001) includes a number of specific chromosomal 
aberrations in its classification of acute leukaemia. As newly characterised 
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abnormalities become associated with distinct biological groups it is likely that 
further aberrations will be added to the classification system. 
1.8  Prognosis 
  The clinical outcome of patients with acute leukaemia is dependent upon 
a number of factors, including WBC count at diagnosis, age, gender and genetic 
subgroup. A number of recurrent genetic rearrangements have been identified 
and characterised in ALL, of variable incidence and prognostic value (Table 1.3). 
The impact of these genetic rearrangements on prognosis has influenced the 
development of current treatment regimes providing a risk–stratified approach 
to therapy. Consequently the accurate identification of genetic abnormalities is 
paramount to the success of treatment. In ALL chromosomal and molecular 
abnormalities often correlate with other clinical and haematological factors of 
prognosis, as well as having independent prognostic value.  
  The overall survival rate in ALL is lower in adults compared to children, 
40% versus ≥ 80% respectively (Pui & Evans, 2006). This is often attributed to the 
higher incidence of poor risk genetic factors in adults (Table 1.3). For example, 
the BCR-ABL1 fusion gene, associated with a poor prognosis irrespective of age, 
has a lower incidence in childhood compared to adult ALL.  
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Adults Childhood    Genetic 
abnormality  Incidence 
(%) 
Prognosis Incidence 
(%) 
Prognosis 
< 45 chromosomes  4-9  Poor  6  Poor 
> 50 chromosomes  2-5  Good  25-30  Good 
t(9;22)(q34;q11.2) 25-30  Poor  3-5  Poor 
t(4;11)(q21;q23) 3-5  Poor  2  Poor 
t(1;19)(q23;p13.3) 3  Poor  5-6  Good 
t(12;21)(p13;q22) <1  NK  20-25 Good 
t(17;19)(q22;p13) <1  Poor  <1  Poor 
t(11q23;V) 3-6  Intermediate  3-5 Poor 
t/del (9p)  10-15  Intermediate  7-12 NK 
t/del (12p)  5  NK  10-12  NK 
del(6q) 5-6  NK  4-13  NK 
 
Table 1.4 Overall incidences of recurrent genetic abnormalities in acute 
lymphoblastic leukaemia. Adapted from Ramondi (Raimondi, 2006). (NK = not 
known). 
 
  The impact of primary genetic changes on prognosis in ALL is 
unequivocal. Rigorous classification systems based on risk of relapse is essential 
in selection of therapy that will maintain a high cure rate, whilst avoiding 
excessive toxicity. With the development of more sophisticated technologies, it 
has been possible to define new genetic subgroups. In turn, the characterisation 
of such abnormalities may provide further insights into their biology, so leading 
to the development of novel drug treatments and possible disease prevention. 
1.9  Aims of research 
  The precise classification and diagnosis of patient groups at high-risk of 
relapse is essential. This project focuses on one newly described chromosomal 
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abnormality, iAMP21. Although the studies outlined above have demonstrated 
that the RUNX1 copy number was over represented in patients with this 
abnormality, it has not been established that this is the underlying mechanism. 
Consequently this study was proposed to further characterise iAMP21, to 
identify the potential causative mechanism driving the leukaemia in these 
patients, which in turn will lead to the development of the most accurate method 
for diagnosis.  
  This study has involved the detailed investigation of a number of 
previously identified iAMP21 cases using a combination of techniques including: 
 
  An investigation into copy number changes along chromosome 21, using a 
combination of array based comparative genomic hybridisation (aCGH) 
and FISH on a small group of iAMP21 patients  
  An interphase FISH profiling study, to screen a large group of iAMP21 
patients to establish if they all have an identical profile in relation to the 
copy number changes 
  Metaphase FISH mapping with clones located along the length of 
chromosome 21 and mBAND to investigate the types and extent of the 
intrachromosomal rearrangements 
  G-banded analysis of all cases to establish whether the morphology of the 
dup(21) chromosome is indicative of distinct subgroups among iAMP21 
patients, as suggested by Harewood et al (2003) 
  Detailed analysis of additional chromosomal abnormalities detected by G-
banding, to establish whether there are specific genetic aberrations 
associated with iAMP21 
  An investigation to determine whether iAMP21 represents a distinct 
subgroup of patients or it is a secondary chromosomal change 
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  The development of a diagnostic test that would allow this genetic 
subgroup to be detected using FISH, PCR or Multiplex ligation probe 
amplification (MLPA) 
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Chapter Two –  
Materials and Methods 
 
 Materials and Methods 
 
2 Materials and Methods 
2.1  Patients 
  Patients with a confirmed diagnosis of ALL and registered to one of the 
UK Medical Research Council (MRC)/National Cancer Research Institute (NCRI) 
treatment trials: ALL 97, MRD pilot, ALL 2003 for children aged 1-18 years, or 
UKALLXII for adults aged 15-55 years, were included in this study. Ethical 
approval and patient consent were obtained on entry to the clinical trial by the 
Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU, 2008). All 
patients were entered to the LRF UKCCG Karyotype Database in Acute 
Leukaemia (LRUKD) database (Harrison et al, 2001) and selected for inclusion in 
this study by searching this database (Section 3.1). The demographic and clinical 
data were collected from the CTSU (Oxford, UK).  
2.2  Patient Material 
  Fixed cell suspensions prepared from diagnostic bone marrow and/or 
peripheral blood, for routine cytogenetic analysis, were obtained from the UK 
regional cytogenetic laboratories. The karyotypes from standard G-banded 
cytogenetic analysis, undertaken by the same laboratories, were obtained on all 
patients. For those patients with an abnormal karyotype, G-banded slides were 
requested for review through the LRUKD. Where available, genomic DNA 
(gDNA) from matched diagnostic samples were obtained from the same 
laboratories.  
2.3  Fluorescence in situ hybridisation (FISH) 
  FISH is a molecular cytogenetic technique that allows detection of a 
specific DNA sequence in situ. It relies on the principle that a fluorescently 
labelled single stranded DNA probe will anneal (hybridise) to a complementary 
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single stranded target DNA. The target DNA from either metaphase 
chromosomes or non-dividing interphase nuclei can be visualised using a 
fluorescent microscope (Czepulkowski, 2001) (Figure 2.1). 
 
Figure 2.1 Diagrammatic representation of the principle of FISH. 
 
  There are a number of different designs of FISH probe available, making 
use of either DNA or RNA. For the purpose of this study six different DNA 
probe types were used: 
  Locus specific probes: unique sequence probes that are designed to detect 
specific regions of a chromosome or gene.  
  Whole chromosome paints (WCP): a library of sequence probes specific 
for individual chromosome pairs which hybridise or ‘paint’ the length of 
the chromosome.  
  Subtelomeric probes: unique repetitive DNA sequences specific for the 
subtelomeric regions of each chromosome.  
  Alpha satellite probes: repetitive DNA sequences specific for the alpha 
satellite centromeric regions of the chromosomes. These probes are 
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usually chromosome specific; however chromosomes 13 and 21 share the 
same sequences. 
  Peptide nucleic acid (PNA) telomeric probes: composed of PNA, which is 
a short synthetic DNA/RNA like molecule which can be used to generate 
probes capable of binding to target DNA. Telomeric PNA probes are 
composed of dye labelled oligomers comprising the common tandem 
repeat sequence (TTAGGG) found in all human chromosome telomeres.  
  mBAND probe, Xcyte 21 (Section 2.3.7). 
2.3.1 Probe selection 
  Plasmid artificial chromosome (PAC) (from libraries RCP1) and bacterial 
artificial chromosome (BAC) (from libraries RCP11) clones, positioned to specific 
chromosomal bands on chromosome 21 were identified using the following 
websites: 
  Ensemble: http//www.ensemble.org/index.html 
  UCSC: http://genome.ucsc.edu/cgi-bin/hgGateway 
  NCBI: http//www.ncbi.nlm.nih.gov/ 
The selected clones were obtained on request through the Wellcome Trust Sanger 
Institute (Cambridge, UK) or Wessex Regional Genetics Laboratory (Salisbury, 
UK).  
2.3.2  Probe preparation 
   Clones were streaked onto pre-prepared Luria-Bertani (LB) (Appendix 2) 
agar plates containing the appropriate antibiotic and placed in a 37˚C incubator 
for 16-20 hours. Following incubation, a single colony was picked out and grown 
at 37˚C overnight in 100ml of LB (Appendix 2) broth in a shaking incubator. 
  The following morning a glycerol stock consisting of 850μl of the 
overnight culture in 150μl glycerol (BDH Laboratory Supplies, UK) was 
produced and stored at -80˚C. 
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2.3.2.1   DNA extraction 
  DNA was extracted using a midi Qiagen plasmid purification kit (Qiagen, 
USA). The principle of this technique is based on a modified alkaline lysis 
procedure, followed by binding of plasmid DNA to an anion-exchange resin 
under low-salt and pH conditions. Impurities, RNA, and proteins are removed 
by a medium-salt wash and the DNA is eluted in a high-salt buffer. DNA is then 
concentrated and desalted by isopropanol precipitation and ethanol washes. The 
overnight culture was spun in a Stovall centrifuge at 5000 rpm for 5 minutes at 
4˚C. The supernatant was discarded and cell pellet resuspended by vortexing in 
4ml of P1 Buffer. The cells were lysed by the addition of the P1 buffer and the 
chromosomal and plasmid DNA denatured by the presence of sodium 
hydroxide in the buffer. 4mls of Buffer P2, previously warmed to 37˚C was 
added to the lysate and mixed by inversion. This was followed by 5 minutes 
incubation at room temperature (RT). After incubation, 3ml of chilled P3 buffer 
was added and the lysate gently mixed by inversion. The P3 buffer neutralizes 
the lysate by precipitating the denatured bacterial DNA, proteins and lipids. The 
plasmid DNA remains in solution. The lysate was placed directly onto a 
QIAfilter cartridge and incubated at RT for 10 minutes to collect the supernatant. 
  Qiagen tips were equilibrated using 4ml of Buffer QBT prior to addition of 
the collected supernatant. The tips were allowed to drain and the supernatant 
discarded. Flow of buffer begins automatically by reduction in surface tension 
due to the presence of detergent in the buffer. Contaminants are removed from 
the column by washing with 10ml of buffer QC. This step was repeated twice 
with the supernatant being discarded each time. The DNA was eluted from the 
column by adding 5ml of buffer QF previously warmed to 65˚C. The eluate was 
collected and 3.5ml of isopropanol added to precipitate the DNA. This sample 
was centrifuged at 14000 rpm at 4˚C for 30 minutes. The supernatant was 
discarded and 2mls of 70% ethanol added to remove any remaining precipitated 
salt. The sample was then spun at 14000 rpm at 4˚C for 10 minutes. The ethanol 
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replaces the isopropanol making it easier for the DNA to dissolve. The DNA 
pellet was left to air dry before resuspending in 2ml of distilled water (dH2O). 
The quality of the extracted DNA was determined by running 8μl on a 1% 
agarose gel (Section 2.4.2). 
2.3.2.2  Preparation of fluorescence labelled DNA probe 
  Probes are fluorescently labelled by one of two methods: 
Indirect labelling: The probe is attached to a reporter molecule, either 
digoxigenin or biotin. A fluorochrome, conjugated to a molecule, such as avidin, 
is added. This combines with the labelled reporter molecule. Further fluorescent 
layers may be added if the signals are weak, by adding an antibody to this 
conjugated molecule. For example, biotin labelled probe is hybridised to the 
target DNA. Fluorescently labelled avidin (which has a strong affinity for biotin) 
is then added, which binds to the biotin. By subsequently adding a biotinylated 
anti-avidin molecule it is then possible to repeat the process, building up layers 
of fluorescence. 
Direct labelling: The probe DNA is directly joined to the fluorochrome and can 
thus be visualised without any further detection steps.  
  Following detection, a counterstain is added so that the chromosomes and 
interphase cells can be visualised and the relative positions of the fluorescent 
probes noted. Analysis is then carried out using an epifluorescence microscope.  
  Probes were labelled using Nick translation. The principal behind this 
technique is the cleaving of DNA (‘nick’) and the synthesis of new DNA with the 
incorporation of fluorochrome–conjugated or hapten-conjugated nucleotides. It 
relies on the activity of two enzymes working simultaneously: DNase1 which 
cleaves the DNA and DNA polymerase1 which both removes and adds 
nucleotides. 
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  To allow for dual colour FISH experiments, probes were labelled with 
either Spectrum Red or Spectrum Green conjugated d-UTP (Abbott Diagnostics, 
US) using a nick translation kit (Abbott Diagnostics, US). 
  Individual labelling reactions containing 2.5μl dUTP (0.2 Mmol Spectrum 
Red or Spectrum Green), 10μl dNTP mix (0.1Mmol each of dATP, dCTP, and 
dGTP), 5μl 0.1mM dTTP and 5μl nick translation buffer were added to a 1.5ml 
microcentrifuge tube and gently mixed together. 17.5μl of extracted DNA was 
added followed by 10μl of nick translation enzyme (a mixture of DNase1 and 
DNA polymerase 1). The samples were incubated at 15˚C for 3 hours. 3μl 0.5M 
EDTA was added to stop the reaction. To remove unbound probe, samples were 
run through a Sephadex G-50 column (Amersham, UK). The Sephadex column 
was flick mixed to resuspend the granules, opened, and placed in a collection 
tube. The column was spun at 4000 rpm at 4˚C for 1 minute, the supernatant was 
discarded, and 50µl of TE buffer (Appendix 2) was added to the column. The 
column was centrifuged as before and the supernatant discarded. The column 
was then placed in a clean collection tube and the nick translated DNA sample 
pipetted into the centre of the column. The column was spun as before and the 
eluate collected. To confirm that the DNA probe had been cleaved and labelled 
the sample was run on an agrose gel (section 2.4.2).  
  To remove repetitive sequences, 10μl labelled DNA probe was co-
precipitated by adding 10μl human Cot1-DNA (1mg/ml) (Invitrogen, UK) in 
40μl 100% ethanol and 2μl 3M sodium acetate (pH 5.2), at -20˚C for 1-2 hours. 
The DNA was then pelleted by centrifugation at 13000 rpm at 4˚C for 30 minutes, 
air dried and resuspended in nuclease free water. Fluorescent probes are 
photosensitive and so care was taken to minimise their exposure to light.  
2.3.3 Slide Preparation 
  Fixed cells were centrifuged and the pellet re-suspended in fresh fixative 
(3:1 Methanol: Acetic acid) until the cloudy suspension became almost clear in 
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appearance. Using a pipette 2- 3μl of this suspension was dropped onto a clean 
previously labelled glass slide. Cell density and metaphase spreading were 
checked using a phase contrast microscope. Cell concentration should be such 
that the cells do not overlap, are flat and have no visible cytoplasm. Slides were 
then air dried slowly to allow the chromosomes time to spread (adding a drop of 
fix to the slide immediately after spreading can slow down the drying process 
and so aid metaphase spreading). Slides were aged on a hotplate at 60˚C for 15 
minutes. 
2.3.4 Hybridisation  
  In order to incorporate the probe DNA into the target DNA, double 
stranded probe and target DNA were denatured by heating in order to render 
them single stranded. As DNA needs temperatures of >90˚C to denature, mixing 
the probe with formamide (an organic solvent) and salt solutions lowers the 
temperature at which denaturation occurs. Hybridisation buffer contains a 
mixture of formamide, saline sodium citrate (SSC), dextran sulphate, salt-dextran 
solution and a blocking DNA. Together these components optimise the 
conditions for hybridisation to take place. Both probe and target DNA may be 
denatured simultaneously (by co-denaturing) on a hotplate, or they can be 
denatured separately using heated formamide solutions. Some probes are single 
stranded and do not require denaturation.  
  Following denaturation, the probe DNA was left to hybridise to the target 
at 37˚C. A 1:10 dilution of probe was prepared using hybridisation buffer (Abbott 
Diagnostics, US). The total volume of probe used is dependent upon the size of 
the coverslip. For 10 or 13mm coverslips a total volume of 3μl was used whilst 
for 22 x 22mm coverslips a total volume of 5μl was used. The probe solution is 
spotted on to the cover slip and the slide inverted over it, aligning the coverslip 
with the sample spot. This upside down approach reduces the formation of air 
bubbles between the slide and the coverslip. The coverslip was sealed with 
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rubber solution and the slide placed on a Hybrite (Abbott Diagnostics, US) a 
temperature controlled hotplate. Probe and patient DNA was co-denatured at 
72˚C for 2 minutes and hybridised overnight at 37˚C. For commercial probes, the 
manufacturers’ protocols were followed with regard to hybridisation, 
temperatures and timing. 
2.3.5 Post hybridisation washing 
  During the process of hybridisation, some probe will bind to non specific 
sequences in addition to binding to the target DNA. This background 
hybridisation is removed by stringent washes to break the weaker bonds of the 
non-specifically bound DNA. The stringency of the wash solution required is 
dependent on the level of background. At higher stringency, there is a greater 
disassociation of the less specific DNA, making the resulting signals cleaner but 
faint. The stringency is adjusted by altering the temperature and salt 
concentration of the washes.  
  The rubber sealant and coverslip were removed (to aid the removal of the 
coverslip, slides may be soaked in 2x SSC solution (Appendix 2) for 30 seconds 
and slides placed in Wash 1: 0.4 x SSC +0.3% Nonidet P40 (NP40) (Roche, 
Germany); pre heated to 73˚C for 2 minutes. Slides were transferred to Wash 2:  
2 x SSC + 0.01% NP40; at RT for 2 minutes.  
2.3.6 Detection and counterstaining 
  Probes are detected by one of two methods depending on the initial 
labelling. For indirectly labelled probes following post hybridisation Wash 2, 
10l blocking agent (Appendix 2) was pipetted onto the areas of slide requiring 
detection. This area was covered with a parafilm coverslip and incubated in a 
humidified chamber at RT for 10 minutes. Following incubation, the excess block 
was drained from the slide and 10l detection reagent applied: Avid-Fluorescein 
for biotin labelled probes (Roche, Uk) and Anti-Digoxigenin-Rhodamine Fab 
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fragments for digoxigenin labelled probes (Roche, UK), The area was covered 
with a parafilm coverslip and incubated for 10 minutes in a humid chamber. The 
slide was then placed in Wash 3 (Appendix 2) for 1-2 minutes to remove the 
unbound detection reagent. Directly labelled probes require no detection.  
  The counter stain, 4',6-diamidino-2-phenylindole (DAPI), is required for 
visualisation of metaphase and interphase cells. The stain is preferentially taken 
up by the adenine (A)-thymine (T) rich chromosomal regions which produces a 
staining pattern similar to that seen with G-banding. As both the fluorochromes 
and DAPI are light sensitive, an antifade solution is added to reduce the rate of 
photo bleaching that occurs on exposure to light. Slides were mounted in 7l 
Vectorshield antifade solution (Vector Laboratories, UK) containing DAPI 
(Vector Laboratories, UK) and sealed with nail varnish. The slides were kept in 
the dark until required. 
2.3.7 Analysis 
  Visualisation of the FISH signals was undertaken using an Axioplan 
fluorescent microscope (Karl Zeiss, Germany) and images were captured using a 
charge-coupled device (CCD) camera and MAC probe software (Applied 
Imaging International, UK). Copy number changes were determined by counting 
either the number of signals for specific probes in 200 interphase cells; or the 
number of signals in 100 abnormal (RUNX1 amplified) interphase cells. The 
locations of specific probes on metaphase chromosomes were noted and where 
possible images were captured and stored. For scoring purposes, the signals on 
the normal chromosome 21 served as internal positive controls. 
2.3.8 mBAND 
  mBAND is a high resolution multicolour banding technique based on 
region-specific chromosome paints combined with quantitative colour ratio 
analysis. Following micro-dissection of a specific chromosome, partial 
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chromosome paints are generated by labelling each individual chromosomal 
region with a unique combination of fluorochromes, which partly overlaps with 
its neighbouring one. The resulting fluorescence intensity pattern along the 
chromosome axis shows a continuous change of fluorochrome ratios. This allows 
for the assignment of pseudo colours to each of the chromosome sections with 
similar ratios, producing a reproducible colour banding pattern that does not 
depend on chromosome condensation (Figure 2.2). This quantitative ratio 
analysis effectively multiplies the resolution of the region specific probes. 
 
Pseudo colours Fluorochromes Pseudo colours Fluorochromes
 
 
Figure 2.2 High resolution mBAND of chromosome 6. Using five different 
fluorochromes, 20 pseudo colour bands are generated (the ratio analysis 
multiplies the initial resolution of the probe kit by a factor of 3 to 4).  
 
   The Xcyte 21 mBAND probe (Metasystems®, Germany) is a mixture of two 
region specific areas of chromosome 21, generated by micro-dissection. The two 
regions are labelled with two different fluorochromes, Fluorescein (FITC) and 
Texas red. The partial overlap of adjacent banding probes results in seven 
pseudo colour regions along the chromosome. This produces a higher level of 
precision banding within one chromosome and improves the detection of 
intrachromosomal rearrangements.  
  This probe was chosen to specifically analyse chromosome 21 
rearrangements in metaphases.  Slide preparation was carried out as outlined in 
section 2.3.3. Hybridisation and post hybridisation washes were carried out 
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according to the manufacturer’s instructions. Analysis of XCyte 21 mBAND 
probe was undertaken using a Zeiss Axioplan 2 microscope (Karl Zeiss®, 
Germany) and Isis capture software (MetaSystems®, Germany). 
2.3.9 Sequential FISH 
  Rehybridisation of the same metaphase with different probes can be 
undertaken several times to allow for direct comparison of location of probes 
relative to each other in the same chromosome, as well as to confirm 
chromosome identification (Pinson et al, 2000).  
  Following initial hybridisation and analysis, the coverslip was gently 
removed and the slide immersed in 2xSSC for 1 hour. The slide was then placed 
in Wash 2 for 20 minutes at RT. It was then dehydrated by passing through a 
70%, 85% and 100% ethanol series for 1 minute in each solution and left to air 
dry. The slide was then rehybridised with a new probe following the same 
hybridisation procedure as previously outlined (Section 2.3.4). Although this 
procedure may be repeated several times, the quality of the preparation 
deteriorates with each hybridisation. 
2.4  DNA Extraction  
  For those samples with no DNA provided from the referral laboratory, 
DNA was extracted from the fixed cell suspensions using the Qiagen DNeasy 
tissue extraction kit (Qiagen, USA). The basic principle is; following lysis with 
proteinase K, the lysate is loaded onto the DNeasy Mini spin column where 
buffering conditions are adjusted to provide optimal DNA binding. During 
centrifugation, DNA selectively binds to the DNeasy membrane as contaminants 
pass through. Remaining contaminants and enzyme inhibitors are removed in 
two efficient wash steps and DNA is then eluted in water or buffer, ready for 
use. 
  Fixed cell suspensions were spun at 13000 rpm for 5 minutes, the 
supernatant was discarded and the pellet resuspended in 1ml of phosphate 
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buffered saline (PBS) (Sigma, UK). This step was repeated to ensure that all the 
fixative was removed. The resulting pellet was resuspended in 200 µl PBS, 20µl 
proteinase K followed by 200µl Buffer AL were added to the sample which was 
thoroughly mixed by vortexing and incubated at 56˚C for 10 minutes. After 
incubation, 200µl 100% ethanol was added to the sample and mixed.  
  The mixture was pipetted into a DNeasy Mini spin column placed in a 
2ml collection tube and centrifuged at 8000 rpm for 1 minute. The collection tube 
and flow were discarded. The column was placed into a second collection tube 
and 500µl buffer AW1 added, followed by centrifugation at 8000 rpm for 1 
minute. The collection tube and flow through were discarded. The column was 
placed into a new collection tube and 500µl AW2 added. It was then centrifuged 
at 14000 rpm for 3 minutes. The collection tube and flow through were discarded 
and the column placed into a clean microcentrifuge tube and 200µl Buffer AE 
was pipetted into the column. This was left for 1 minute before spinning at 8000 
rpm. The eluted DNA was collected, placed onto the column and the elution 
stage repeated.  
2.4.1 DNA concentration 
  The quality and concentration of the DNA was determined using a 
Nanodrop spectrophotometer. The quality of extracted DNA, as measured by the 
ratio of the absorbance values at A260nm/A280nm, should be between 1.7-1.9 
and the absorbance scans should show a symmetric peak at 260 nm, confirming 
high purity. 
2.4.2 Gel electrophoresis 
  The quality of DNA can alternatively be assessed using gel 
electrophoresis. The principle of the technique relies on DNA being separated by 
differential migration through agrose gel. When an electric current is applied to 
the gel, the negatively charged DNA will migrate towards the cathode. The 
smaller molecules migrate faster through the polymer than the larger ones. To 
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visualise the DNA, ethidium bromide is added, which fluoresces under UV light. 
A 1% agarose gel was prepared by heating 0.5gm agarose (Sigma, UK) in 50ml 1x 
Tris-borate buffer (Sigma, UK) in a microwave. Following cooling 0.4mls 
Ethidium bromide (Sigma, UK) was added and the liquid gel poured into a gel 
tank fitted with an appropriate sized comb. Once set, the gel was immersed in 
TBE buffer (Appendix 2) and the comb removed. 8µl test DNA mixed with 2µl of 
loading dye was loaded into the appropriate lane. To allow for a quantitative 
comparison, a 1kb DNA ladder was loaded into a lane at the end of the comb. 
The gel was run at approximately 80 volts for 20 minutes and the bands were 
visualised using a UV transilluminator.  Good quality DNA will have a sharp 
band whilst poor quality degraded DNA will produce bands that appear 
smeared.  
2.5 Array-based Comparative Genomic Hybridisation 
  Array-based comparative genomic hybridisation (aCGH) is a 
sophisticated molecular technique that is used to identify and characterise DNA 
copy number alterations at the genome level. Two samples of genomic DNA, a 
test DNA and a reference DNA, are differentially labelled with fluorescent dyes 
and hybridised to known mapped genetic sequences spotted onto a glass slide 
(Figure 2.3) (Pinkel et al, 1998). The intensity of the different fluorochromes is 
measured and a CGH profile of each chromosome generated from the log2 
fluorescent ratios. Regions in which there is no deviation from the normal will 
have a ratio of 0, whilst those regions with duplications will have positive ratio 
values. Conversely those with deletions will have negative ratio values. The 
signal intensity is not a direct measure of copy number, rather an arbitrary value, 
thus an alternative method, for example FISH, is required to confirm the actual 
DNA copy number. The resolution of the array platform is variable depending 
upon the design. Initial designs were based on BAC clones. The clones in these 
platforms were approximately 200kb long and usually each platform contained 
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on average 3000 clones, spaced approximately 1Mb apart. Although they 
provided precise identification of the chromosomal regions involved in the copy 
number change, their resolution was insufficient to identify aberrations within 
specific genes. To overcome this limitation, oligonucleotide probes have been 
developed, which have a higher resolution to the level of 6kb. Agilent 
oligonucleotide Human Genome CGH Microarray Kits 185A and 244A (Agilent, 
UK) were chosen for the study of two patients with amplification involving both 
chromosomes 15 and 21.  
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Figure 2.3 An overview of aCGH. a) Genomic DNA from test and control are 
differentially labelled and hybridised to a microarray. The fluorescent ratios of 
each array spot are calculated and normalised so that the median log2 ratio is 
0.b) Plotting of the data for chromosome 9 shows that most spots have a ratio 
near 0. However, the spots nearest pter (red arrow) have a ratio of -1, indicating a 
deletion. Adapted from Pinkel (2005). 
2.5.1 Sample Preparation 
2.5.1.1   Restriction Digestion 
  Using the Agilent Human Genome CGH Microarray Kit (Agilent,UK) 
patient gDNA and sex matched commercial reference gDNA (Promega, UK) at a 
concentration of 1.5ug were made up to a total volume of 20.2µl with nuclease-
free water, in separate microcentrifuge tubes. The tubes were placed on ice and 
to each 2.6µl 10xBuffer C, 0.2µl Acylated BSA, 0.5µl each of Alu1 and Rsa 1 
enzymes and 2µl nuclease-free water (digestion master mix) were added. 
Samples were incubated in a 37˚C water bath for 2 hours. The tubes were 
transferred to 65˚C for 20 minutes to stop the reaction by inactivating the 
enzymes. 5µl 10x Random Primers were added to each reaction tube. Tubes were 
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transferred to 95˚C hot block for 3 minutes then moved to ice for a further 5 
minutes.  
2.5.1.2  Sample Labelling 
  The Agilent gDNA kit uses random primers and an exonuclease free 
Klenow fragment (a genetically engineered enzyme in which the 3’ to 5’ 
exonuclease activity has been removed) to differentially label the gDNA with 
fluorescently labelled nucleotides. The test sample is labelled with one dye whilst 
the reference is labelled with another. To each tube, 10μL 5x Buffer, 5μL 10x 
dNTP and 1μL Exo-Klenow (labelling master mix) (Agilent, UK) were added 
followed by: to the test gDNA 3μL Cy5-dUTP and to the reference gDNA 3μL 
Cy3-dUTP. The fluorescent labelled dyes are light sensitive, thus should have 
minimum exposure to light. The samples were mixed well by gentle pipetting, 
incubated at 37˚C for 2 hours and the reaction stopped by transferring to a water 
bath at 65˚C for 10 minutes. Following incubation samples were transferred to 
ice.  
  The samples were purified using Micron centrifugal filter devices. To each 
tube 430µl 1xTE Buffer (Appendix 2) was added and mixed using gentle 
pipetting. A Micron YM-30 filter was placed into a pre labelled 1.5ml 
microcentrifuge tube and loaded with either the test gDNA or reference gDNA. 
The tubes were spun at 6.5 rpm for 10 minutes and the flow through discarded. 
This step was repeated with the flow through again being discarded. The 
columns were inverted and placed into fresh microcon tubes. Tubes were spun at 
6.5 rpm for 1 minute. The volume of each eluate was determined, if it was ≤ 
80.5µl, sufficient nuclease free water was added to make the final volume 80.5µl. 
If the volume was ≥ 80.5µl the eluate was returned to the column and spun at 6.5 
rpm for 1 minute as previously described. The two samples were combined to 
give a total volume of 161µl.  
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2.5.2 Array processing 
2.5.2.1  Hybridisation 
  To the combined sample, 50µl Cot-1-DNA, 52µl 10x Blocking Agent and 
260µl Agilent 2x Hybridization buffer (Agilent, UK), was added and the sample 
gently mixed. The tubes were pulse spun before being placed on a hot block at 
95˚C for 3 minutes. Immediately the tubes were transferred to 37˚C water bath 
for 30 minutes. Following incubation, the samples were removed from the water 
bath and spun at 13000 rpm for 1 minute. A pre-labelled gasket slide was loaded 
into the Agilent SureHyb chamber with the gasket label face up. Slowly 490µl 
suspension was dispensed onto the slide. The slide was placed onto the SureHyb 
chamber, ensuring that the active side was face down. The chamber cover was 
positioned over the slide and secured in place. The assembled chamber was 
rotated to wet the slide and ensure that no stationary air locks were present. This 
was then placed into the hybridisation oven at 65 ˚C and rotated at 20 rpm for 40 
hours.  
2.5.2.2  Post-hybridisation washes 
  Excess unbound test and reference gDNA is removed by post 
hybridisation washes. At the same time it is important to stabilise and dry the 
hybridised array slide. As Cyanine 5 is sensitive to ozone degradation, 
stabilisation and drying solutions have been designed to minimize the ozone 
induced degradation.  
  The required volume of Wash Buffer 2 (Agilent, UK) was pre-warmed in a 
37˚C water bath overnight. If the stabilisation and drying solution showed a 
visible precipitation, this too required pre-warming at 37˚C overnight. Five slide 
staining tanks were filled with the following solutions; 
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  Tank 1 - Wash Buffer 1 
  Tank 2 - Wash Buffer 1 filled to a sufficient level to cover a slide rack 
  Tank 3 - Wash Buffer 2 at 37 ˚C  
  Tank 4 - Acetonitrile (Sigma, UK) 
  Tank 5 - Stabilisation and Drying Solution (Aglilent, UK) 
 
  In addition to the solutions, tanks 2-5 contained a magnetic flea and all 
four tanks were placed on a magnetic stir plate which was set at a speed of level 
3. The slide was removed from the SureHyb chamber and placed in tank 1. 
Whilst submerged in the wash, the slides were gently prised apart, and placed 
into the slide rack before being quickly transferred to tank 2. The slides were left 
for 5 minutes before being transferred to tank 3, where they were left for 1 
minute. The rack was transferred to tank 4 and left for 1 minute. Finally the rack 
was transferred to tank 5 for 30 seconds. Very slowly the slides were removed 
from the tank, taking care to ensure that there were no droplets on the slide. The 
slides were than scanned on an Agilent scanner using the default scan settings. 
The scan resolution was set to 5µm as recommended for 244k density arrays. 
2.5.3 Data Extraction 
  The Feature Extraction (FE) software version 9.1 (Agilent, UK) converts 
the tiff images obtained from the scanner into a reduced representative set of 
features, which are required to describe a large set of data accurately. The arrays 
were then analyzed using the Agilent CGH Analytics 3.4.27 software, which is 
based on the UCSC May 2004 assembly (HG17). The ratio of the fluorescent 
intensity of the test gDNA compared to the reference gDNA was calculated and 
averaged for each replicate before being converted to a log ratio, which was then 
normalised using z-scoring, with the modal ratio of the array being set to zero. 
Aberrant regions were identified for each point in the data by calculating the 
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moving average within a 2Mb window. Outliers were classified using a cut off of 
+/- 0.25.  
  Following the initial identification of a deviation, the data was then 
subjected to an aberration detection method 1 (ADM-1) algorithm (which takes 
into account the number of probes in an aberrant region as well as the extent of 
their deviation from zero) to give a true estimation of the aberrant section. Five 
consecutive deviant spots were required for an aberrant call. 
2.6  Quantitative PCR (Q-PCR) 
  The standard polymerase chain reaction (PCR) is a method for amplifying 
in vitro a specific target DNA sequence present within a heterogenic DNA 
sample. Two oligonucleotide primers (one forward and one reverse), specific for 
a target sequence, are added to a denatured template DNA. They bind to 
complementary DNA sequences at the target site and in the presence of a heat-
stable DNA polymerase (Taq) and DNA precursors, initiate the synthesis of new 
DNA strands, complementary to the target DNA segment. This newly 
synthesized DNA strand then acts as a template for further DNA synthesis in 
subsequent cycles, so allowing for the exponential amplification of the target 
DNA. The reaction consists of three main steps: 
 
  Denaturation, typically at about 93–95˚C for human genomic DNA.  
  Reannealing at temperatures usually from about 50˚C to 70˚C.  
  DNA synthesis, typically at about 70–75˚C. 
 
  PCR techniques can be used to quantify DNA in an optimised reaction as 
the quantity of target DNA will approximately double during each amplification 
cycle. By linking the amount of amplified product to a fluorescent reporter 
molecule and measuring the subsequent fluorescence intensity, it is possible to 
calculate the quantity of the initial DNA. The florescence signal can be measured 
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either at the end of the reaction (endpoint PCR) or during the reaction real time 
(RT-PCR). 
 
 
a b a b  
 
Figure 2.4 SYBR® Green detection mechanism. Double-stranded DNA (dsDNA) 
in the reaction is bound by the dye. In the bound state (b), SYBR® Green is 
1000fold more fluorescent than in the unbound state (a) As PCR amplification 
increases the amount of dsDNA present, the fluorescence signal increases 
proportionately. 
 
2.6.1 Relative quantitative PCR (Q-PCR)  
  Real time quantitative PCR (Q-PCR) measures the fluorescence level at 
each cycle of the PCR amplification phase. Using the double stranded DNA 
binding dye SYBR® Green as a fluorescent reporter molecule, it is possible to 
monitor the progress of each PCR cycle, as the intensity of the fluorescence 
increases proportionally to the increased target DNA concentration. The first 
cycle at which the fluorescence intensity is above that of the background 
(threshold cycle “Ct”) can be directly correlated to the starting concentration of 
the sample.  
  Often the absolute value of the target DNA is not required, rather the 
amount of target DNA relative to a reference DNA sequence. Relative 
quantitative RT-PCR compares the ratio of a target DNA to a reference DNA 
sequence in an unknown sample and the ratio of the same two sequences in a 
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standard sample. The results are expressed as the fold-change of the target DNA 
relative to the standard.  
  Using relative quantification Q-PCR it is possible to generate reliable 
results that can be compared between different samples and different 
experimental systems. Q-PCR was chosen to establish the relative amounts of 
three genes, STCH, RUNX1 and PRMT2 located on chromosome 21. CYP27C1 
was used as the house keeping gene located to the long arm of chromosome 2. 
All primers used in the relative quantification RT-PCR are presented in 
Appendix 2. 
2.6.1.1  Q-PCR method 
  The following master mix was prepared (volumes given for a single 
reaction): 
  0.4 µl 10x Buffer (Invitrogen, UK) 
  0.4 µl dNTP mix (Promega, UK) 
  0.3 µl MgCL2 (50mM) (Invitrogen, UK)  
  0.5 µl primer mix (0.5 µM; MWG, Germany) 
  µl SYTO 9 (5µM; Invitrogen, UK) 
  75 µl PCR grade H2O  
  0.05 µl Taq (Invitrogen, UK) 
 
For each reaction, 2µl of sample DNA at a concentration of 5ng/µl was added to 
the master mix. For the negative control, an equal volume of PCR grade H2O was 
added to the master mix in place of the sample DNA. 
  The PCR reactions were performed on a Roche Light Cycler 480 system. A 
96-well plate was designed to include six patient samples, a negative control and 
a normal male genomic DNA (Promega, UK). Each sample was run in triplicate 
and the plate design was such that for each sample all four primers were run on 
a single plate.  
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10µl PCR mix was added to each well. The plate was sealed with a clear plastic 
film to prevent evaporation and pulse spun to ensure that the reaction mix was 
positioned at the bottom of the plate. Plates were loaded into the analyser and 
the cycling conditions were set as follows: 
1 cycle: 
95˚C 10 mins to activate the Taq enzyme followed by 40 cycles: 
  95˚C 15 seconds 
  60˚C 30 seconds 
  72˚C 30 seconds 
  4˚C hold 
Results were analysed using the LightCycler 480 Relative quantification 
Software. 
2.7  Multiplex Ligation-dependent Probe Amplification 
 Multiplex  Ligation-dependent  Probe  Amplification (MLPA) (Figure 2.5) is 
a novel molecular technique able to detect copy number changes of up to 45 
different target nucleic acid sequences in a single PCR reaction (Schouten et al, 
2002). For each specific DNA target sequence, a complementary MLPA probe is 
designed, consisting of two oligonucleotides that hybridise to sites immediately 
adjacent to each other. Attached to the 5’ end of one of the short synthetic 
oligonucleotides is the forward PCR primer, whilst at its 3’ end is the target DNA 
hybridizing sequence. The second oligonucleotide has a hybridizing sequence at 
its 5’ end and the complementary (reverse) PCR primer at its 3’ end.  
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Figure 2.5 Schematic outline of MLPA reaction. Adapted from Hogervorst et al 
(2003). 
 
  Following hybridisation of the MLPA oligonucleotides with the target, the 
two parts of the probe are ligated by a specific ligase enzyme. This reaction is 
precise and only those probes that are directly adjacent to one another will ligate 
(this allows for the detection of sequences that differ from one another by only a 
single nucleotide at the site of ligation). After the ligation reaction, the resulting 
fragment contains both PCR primer sequences which amplify exponentially 
during the subsequent PCR reaction. Any oligonucleotides that are not ligated 
contain only a single PCR primer sequence and so will not be exponentially 
amplified.  
  Each MLPA probe is designed to give rise to an amplification product of a 
unique size, with the total size range between 120-480 nucleotides for each of the 
different target sequences. This is achieved by the addition of a sequence which 
does not hybridise to the target sequence known as a ‘stuffer’ sequence (Figure 
  69Materials and Methods 
2.6). This sequence usually increases in length by 6 - 9 nucleotides between 
probes. The size range of the probes is optimal for fragment separation and low 
background levels. These fragments are detected and quantified by capillary gel 
electrophoresis. By comparing the profiles obtained from the test sample to a 
control, it is possible to calculate the relative copy number of a specific target 
sequence.  
2.7.1 Synthetic Probe Design 
  Commercial MLPA kits are available from MRC-Holland for a wide range 
of disorders and specific gene characterisations. These kits can be enhanced by 
the addition of home designed probes in order to tailor the target areas to a 
specific query. The process involved in designing a synthetic probe follows a 
number of stages: 
The region of interest is determined and a specific target selected using one of the 
following websites: 
  http://www.ncbi.nlm.nih.gov   
  http://www.ensembl.org/index.html 
For each target DNA area of interest, a 48 base pair region is selected.  
This sequence is checked for single nucleotide polymorphisms (SNPs) to rule out 
polymorphisms and run through a Blast program to ensure that it is unique in 
the genome. 
  The probe is then designed using the following criteria:  
The total length should be evenly spread over right side probe oligo (RPO) and 
the left side probe oligo (LPO) to avoid too long oligonucleotides (Figure 2.6). 
Each hybridising sequence should be 24 base pairs in length and approximately 
50% GC rich. When synthetic probes are used with an existing MRC-Holland kit, 
they are usually designed to fit into the gap at the start of the kit. The total probe 
length (LPO + RPO, plus a 42 base pair of primers) is between 96-130 bp, with a 
minimum length difference between probes of 4 base pairs. In order to achieve 
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the correct length a stuffer sequence may be inserted between the hybridising 
sequence and the PCR primer sequence. This stuffer sequence is inserted into the 
RPO and is uncomplimentary to the sequence following the 48 bp target (by 
swapping A with C and G with T this part of the sequence will not bind as the 
purines will be opposite purines and pyrimidines opposite pyrimidines). 
  The RPO requires a 5’ phosphate group added to its 3’ end to allow for 
ligation. For each target DNA a 5’ and 3’ primer sequence is required; 
 
     LPO  GGGTTCCCTAAGGGTTGGA 
  RPO    TCTAGATTGGATCTTGCTGGCAC 
 
These are the binding sites for the MRC- Holland primers which are supplied 
with the SALSA MLPA kit. One of the PCR primers in the MLPA kit has a 
fluorescent label in order to allow for detection of the PCR products.  
 
3’
Stuffer sequence’
5’
Forward primer 
sequence
Reverse primer 
sequence
Hybridising sequences
Left hand oligonuclotide Right hand oligonuclotide
3’
Stuffer sequence’
5’
Forward primer 
sequence
Reverse primer 
sequence
Hybridising sequences
Left hand oligonuclotide Right hand oligonuclotide
 
 
Figure 2.6 MPA probe design. Red lines indicate the forward and reverse primer 
sequences; blue lines = hybridisation sequences and black = stuffer sequence. 
 
  The self design probe oligonucleotides were obtained from Thermo-
Hybaid (Germany). These probes were diluted with TE buffer to give a 
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concentration 0.00133µM and denatured in a total volume of 3.5µl as outlined in 
section 2.7.2. When making up the probe mix for the overnight hybridisation 
(Section 2.7.2) a master mix containing 1.5µl each of MLPA buffer, the commercial 
MRC probe mix and the synthetic probe was prepared. 4.5µl of this was added to 
the denatured DNA. The protocol as outlined in section 2.7.2. was then followed. 
2.7.2 Sample Denaturation and hybridisation 
  3.5µl of test gDNA diluted with TE (Appendix 2) to a concentration of 
30ng/ml was added to a 200 µl PCR tube. The tubes were briefly spun to collect 
DNA in the bottom of the tube and a drop of mineral oil placed on the top to 
prevent evaporation and condensation during denaturation and hybridisation.  
The tubes were placed in a PCR thermal cycler and denatured at 98˚C for 7 
minutes. The samples were then cooled to 25˚C and 4.5µl master mix containing 
1.5µl MLPA buffer, 1.5µl commercial MLPA probe mix (to provide control 
probes for comparison) and 1.5µl homemade probe mix (section 2.7.1) was added 
to each reaction tube. The samples were mixed well by pipetting up and down. 
The reaction tubes were heated to 95˚C for 1 minute cooled to 60˚C and left to 
hybridise over night (a minimum of four hours is required). 
2.7.3 Ligation reaction 
  Ligase buffer master mix was prepared by mixing 3µl Ligase buffer A 
with 3µl Ligase buffer B and 25µl dH2O. Mixed by vortexing and prior to use 1µl 
of Ligase-65 added (Ligation-65 mix can be made 1 hour prior to use and stored 
on ice). The temperature of the thermal cycler was reduced to 54˚C and 32µl 
Ligase-65 mix added to each sample, mixed well by pipetting up and down. The 
sample was incubated for 23 minutes at 54˚C, then heated for 5 minutes at 98˚C 
to denature the ligase, before cooling to 4˚C. The two MLPA probes were then 
ligated and at this point the ligate can be stored at -20˚C for one week. 
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2.7.4 PCR reaction 
On ice the following master mix was prepared (volumes given for a single 
reaction): 
 
1µl of SALSA PCR-primers  
  2µl of SALSA buffer  
  1µl l of Enzyme buffer   
  15.75µl of dH2O 
 
Mixed well before adding 0.25µl of SALSA polymerase.  
To a clean pre labelled PCR tube 20µl of the above master mix was added 
together with 5µl of ligate and mixed gently. The tubes were placed in the PCR 
thermal cycler and the cycling conditions set as follows:  
 
 33 cycles: 
  95˚C 30 seconds 
  60˚C 30 seconds 
  72˚C 60 seconds  
 
Followed by  
  72˚C for 20 minutes 
  4˚C hold 
2.7.5 Separation of amplification products by electrophoresis 
  Following PCR, the products were separated on an ABI 3100 genetic 
analyzer. For each sample 1µl PCR product was mixed with 9µl deionized 
formamide and 0.1µl Genescan-500 ROX standard (Applied Biosystems, USA). 
The samples were run using the GeneScan POP 3100 module. 
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2.7.6 MLPA Data Analysis 
  Peak areas were exported to an Excel spreadsheet (Microsoft, USA), 
designed to assess the ratios of each test peak relative to all other peaks for that 
individual. Ratios of target peaks to other peaks in each patient sample were 
compared with the same ratios obtained for 2 healthy individuals, included in 
each run. For normal sequences, a dosage quotient of 1.0 is expected; if a single 
deletion or duplication is present the dosage quotient should be 0.5 and 1.5, 
respectively. For multiple duplications, each extra copy will increase the ratio by 
0.5, e.g. a triplication will have a relative ratio of 2. 
2.8  G-Banded review  
  The principle behind G-banding is that following enzymatic treatment or 
denaturation of metaphase chromosomes, application of Giemsa (a DNA specific 
dye) stains the chromosomes in such a way as to produce crossways patterns of 
light and dark bands. These bands are unique to each chromosome pair. They are 
thought to reflect the differences in base composition, replication time, chromatin 
conformation and gene density within the chromosome. The dark G-bands are 
rich in condensed heterochromatin, have a higher concentration of adenine-
thymine (AT) base pairs and are late replicating, whilst the pale or light bands 
have fewer condensed structures, a higher concentration of cytosine-guanine 
(CG) base pairs and are early-replicating. The pale areas are gene rich and so are 
transitionally more active than the dark bands (Czepulkowski, 2001). 
  Conventional cytogenetic analysis of the diagnostic bone marrow samples 
was carried out by the UK regional cytogenetic laboratories. Karyotypes, written 
according to the International System of Human Cytogenetic Nomenclature, 
were collected through the LRUKD and entered into the LRUKD database (ISCN, 
2005). G-banded slides from iAMP21 patients with an abnormal karyotype were 
requested, and the morphology of the dup(21) reviewed. Where possible the 
appearance of the dup(21) chromosome was observed in ≥ 5 abnormal 
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metaphases and classified into one of five groups (Table 1.3) based on their 
morphology. Karyograms were generated using MacKtype® software (Applied 
Imaging International, UK). Karyotypes of all iAMP21 patients were collected 
from the LRUKD database. 
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Chapter Three - Results 
 
 Results 
 
3 Results 
3.1  Identification of Patients to Include in Study 
3.1.1 Introduction 
  A review of the literature in which patients with iAMP21 were described 
(section 1.6.3) disclosed, that in the majority of studies, patients had been 
identified by chance, during screening for the ETV6-RUNX1 fusion using FISH 
probes specifically designed for this purpose. In those cases where RUNX1 copy 
number had been established, the number of  signals was ≥ 5, with three or more 
of the signals being localised to a dup(21) chromosome composed entirely of 
chromosome 21 material (Harewood et al, 2003;Soulier et al, 2003). In those 
patients with no metaphases available to confirm the presence of a dup(21), the 
RUNX1 copy number by interphase FISH was used to define the abnormality 
(Najfeld et al, 1998;Mikhail et al, 2002). In these cases it was usual to see the 
signals displayed in a characteristic cluster together with a single signal, 
assumed to represent the normal 21, located apart (Figure 3.1). To date, there are 
no reports of patients with ALL and amplification or over representation of 
chromosome 21 on a single marker chromosome, which do not involve 
amplification of the RUNX1 gene. However, it has not been clearly established if 
these were accurate findings or a reflection of selection bias, incurred by only 
selecting cases based on RUNX1 copy number. Therefore, before using these 
criteria to select the patients to be included in this research, it was important to 
determine that selection would not be biased by the use of FISH to select 
iAMP21, when there may be other cases with dup(21)/iAMP21 involving other 
regions of chromosome 21 amplification. To address this problem, patients not 
previously identified as iAMP21 were selected by their cytogenetic result, having 
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a distinctive marker chromosome and the associated loss of one copy of a normal 
chromosome 21. Their RUNX1 copy number was determined using FISH.  
 
 
 
Figure 3.1. Vysis LSI TEL-AML ES®. (a,b) Vysis LSI TEL-AML ES®  hybridised to 
interphase nuclei from patients 4623 and 3956, respectively. The RUNX1 (AML1) 
signals are red and the TEL (ETV6) green). The RUNX1 signals cluster in a 
distinct pattern with the normal chromosome 21 represented by a single red 
signal located apart from the cluster. (c) Probe on metaphase from patient 3368. 
The dup(21) and normal 21 are painted (yellow) with WCP 21. (d) Cosmid 
probes to RUNX1 exons 1-5 (ICRF C0664) and exons 5-7 (ICRF HO8116) on 
patient 7980. The RUNX1 exon signals (labelled red) are arranged in tandem 
along the dup(21). (e) Vysis LSI TEL-AML ES® probe design. Adapted from 
Robinson et al.(2007) 
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  One important consideration is that, although currently iAMP21 is 
defined by the presence ≥ 5 RUNX1 signals in interphase, not all patients with 
this copy number have iAMP21. Previous studies have shown (Moorman et al, 
2003;Sutcliffe et al, 2005;Heerema et al; 2007) that pentasomy of chromosome 21 
may occur in high hyperdiploid ALL, although to a much lesser extent than tri- 
or tetrasomy 21. Isochromosome 21 [i(21)(q10)] has been described in BCP-ALL 
at an incidence of 1.4% (Martineau et al, 1996). In these cases one copy of a 
normal chromosome 21 is replaced by an i(21)(q10) involving a duplication of the 
whole long arm of chromosome 21. Occasionally, the isochromosome is 
duplicated, resulting in pentasomy for 21q. In both of these cytogenetic 
subgroups, FISH with the RUNX1 probe will result in a copy number of 5 
signals. This raised the question: if cases with high hyperdiploidy, i(21)(q10) and 
those with additional copies of intact chromosome 21 with a RUNX1 copy 
number of ≥ 5 are excluded from the selection, are the remaining cases 
exclusively iAMP21? To address this issue, a number of cases previously 
screened with the Vysis LSI TEL-AML ES® probe were reviewed to establish the 
incidence of those cases with ≥ 5 RUNX1 signals and determine their karyotypic 
origin.  
3.1.2 Method 
  A retrospective search of the LRUKD cytogenetic database was 
undertaken in order to identify potential iAMP21 cases for study. As this 
abnormality has previously been associated with childhood ALL (Harewood et 
al, 2003;Soulier et al, 2003) , the search was initially restricted to patients 
registered to the childhood UKALL97 treatment trial. As none of the previously 
reported cases had included known recurrent chromosomal abnormalities, this 
was taken into consideration when designing the selection criteria. To ensure 
that cases were accurately identified, irrespective of their RUNX1 copy number, 
the search was divided into two phases: 
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1.  To identify patients with chromosome 21 abnormalities based on their G-
banded karyotype.  
o  They were selected if their karyotypes contained one of the 
following abnormalities:  
  -21, +mar 
  add(21) 
  dup(21)  
  der(21)  
o  They were excluded if they were:  
  high hyperdiploid 
  near haploid/low hypodiploid 
  i(21)(q10) positive by cytogenetics 
  ETV6-RUNX1 fusion positive 
  BCR-ABL1 fusion positive  
  Positive for a MLL gene rearrangement  
 
2.  To identify patients with additional copies of RUNX1 detected by FISH: 
o  Cases were selected if their interphase cells had ≥ 5 RUNX1 signals 
by FISH as well as having a successful karyotype.  
o  They were excluded if: 
  The RUNX1 copy number corresponded to the number of 
copies of chromosome 21, which would include high 
hyperdiploidy, near-haploidy, low hypodiploidy 
  The karyotype included an i(21)(q10) 
  They were  
  ETV6-RUNX1 fusion positive 
  BCR-ABL1 fusion positive  
  Positive for a MLL gene rearrangement 
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  Cases identified from Search 1 were further investigated by FISH with the 
LSI TEL-AML ES® (Vysis, UK) probe and chromosome 21 WCP to establish the 
copy number and chromosome location of the RUNX1 gene.   
  Prospective screening, using the selection criteria applied to Searches 1 
and 2, was carried out on new cases entered to the LRUKD database to increase 
the number of patients available for study.  
3.1.3 Results 
  Of 2094 cases registered to the childhood ALL treatment trial, UKALL97, 
and the LRUKD database, 2083 had a successful result from either G-banded 
analysis and/or FISH. Among these cases, 1205 had abnormalities of 
chromosome 21. Twelve patients were identified (Appendix 3, Table A3.1) with a 
marker associated with the loss of one copy of a normal chromosome 21. In six of 
these patients the description of the marker chromosome morphology in the 
karyotype was similar to that previously used to define iAMP21 (Table 3.1). In 
three of these patients (2647, 2904, and 3767), material was available to test for 
RUNX1 involvement. No slides were available for review on one case (5661) in 
which an add(21) had been described. In another patient (2647) two copies of a 
derivative chromosome 21 were present which had replaced the two normal 
copies of chromosome 21. In case 2848, previous studies had confirmed that the 
add(21) was composed entirely of chromosome 21 material using WCP 21; 
however insufficient material was available to test for the involvement of 
RUNX1. In case 5661, FISH confirmed RUNX1 amplification in interphase cells, 
although no metaphases were seen. In two cases (2848 and 2752) the involvement 
of RUNX1 could not be established. 
  FISH with the LSI TEL-AML ES® (Vysis, UK) probe indicated RUNX1 
involvement with ≥ 5 copies scored for all four patients.  
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Patient 
ID 
RUNX1  
copy No 
dup(21) 
morphology 
Abnormal Karyotype 
2647 7  SA  47,XY,+X,dup(21)(q11q22),dup(21)(q11q22)[7] 
2752 NM  LM 
46,XX,add(9)(q34),del(11)(q23),der(18),t(18;20) 
(q25;p1?1),der(20)t(11;20)(q?;p?),add(21)(q22)[3] 
2848 NM  SA  46,XY,add(21)(q11)[7] 
2904 9  LA  46,XX,del(7)(q22q32),add(21)(q22)[16] 
3767 5  LM  46,XX,+X,dup(21)(q?)[2] 
5661 5  NA  47,XX,+X,del(11)(q?),add(17)(q?),add(21)(q?),inc[cp10] 
4746 5  rea(21)* 
50,XY,+X,+14,der(20)t(20;21)(q13;q?),rea(21), 
+rea(21)x2[16] 
5047 5  add(21)  47,XX,+X,-8,-17,-17,add(21)(q?2),+3mars[cp5] 
 
Table 3.1 Karyotype, marker chromosome 21 morphology and RUNX1 FISH 
copy number of patients identified as being potential iAMP21 patients from 
the G-banded review. NM: no material. *Although rea is not a currently 
accepted ISCN abbreviation, it is used here as there is no other appropriate 
description for these chromosomes. 
 
  In the six patients not listed in Table 3.1, the morphology resembled a 
standard duplicated chromosome 21 in three patients, loss of chromosome 21 in 
two, and in a single case no slides or material were available to review.  
  Search 2 identified a total of 32 patients, of which 30 had been previously 
defined as iAMP21. In the two additional cases (4746 and 5057, Table 3.1), 
although the RUNX1 copy number was consistent with iAMP21, the signal 
location and the karyotype, in relation to chromosome 21, was not. These cases 
are described in more detail in section 3.3.2. 
3.1.4 Conclusion 
  Searching for patients with iAMP21 based on their G-banded morphology 
identified six patients. In four of these cases with material available, FISH 
detected RUNX1 amplification. In partial support of the abnormality being 
iAMP21 in one case with no available material, WCP 21 had previously shown 
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that the marker was composed entirely of chromosome 21 material. Although it 
was not possible to test all six cases by FISH, this study did not detect a marker 
chromosome 21 without RUNX1 amplification. These results, coupled with those 
of previous studies (Niini et al, 2000), established that RUNX1 is always 
amplified in iAMP21. Thus, we were able to conclude that selection of patients 
on the basis of RUNX1 copy number, using the criteria outlined above, was 
appropriate to identify cases in an unbiased fashion for inclusion in this study.  
  Screening for cases with ≥ 5 RUNX1 signals identified 30 patients 
previously defined as iAMP21 and two additional cases. These may represent 
morphological variants, as discussed under a separate heading (Section 3.3.2).  
3.2  Characterisation of the iAMP21 chromosomal abnormality 
3.2.1 Introduction 
  The characterisation of high-risk cytogenetic groups in ALL is important 
in order to ensure their correct classification and appropriate risk group 
stratification. Although the involvement of RUNX1 in iAMP21 patients has been 
clearly demonstrated by a number of studies (Section 1.6.3), the contribution of 
other genes located within the amplified region of the abnormal chromosome 21 
is unclear. Thus iAMP21 remains unclassified at the molecular level and the 
initiating mechanism is unknown. Previous reports (Le Coniat et al, 1997; Niini et 
al, 2000;Busson-Le Coniat et al, 2001) have demonstrated that regions both 
centromeric and telomeric of RUNX1 were also amplified. To investigate the 
extent of the chromosome 21 involvement in iAMP21, a profiling study was 
designed to screen a number of patients with probes spanning the length of 
chromosome 21 using a combination of FISH and BAC array comparative 
genomic hybridisation (BAC aCGH). The FISH profiles were qualitatively 
compared to those derived from complementary BAC aCGH.  
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3.2.2 Method 
  Ten patients, previously identified as iAMP21 with the commercial LSI 
TEL-AML1 ES® probes were selected. A further two BCP-ALL patients, one with 
tetrasomy of chromosome 21 in a high hyperdiploid karyotype and one with an 
apparently normal karyotype (6899, 6009, respectively) were included as control 
samples. BAC clones were selected to use as FISH probes which corresponded to 
those covering chromosome 21 in the 32k BAC aCGH system (Spectral 
Genomics, Genosystems®, France). This BAC array comprises twenty six clones 
located along chromosome 21q, starting at the centromeric genomic position of 
15.1Mb, terminating at the telomeric genomic position of 46.9Mb and spanning 
the chromosome bands 21q21-q22. The clones were positioned approximately 
1Mb apart. To allow direct comparison, 21 of the same BAC clones as spotted 
onto the arrays were used as locus specific FISH probes (Genosystems®, France) 
(Appendix 3, Table A3.2) to determine copy number changes along the length of 
chromosome 21. Two additional probes were included: a commercial 
chromosome 21q subtelomeric probe, Tel21q (D21S1446) (Molecular 
cytogenetics, Qbiogene®, UK), and the LSI TEL-AML1 ES® probe (Vysis, UK). 
These probes were selected to detect copy number changes in the subtelomeric 
region and at the RUNX1 locus of the derivative chromosome 21. The number of 
signals in interphase cells was recorded for each clone. Amplification was 
defined as ≥ 5 signals, whilst gain was defined as 3 or 4 copies. Where a range of 
signals was observed at any one clone position, the modal number was recorded 
and the range of signals noted. DNA was available to carry out BAC aCGH on 
seven patients. The BAC array work was carried out by Dr Jon Strefford, 
(Leukaemia Research Cytogenetic Group [LRCG]) as part of an ongoing 
molecular investigation of iAMP21 patients. A qualitative comparison of the 
profiles obtained from the two techniques was made. 
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3.2.3 Results 
3.2.3.1  Interphase FISH results 
  The results, recorded as the modal number of signals seen for each clone 
are displayed in Table 3.2. In all cases the most highly amplified region, referred 
to as the amplicon, included the RUNX1 locus. A minimal common region of 
amplification (CRA) of ~3Mb in size located to band 21q22 was defined for all 
patients, which included RP11-79A12 and the RUNX1 locus (genomic positions 
32.3 and 35.3Mb, respectively). In four patients (4405, 6788, 7219, 7255), the 
amplicon extended upstream and downstream to include, the BAC probes RP11-
80N20 and AF121782, (genomic positions 23.8 and 40.0Mb, respectively). Two 
amplicons were identified in patient 6092, positioned between the BAC probes 
RP11-97F14 and RP11-15H6, (genomic positions 22.9 to 31.4Mb) and RP11-191I6 
and AF121782, (genomic position 31.4 to 40.0Mb), respectively. Patient 6957 also 
had two amplicons positioned between RP11-88D18 and RP11-191I6, (genomic 
position 25.5 to 31.4Mb), RP11-79D9 and RP11-120C17, (genomic position 33.2 to 
41.7Mb). In patient 4134 three amplicons were detected positioned between 
RP11-15E10 and RP11-49B5 (genomic position 18.7 to 20.3Mb), RP11-97F14 to 
RP11-191I6, (genomic position 22.9 to 31.4Mb) and RP11-79D9 and RUNX1 
(genomic position 33.2 to 35.3). Within each of these three patients the amplicons 
were separated from each other by the gain or loss of one signal.   
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Bac Probe 
Clone 
Position 
Mb 
FISH 
  
Control 
patients 
      4405 4134  4279  5898  6092  6783  6788  6957 7219 7255    6009  6899 
AF127936 15.1  2  3  2  1  2  4  2  2  4  3    4  2 
RP11-15E10 18.7 3  5  Fail  1  2  2  2  2  4  1    4  2 
RP11-375O2 19.3  3  5  3  1  2  2  2  2  3  1    4  2 
RP11-49B5 20.3 3  5  4  1  2  2  3  2  5  3    4  2 
RP11-64I12 22.1 5  4  4  2  4  2  3  3  2  3    4  2 
RP11-97F14 22.9 5  5  4  3  6  2  3  3  3  3    4  2 
RP11-80N20 23.8  7  7  3  3  6  3  5  4  6  5    4  2 
RP11-13J15 24.1 7  7  3  3  5  3  5  4  5  6    4  2 
RP11-88D18 25.5  7  5  4  3  5  2  5  5  5  5    4  2 
RP11-15H6 26.7 8  5  4  3  6  3  5  5  6  7    4  2 
RP11-90A17 27.7 10  8  4  4  4  3  7  6  8  6    4  2 
RP11-79G23 29.3  9  5  5  5  4  2  6  5  6  7    4  2 
RP11-30N6 29.7 8  5  5  5  4  2  5  5  6  6    4  2 
RP11-191I6 31.4 8  5  5  5  6  3  5  5  7  7    4  2 
RP11-147H1 32.3 10  4  5  5  6  5  5  4  6  7    4  2 
RP11-79D9 33.2  10  5  5  5  5  4  5  5  7  6    4  2 
RP11-79A12 34.7  9  8  5  5  6  5  5  5  6  7    4  2 
RUNX1  35.3  10  8  5  5  6  5  5  5  8  10   4  2 
AF121782 40.0  5  3  5  5  6  3  5  5  4  8    4  2 
RP11-114H1 41.2  1  1  5  4  2  4  5  5  1  2    4  2 
RP11-120C17 41.7  1  5  4  5  2  4  5  5  1  2    4  2 
RP11-88N2 43.7 1  3  1  1  2  4  5  4  1  2    4  2 
21qtel 
D21S1575 
46.9 
1  1  1  1  2  2  3 
 
1  1  2 
  
4  2 
 
Key  Deletion :1 Normal : 2 Gain : 3-4 Amplification : >5  
Table 3.2 Copy number changes detected by interphase FISH screening along 
the length of chromosome 21 in ten iAMP21 patients and two control patients 
(6899, 6009). Columns represent patients and rows represent the individual 
probes. Probes run from top to bottom in a centromeric to telomeric direction. 
Copy number is expressed as the modal number for each location. 
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  The largest amplicon (~22.5Mb) was seen in patient 6788, where it 
extended from BAC probe RP11-80N20 (genomic position of 23.8Mb) 
downstream to RP11-88N2 (genomic position 43.7Mb). The smallest amplicon 
(~1Mb) was seen in patient 6783, running from clone RP11-79A12 (genomic 
position of 34.7Mb) downstream to the RUNX1 locus (genomic position 35.3Mb).  
  The control patients 6009 and 6899 showed a consistent copy number 
change at each BAC clone location. In patient 6899, two copies of each clone were 
found, whilst in the patient with high hyperdiploidy (6009), the copy number 
observed was 4. In both patients the results were consistent with the number of 
chromosomes 21 observed in their diagnostic karyotype (Table 3.5). 
  When the signals were numerous their distribution in interphase was such 
that they were often in close association making accurate enumeration difficult. 
In a number of cells the signals appeared as doublets, if the distance between 
these two signals was smaller than the estimated diameter of an individual 
signal, they were counted as one. For the 12 patients tested, FISH was successful 
for 23 probes. One clone, RP11-15E10, failed in one patient (4279). The range of 
signal numbers (excluding the normal copy number of 2) was recorded for the 
probes that corresponded to those areas defined as amplified. At the locations 
where a gain was noted, the range was substantially lower, whilst in those 
regions with a deletion, in only two patients (6783 and 7219) was a range of 
signals (1-3) noted (Appendix 3, Table A3.3). 
  Gain of signals was seen within the region centromeric to the amplicon in 
all patients. Deletions in this region were also recorded for patients 5898 and 
7255. In three patients (4279, 6957 and 6783) a gain of signals was seen 
downstream of the amplicon. 
  A deletion of the 21q22.3 subtelomeric region was observed in seven of the 
ten cases (4405, 4134, 4279, 5898, 6783, 6957, and 7219). Although the size of the 
deletion was variable between patients, it was possible to define a minimum 
common region of deletion (CRD) at the site of the subtelomeric probe. In three 
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patients (4134, 4279, 5898), the deletion extended upstream to include the RP11-
88N2 clone, at genomic position 43.7Mb, providing evidence of a deletion of 
~3.5Mb in size. In two patients (4405, 7219) the deletion was further extended 
and included clones RP11-120C17 and RP11-114H1, at genomic positions 41.2 
and 41.7Mb, respectively. The smallest deletions in this region were seen in 
patients 4134, 6783 and 6957, with only the subtelomeric clone missing. Patients 
6783 and 7219 had mixed populations of cells with some appearing to harbour a 
deletion, whilst others showed gain of the subtelomeric probe indicating the 
presence of different populations.  
  The degree of amplification, as established by signal copy number, was 
variable both within and between patients. The highest frequency of 
amplification was consistently observed in the minimal CRA for all patients, 
which encompassed the RUNX1 locus, with copy numbers ranging from 5 to 14.  
3.2.3.2  BAC array CGH results 
  The results obtained from BAC aCGH are displayed in Table 3.3. 
Successful array profiles were obtained for all samples tested (Appendix 3, 
Figures A3.1). Control samples 6009 and 6899 showed consistent copy number 
changes at each location. In sample 6009, (high hyperdiploidy) a ratio of 1.5-2.0 
was recorded for each clone, whilst in the sample from the patient with a normal 
karyotype (6899), a ratio of 1 was recorded at each location. Imbalances were 
observed for all seven iAMP21 patients, with each one showing a unique profile. 
A minimal CRA (defined as an area with the highest level of gain) was recorded 
at the genomic position of 35.5 Mb, corresponding to the RUNX1 locus in all 
patients.  Results 
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   4279  5898  6783  6788 6957 7219 7255     6009 6899 
15.1  2  1 4 2  2 4 3     4  2 
15.7                               
18.7     1  2  2  2 4 1     4  2 
19.3  3  1  2  2  2  3  1     4  2 
20.3  4  1  2  3  2  5  3     4  2 
21                               
22.1  4  2  2  3  3  2  3     4  2 
22.9  4  3  2  3  3  3  3     4  2 
23.8  3  3  3  5  4  6  5     4  2 
24.1  3  3  3  5  4  5  6     4  2 
25.5  4  3  2  5  5  5  5     4  2 
26.7  4  3  3  5  5  6  7     4  2 
27.7  4  4  5  7  6  8  6     4  2 
29.3  5  5  2  6  5  6  7     4  2 
29.7  5  5  2  5  5  6  6     4  2 
31.4  5  5  3  5  5  7  7     4  2 
32.3  5  5  5  5  4  6  7     4  2 
33.2  5  5  4  5  5  7  6     4  2 
34.7  5  5  5  5  5  6  7     4  2 
35.3                          4  2 
40  5  5  3  5  5  4  8     4  2 
41.2  5  4  4  5  5  1  2     4  2 
41.7  4  5  4  5  5  1  2     4  2 
43.7  1  1  4  5  4  1 2     4  2 
46.7                               
46.9  1  1 2 3  1  1 2     4  2 
 
Table 3.3 Combined BAC aCGH and interphase FISH data. Columns represent 
patients and rows represent BAC clones with their genomic positions indicated 
from centromere to telomere. For clone names refer to Appendix 3, Table A3.2. 
BAC array data are represented by coloured boxes (see key). FISH copy number 
data, expressed as a mode are shown as a numeric within the boxes. 
 
Key Fail  Deletion  Normal  Gain  Amplification 
High 
Amplification 
Ratio     < 1  1  1-1.5  1.5-2.0  2.0-4.0 
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  A further two common regions of gain were recorded at genomic 
positions 23.8 Mb and 26.7 to 27.7Mb, which were seen in all patients. The overall 
level of gain was less in these two areas than the minimal CRA (ratio values of 1-
<1.5 and 1.5->2.0).  
  Deletions in the telomeric region were found in three patients, whilst in a 
further three patients the array failed to produce a result for this locus. The size 
of the amplicon was variable between patients. The largest amplicon was found 
in patient 6788 and extended from genomic position of 23.8Mb through to the 
telomere, whilst the smallest amplicon was detected in 6783 where the areas of 
highest amplification was found at genomic position 35.3-43.7Mb. The profiles 
from the FISH and BAC aCGH were compared. The variation in copy number 
observed by FISH along the length of 21q in all seven patients reflected the BAC 
aCGH profiles at locations distal to and including the clone at 23.8Mb. Both 
techniques detected the same copy number imbalances, demonstrating a high 
concordance between the two methods, as demonstrated in Figure 3.2.  
  Discrepant results were noted at 22.1Mb and 22.9Mb for four patients 
(4279, 6783, 6788 and 6957). In all four patients the copy number recorded by 
FISH was greater than that seen with BAC aCGH. In patient 5898 discrepant 
results were seen at clone positions 22.1Mb and 24.1Mb with FISH recording a 
normal copy number change in comparison to a BAC aCGH gain and a gain of 
copy number in comparison to a BAC aCGH normal, respectively. Results 
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Figure 3.2 Combined BAC aCGH and interphase FISH from patient 5898. (a) 
BAC aCGH result with BACs positioned from left to right, centromere to 
telomere. Dye swap experiments are shown by red and blue lines. A deviation of 
>1 shows loss or gain of material. FISH confirmation of each circled area using 
interphase FISH is illustrated in (b), with the corresponding copy number found 
at each site shown in (c). Adapted from Strefford et al (2006)   
 
3.2.4 Conclusion 
  In this direct comparison between FISH and aCGH, the relative 
advantages of these techniques in the investigation of iAMP21 became apparent. 
As aCGH employs a whole genome approach, the full extent of the chromosome 
21 involvement was revealed. Although conventional cytogenetic and FISH 
techniques had originally identified iAMP21, they had failed to precisely define 
the level and extent of the intrachromosomal imbalances within iAMP21. FISH 
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and aCGH are able to detect copy number change, but one disadvantage of FISH 
is that it is time consuming, especially in terms of whole genome coverage.  
  Array CGH has been successfully employed in a number of studies of 
haematological malignancies to identify disease specific copy number changes. 
There are a number of different platforms available and each one is able to 
provide different levels of performance depending on its application (Pinkel & 
Albertson, 2005;Parker et al, 2008). The 32K BAC array employed in this 
investigation successfully identified regions of gain and loss, but was limited in 
providing precise data with regards to boundaries of deletion or amplification. 
High resolution arrays, such as the Agilent 244K Oligonucleotide array 
subsequently used to further characterise iAMP21, identified the distinct pattern 
of ‘step wise’ gain seen along 21q in these patients (Strefford et al, 2006). It is 
known that smaller array elements can provide higher genomic resolution when 
looking at multiple copy aberrations, however they are more sensitive to 
background noise (Pinkel & Albertson, 2005). Discrepant results were recorded 
at a number of sites when compared directly to the FISH result. Interphase FISH 
screening provides an accurate reflection of copy number for any one specific 
probe providing that the region of interest has not been rearranged in such a way 
as to cause the probe to split. It is the current gold standard employed to detect 
copy number change at individual loci.   
  The discrepancies seen in this study may be due to poor hybridisation of 
the aCGH slides, or a reflection of the difficulty in the interpretation of the 
fluorescence ratios, when considering deviation from the expected values by loss 
or gain of a single copy. It may be a reflection that the two probes sourced from 
different laboratories do not cover complementary regions. Lastly, it may be that 
the contaminating normal cells within the bone marrow sample from which the 
DNA was extracted may reduce the overall level of amplification, which would 
have more effect on small genomic regions. 
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3.2.5 Combined FISH and G-banded Study 
3.2.5.1  Introduction 
  The combined results of interphase FISH and BAC aCGH on a series of 
iAMP21 patients pointed to a highly complex chromosome 21 abnormality in 
these patients with each case having a unique genomic profile. A region of 
gain/amplification between genomic position 24.1 (band 21q21) - 40Mb (band 
21q22) and a region of deletion located at the subtelomeric region of chromosome 
21, were identified.  Regions with high copy number changes often harbour 
genes of interest, consequently it was important to establish whether this region 
was common to a larger group of patients. 
  An earlier study (Harewood et al, 2003) grouped patients according to the 
morphological form of the dup(21) using conventional cytogenetics, implying 
common chromosomal features between patients. This appeared to contradict 
the findings from FISH and BAC aCGH showing unique patient profiles. 
Although the interpretation of marker chromosomes from G-banded analysis is 
limited due to both low resolution and the lack of recognition of specific 
chromosomal landmarks, it seemed unlikely that each patient within any one 
morphological group would have a unique profile. As the initial FISH and aCGH 
study was carried out on only ten patients, it could not be ruled out that the 
findings were a reflection of the differences in the G-banded form of the dup(21) 
chromosome rather than each patient having a truly unique profile.   
   In order to further investigate these observations as well as to characterise 
this abnormality in a larger group of patients, an expanded FISH study was 
undertaken. This was appropriate as the only material available was fixed cells. 
The aims of this second FISH investigation were to: 
 
  Determine whether the minimal CRA established from the preliminary 
study was consistent among iAMP21 patients  
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  Establish the incidence and extent of the deletion involving the 
subtelomeric region of the dup(21) 
  Investigate the relationship between the amplicon size and G-banded 
morphology 
3.2.5.2  Method 
  A combinatorial approach, using both interphase and metaphase FISH 
together with conventional G-banded cytogenetics of the same sample, was 
considered to be the most suitable method of investigation. Rather than 
screening all patients with each of the BAC clones used in the previous study, 
five of these probes (BAC LSI probes, Genosystems®, France) were selected 
together with the Vysis LSI TEL-AML1-ES® probe and the 21q subtelomeric 
probe-Tel21q (D21S1446) (Molecular cytogenetics, Q-BIOgene®, UK). The BAC 
clones were located along 21q, with three clones positioned centromeric to 
RUNX1 and two clones telomeric (Figure 3.3). They were chosen to represent 
those areas, either side of the previously identified minimal CRA, which had 
been shown in the preceding study to be gained/amplified or lost. As with the 
initial study, dual probe, dual colour experiments were carried out, with the 
same probe combinations being used on all patients. Probes RP11-147H1 (C), 
RP11-30N6 (B) and AF121782 (E) labelled with Spectrum red were combined 
with RP11-13J15 (A), RP11-88N2 (F) and Tel21q (D21S1446) (G) labelled with 
Spectrum green, respectively. The Vysis LSI TEL-AML1-ES® (D) probe was 
hybridised as a single experiment. Copy number was determined by counting, 
where possible, the number of signals in 50 abnormal interphase cells. In 
addition to the ten patients initially screened a further 38 iAMP21 patients were 
selected based on the criteria outlined in section 3.1. 
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Figure 3.3 The chromosomal band locations and genomic positions of the LSI 
BAC FISH probes. The red and green boxes on the chromosome 21 ideogram 
indicate the labelling of the probes with either Spectrum red or green. Interphase 
nuclei from patient 4444 displaying the BAC probe signals are shown for (a) 
probes A and C, (b) B and F, (c) E and G. 
Key to probes: A = RP11-13J15, B = RP11-30N6, C= RP11-147H1, D= RUNX1, E= 
AF121782, F = RP11-88N2, G= Tel21q (D21S1446). Adapted from Robinson et 
al(2007). 
 
 
 
  The previous FISH study had demonstrated that in the majority of 
patients the amplicon appeared to be continuous. So for the purpose of this 
study, if amplification was noted at two consecutive sites, it was assumed that 
the area between these points was also amplified. 
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3.2.5.3  Results 
24.1 29.8 32.3 35.5 40.0 43.7 46.9
ABCDEFG
RP11-
13J15
RP11-
30N6
RP11-
147H1
RUNX1 AF121782
RP11-
88N2
21qtel
3131 LM 5 3.5 6.5 5.5 4.5 5 3.5
5754 LM 3 6.5 5.5 5.5 5 6.5 1
5898 LM 3555411
6020 LM 3 4 . 5 76411
6788 LM 4.5 4 4.5 4 5 4.5 4
6957 LM 44 . 556 . 55 5 1
7045 LM 56 6 . 5 6 . 5 661
7829 LM FAIL 6.5 FAIL 7.5 7.5 1 1
3956 LA 5 6 . 5 6 . 5 8761
4134 LA 6.5 5 5 5.5 3.5 3 1
4178 LA 4.5 6.5 7 7 7.5 1 1
4623 LA 2 477 7 . 5 11
6008 LA 555 7 . 5 6 . 5 11
6783 LA 3 2 55342
6937 LA 2 4.5 7.5 8.5 8 1 1
7219 LA 6667 4 . 5 11
7255 LA 63 . 597 . 5 6 . 53 2
8743 LA 4544 4 . 5 4 . 5 1
2776 R 33357 6 . 5 1
3743 R 22 4.5 5.5 4.5 5 3
3970 R FAIL 3.5 FAIL 4.5 6.5 1 1
4405 R 688 6 . 5 6 . 5 11
4444 R 5 5 5 5.5 7 6.5 1
5607 R 62 . 56 5 FAIL 5.5 FAIL
5674 R 15 FAIL 76 . 51 1
5809 R 34 6 . 5 7611
7583 R 33 4 . 5 54 4 . 5 1
7650 R 4 . 5 577611
3527 SA 3 3.5 4.5 4.5 3 22
4780 SA 2 44 . 552 . 522
3745 SM 6 . 5 4 . 5 77561
4135 SM 7 6 6 7.5 6.5 4.5 1
4237 SM 7 6 6.5 6.5 6.5 6 1
4279 SM 3.5 4.5 5.5 6.5 4 1 1
5655 SM 531 5 . 5 4 . 5 11
6868 SM FAIL 7 FAIL 7 FAIL 7 FAIL
4316 n/a FAIL 3 FAIL 44 . 53 3
5858 n/a 3.5 6 6 6 6.5 4 4
6092 n/a 53 . 566 . 55 22
6111 n/a FAIL FAIL FAIL 7 FAIL FAIL 1
6996 n/a 7 FAIL 9 10.5 8.5 1 1
7024 n/a 3.5 1 4.5 6 7.5 1 1
7093 n/a 4667611
7100 n/a 3 3 . 5 4 . 5 5332
7732 n/a 34 FAIL 5 . 5 651
7828 n/a 56 . 58 66 . 51 1
8767 n/a 355 5 . 5 611
8983 n/a 61 FAIL 6.5 FAIL 11
Key Fail Deletion Normal Gain
Patients dup(21)
Amplification  
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Table 3.4 Interphase FISH screen of 48 iAMP21patients. Columns represent 
probes and rows represent patients. The results are grouped according to the 
morphology of the dup(21) (column 2). The boxes relate to the results from 
individual probe hybridisations for each patient (columns A-G). The numbers 
indicates the mean copy number for each probe. 
Key: LM= large metacentric; LA=large acrocentric; R=ring; SA=small acrocentric; 
SM= small metacentric; n/a= not available.  
F=Fail; D=deletion (1 copy); N= Normal (2 copies), G=Gain (3-4 copies); A= 
Amplification (> 5 copies). 
 
3.2.5.3.1  Interphase FISH 
  The FISH screening results for all 48 iAMP21 patients are displayed in 
Table 3.4. Patients previously defined as iAMP21 are ordered according to the 
morphology of the dup(21) (section 1.6.3) and the number of signals in 50 
abnormal cells is recorded as a mean. FISH for at least two probes was successful 
on all patients, with 38 patients having a successful result with all seven probes. 
The size of the amplicon (extent of dark green in Table 3.4) and the degree of 
amplification (number of signals) was highly variable, with each patient 
exhibiting a unique pattern of imbalance (Appendix 3, Table A3.4). In 25 (66%) of 
those patients with successful FISH, the size of the amplicon was comparatively 
large (≥ 10.2Mb), in agreement with the results of the initial study. In every case 
the amplicon included the RUNX1 locus and, in the majority of cases, extended 
~2Mb proximally to include the BAC probe RP11-147H1, genomic position 
32.2Mb, and ~5Mb distally, to include AFA121782, at genomic position 40.0 Mb 
(Table 3.4). This confirmed the location of the minimal CRA to band 21q22.1.   
  The level of amplification as determined by copy number was variable. A 
comparison between the level of amplification (as measured by mean copy 
number) and probe position showed that for all patients the highest levels were 
recorded for the RUNX1 locus. In two patients (5858, 6996) interphase FISH 
showed two clusters of signals together with a single signal at a different location 
in the cell. This indicated that there might be two copies of the dup(21) and a 
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normal chromosome 21 present. No metaphases were available to confirm these 
findings.  
   A deletion of the subtelomeric clone was observed in 35 (76%) of the 46 
iAMP21 patients with a successful FISH result for this probe. In 20 (59%) of these 
patients the deletion extended proximally to include BAC RP11-88N2, genomic 
position 43.0Mb, so confirming the minimal CRD of 3.5Mb, found in the previous 
study. In six patients normal copy number was noted for this region, whilst in 
four (3743, 3131, 4316, 5809) a gain was observed.  
  In four patients (5655, 5674, 7024, 8983) deletions were noted at sites 
centromeric to RUNX1. There was no common region of deletion in these areas. 
3.2.5.3.2  Amplicon Size and dup(21) morphology 
  A comparison between the size and location of the amplicon and the 
dup(21) morphology is shown in Figure 3.4. Apart from the small acrocentric, 
group it was not possible to associate a particular dup(21) morphology with a 
particular level or region of amplification. Patients with large acrocentric (LA) 
marker chromosomes had amplicons that spanned large regions of 21q 
(Appendix 3, Table A3.5). The exception to this was patient 6783, for which the 
G-banded morphology of the chromosome resembled that described as a large 
metacentric (LM), although the FISH amplicon size was small. Detailed results 
from karyotyping studies on this patient are given in section 3.5.3.  
  The size of the amplicon in the other morphological groups was also 
extensive, reflecting the substantial size of the G-banded forms of the dup(21) in 
comparison to a normal chromosome 21. The level of amplification and the size 
of the amplified region in the two patients with a small acrocentric morphology 
(SA) were similar to each other, and smaller than seen in other patients. Neither 
case had a deletion of the subtelomeric probe. Among the group of patients with 
a failed G-banded cytogenetic result, FISH profiles similar to those seen for all of 
the subgroups were noted. 
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Figure 3.4 Amplicon size as determined by FISH compared to the G-banded 
morphology of the dup(21). Vertical lines to the right hand side of the ideogram 
represent the size and location of individual patient amplicons. Coloured bars on 
chromosome 21 ideogram represent the probe location, which is the same as 
shown in Figure 3.3. 
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3.2.5.3.3  dup(21) G-banded review 
  A direct comparison of the G-banded morphology of the dup(21) 
chromosomes within each of the morphological subgroups is shown in Figure 
3.5. Although the morphological description was correctly assigned, it was 
obvious from this visual comparison that the dup(21) morphology was also 
different between patients in each group so providing further support for a 
unique profile.  
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Figure 3.5 G-banded morphology of dup(21) chromosomes from 28 iAMP21 
patients. The chromosomes are ordered in rows according to the G-banded 
morphology group to which they were assigned. A normal chromosome 21 is 
shown in the box in the bottom right. *G-banded form of dup(21)(q) from patient 
6783, identified as a der(15;21)dup(15;21) (Section 3.5.3). 
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3.2.5.4  Conclusion 
  Analysis of a large group of iAMP21 patients using interphase FISH and 
conventional cytogenetics has confirmed the variability seen by more detailed 
FISH and aCGH as described in the previous section. Each patient was found to 
have a unique genomic profile by FISH. Detailed analysis of the G-banded forms 
of the dup(21) chromosomes in any one morphological group concurred with 
this observation. The size of the amplicon was relatively large in most patients 
and the region with the highest levels of amplification was located to band 
21q22, which included the RUNX1 locus in all patients. Deletions of the 
subtelomeric region were found in 76% of the patients analysed. G banded 
review illustrated the morphological form of the dup(21) chromosome was 
variable within any one morphological group. This provided supporting 
evidence of the unique profiles observed by FISH and BAC aCGH.  
3.2.6 Metaphase FISH 
3.2.6.1  Introduction 
  Although interphase FISH and BAC aCGH are able to provide sensitive 
and reliable information for the analysis of copy number changes at the 
molecular level, neither technique is able to provide information about structural 
rearrangements at the chromosomal level in relation to these changes. Interphase 
FISH and aCGH indicated that each iAMP patient had a unique profile and 
review of the G-banded morphology of the dup(21) supported these findings. 
The results implicated that this abnormality was highly complex and may have 
arisen from mechanisms other than straight forward duplication and deletion. 
Metaphase FISH mapping was undertaken in five cases, using the same probes 
as described in section 3.3.2, to determine the complexity of the rearrangements 
giving rise to the dup(21) chromosome. In 76% of patients a deletion of the 
subtelomeric region had been found by interphase FISH. Studies in animal 
models have shown that the shortening of telomeric DNA repeats (Gisselsson et 
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al, 2001) can lead to loss of the protective proteins from the chromosome ends, 
which in turn can lead to the formation of ring chromosomes. In order to 
establish whether the loss of subtelomeres resulted in the formation of ring 
chromosomes in iAMP21 patients, further FISH investigations were undertaken 
using probes to span the telomeric repeat sequences found in all chromosomes. 
3.2.6.2  Method 
  In five cases (3131, 3956, 4623, 6937, and 6788), metaphase FISH with 
seven LSI probes as shown in Figure 3.3, was carried out. For each probe, 
different chromosomes were analysed, as sequential FISH with probes located 
too close together was difficult to interpret. For each patient, a comparison of the 
location of each probe was made in relation to the other probes. This was limited 
to a certain extent by the low resolution resulting from the contracted 
morphology of chromosomes in the leukaemic cells. Dual probe, dual colour 
experiments were carried out, with the same probe combinations being used, as 
previously described in Section 3.3.2 : probes RP11-147H1 (C), RP11-30N6 (B) 
and AF121782 (E) labelled with Spectrum red were combined with RP11-13J15 
(A), RP11-88N2 (F) and Tel21q (D21S1446) (G) labelled with Spectrum green, 
respectively. The Vysis LSI TEL-AML1 ES® (D) probe was hybridised as a single 
experiment. The same five cases were screened with PNA telomeric probes to 
detect common telomeric sequence found on all chromosomes. This was then 
followed by sequential FISH using WCP21 to confirm the dup(21). 
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3.2.6.3  Results 
AB C E F G D* AB C E F G D*
 
 
Figure 3.6 Metaphase FISH and G-banded appearance of the dup(21) from five 
iAMP21 patients. The chromosomal band locations and genomic positions of the 
LSI probes, A-G is shown in the chromosome 21 ideogram (as Figure 3.3). The 
red and green boxes indicate the labelling of the probes with Spectrum red and 
green, respectively. The patients are arranged in rows, whilst the probes are 
arranged in columns: LSI probes A-G, and G-banded morphology. (Key Probe: as 
for Figure 3.3) 
 
  In all patients the location of the probe signals confirmed that they were 
restricted to the normal and dup(21) chromosomes and not translocated to other 
regions of the genome. The normal chromosome 21 showed a single copy of each 
probe in the appropriate location. There was extensive heterogeneity with regard 
to number, location, size and intensity of probe signal on the dup(21). This 
variability was further emphasised when comparisons were made between 
patients, with no two patients displaying the same profile. A significant finding, 
F
A
B
C
D*
E
G
G-band
3131
6788
4623
6793
3956
G-band
3131
6788
4623
6793
3956
F
A
B
C
D*
E
G
  103Results 
was that in all patients the signals were located in unexpected patterns on the 
dup(21), indicating that complex rearrangements involving a number of 
chromosomal breaks must have occurred.   
  In case 3131 (Figure 3.6), the dup(21) morphology was that of a large 
metacentric chromosome. Detailed FISH mapping showed that there were four 
copies of probe A (RP11-13J15), but only two copies of probe B (RP11-30N6). The 
orientation of these probes relative to each other provided evidence of an 
inversion in each arm of this chromosome, with probe B being located between 
the two copies of probe A. Multiple copies of probes C, D, and E (RP11-147H1, 
RUNX1, AF121782) were distributed in a ladder like fashion along the length of 
the dup(21), signifying numerous breaks had also occurred within these regions. 
In case 3131, there was evidence of an inversion, the location of probe C (RP11-
147H1) was proximal to probe A (RP11-13J15) when it should have been in a 
distal position. The two copies of the subtelomeric probe G, were located to the 
centre of each arm of the dup(21), whilst probe F (RP11-88N2) was located in a 
position distal to this, providing evidence of another inversion. In case 6788, also 
described as a large metacentric chromosome, the distribution of the probes was 
uneven between the two chromosome arms. The signal distribution pattern in 
the large acrocentric chromosomes from cases 4623 and 6793 were similar to each 
other. In both cases, it was noted that the size and signal intensity of one of the 
two copies of probe B (RP11-30N6) was larger and more intense than the same 
probe located at a position proximal to this, suggesting localised amplification of 
this region. In both cases deletions of probes F (RP11-88N2) and G (subtelomeric 
probe) were found. Detailed analysis of the large acrocentric case 3956 showed 
that the dup(21) composition was different from the two other large acrocentric 
cases. Probe F was positioned in the centre of the dup(21), the size of the signal 
was larger than that seen on the normal 21, providing evidence of amplification 
at this site. In all five patients the probes within the amplicon, as defined by 
interphase FISH (Section 3.3.3.1) probes C,D and E (RP11-147H1, RUNX1, 
  104Results 
AF121782, respectively) were distributed along the length of the chromosome in 
a ladder like fashion. Studies with PNA telomere probes (Appendix 3, Figure 
A3.2) showed that in all patients, investigated telomeric sequences were present 
on the dup(21) chromosome. 
3.2.6.4  Conclusion 
  The signal pattern arrangement in all five cases was highly complex, 
indicating that the dup(21) chromosomes resulted from complex 
intrachromosomal rearrangements, involving multiple chromosome breaks, 
duplications and inversions. In all patients investigated evidence of telomeric 
sequence was present indicating that in these patients the dup(21) chromosome 
was not a ring chromosome.  
3.2.7 mBAND 
3.2.7.1  Introduction  
  Previous studies carried out on solid tumours have shown that recurrent 
chromosomal breaks on amplified chromosomes can highlight the genes 
involved at these locations and so provide information with regards to the 
pathogenic event leading to malignancy (Albertson, 2006). Although metaphase 
FISH mapping indicated the presence of inversions, duplications and deletions 
along the dup(21), the approach was limited as it was difficult to visualize 
accurately the location of all probes relative to each other. It was anticipated that 
the use of multicolour banding (mBAND), which provides simultaneous 
visualisation of all regions of the dup(21), may reveal aberrations not visible by 
other methods and allow further investigation of common regions of interest on 
the dup(21). mBAND FISH was undertaken on the same five iAMP21 cases as 
the FISH mapping (Section 3.3.5.2). 
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3.2.7.2  Method  
  XCyte 21 chromosome paint was hybridised to the five patients 
previously studied in section 3.3.5.2 and compared to the G-banded morphology 
and metaphase FISH with the locus specific probes. 
 
3131 6788 4623 6793 3956 3131 6788 4623 6793 3956 3131 6788 4623 6793 3956 3131 6788 4623 6793 3956 3131 6788 4623 6793 3956 3131 6788 4623 6793 3956 3131 6788 4623 6793 3956 3131 6788 4623 6793 3956
 
 
Figure 3.7 mBAND and G-banding patterns from five iAMP21 patients. a) 
Normal chromosome 21 mBAND and G-banding. b) dup(21) mBAND pattern 
and G-banded morphology of five iAMP21 cases.  
 
3.2.7.3  Results 
  mBAND FISH with the XCyte21 chromosome paint (Figure 3.7) showed 
considerable variation in the mBAND pattern between dup(21) chromosomes 
from the five different cases. The banding pattern along the length of the 
dup(21), indicated by the size of the coloured bands and their distribution, 
confirmed the presence of some of the complex intrachromosomal exchanges 
seen also by the LSI probe mapping (Section 3.3.5). In all cases the mBAND 
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indicated amplification within band 21q22, genomic position ~29-40Mb, 
represented by the yellow/green colour. There was evidence of large inversions 
with the banding patterns indicating telomeric regions (green) located to the 
centromeric areas (case 6788).  
  A comparison between the mBAND patterns of chromosomes within the 
same G-banded morphological group showed different patterns. Cases 4623, 
6793 and 3956 were all classified as having a large acrocentric (LA) morphology 
by G-banding, but in all three cases their mBAND patterns were different.  
3.2.7.4  Conclusion 
  The use of mBAND FISH verified the complexity of the dup(21) 
chromosome in iAMP21 patients. Clear evidence of large inversions, duplications 
and amplification were observed. However, the resolution of the banding was 
limited, making breakpoint assignment impossible. This is likely a reflection of 
the design of the Xcyte 21 paint. As chromosome 21 is very small, the paint is 
composed of only two probes. Consequently the location of a fluorochrome to a 
specific region may result from a duplication/amplification of the region where 
the fluorochromes overlap, or an inversion of one fluorochrome into a different 
region so making precise interpretation difficult. Nevertheless, comparison 
between different cases provided further evidence for the unique structure of the 
dup(21) chromosomes, confirming the results of the FISH and aCGH.  
3.2.8 Karyotype Review 
3.2.8.1  Introduction 
  Conventional chromosomal analysis remains the method of choice for the 
initial detection of cytogenetic abnormalities in leukaemic samples. The most 
relevant abnormalities are considered to be the primary events and are thought 
to reflect the initiation of tumour development, whilst secondary changes reflect 
karyotypic evolution or tumour progression (Mitelman et al, 2007). Although 
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previous studies (Soulier et al, 2003;Harewood et al, 2003) had failed to detect 
other consistent chromosomal changes other than dup(21) in patients with 
iAMP21, it was important to establish whether it represented the primary 
cytogenetic event.  
3.2.8.2  Method 
  Karyotypes from 36 iAMP21 patients with an abnormal cytogenetic result, 
for which G-banded slides were available for review, were studied to determine 
the presence of common chromosomal changes in addition to dup(21). FISH data 
was also available from routine screening carried out in the UK regional 
cytogenetics laboratories to indicate the presence of significant abnormalities: 
namely ETV6-RUNX1, BCR-ABL1 and MLL rearrangements, as well as other 
changes involving these loci (Harrison et al, 2005). 
3.2.8.3  Results 
  The karyotypes are displayed in Table 3.5. The chromosomal complement 
in all patients was near diploid, with a modal number of 45 to 47 chromosomes, 
apart from a single case in which the modal number was 48 (7829). In patient 
3131, a subclone with 51 chromosomes was observed. A pseudodiploid 
karyotype was seen in 18 patients. In all patients the dup(21) replaced one copy 
of a normal chromosome 21, which in seven cases was the sole visible 
chromosomal abnormality. Gain of an X chromosome was observed in nine 
cases, which was the only recurrent associated abnormality distinguished by 
conventional G-banding.  
  The results of breakpoint analysis of both conventional G-banding and 
routine FISH are displayed in Figure 3.8. No consistent change was found 
amongst all cases, although breaks at chromosome band 7q22, 12p and 15q2 were 
detected in five, four and four patients, respectively. FISH with the LSI TEL-AML 
ES® probe identified five cases with a deletion of one copy of the ETV6 gene and 
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six cases had loss of one copy of the MLL gene at 11q23. In one patient a 
constitutional Robertsonian translocation, der(15;21)(q10;q10), was observed. 
 
 
 
Figure 3.8 Diagrammatic representation of the distribution of breakpoints in 
iAMP21 patients, as determined from G-banded (blue triangle) and interphase 
FISH (red spots) screening. Solid blue bars represent arm involvement without 
defined breakpoint. 
 
3.2.8.4  Conclusion 
  Review of G-banded metaphases from 36 iAMP21 patients with abnormal 
karyotypes confirmed that the dup(21) chromosome was present in all patients 
and in seven cases it was the sole karyotypic change. This suggested that the 
dup(21) may be the primary cytogenetic event in these patients. Studies using 
whole genome aCGH (Kuchinskaya et al, 2007;Strefford et al, 2007) have failed to 
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detect any common copy number alterations in iAMP21 patients, providing 
further evidence that the dup(21) may be the primary event.  
  In the remaining 28 cases, a number of structural and numerical 
chromosomal abnormalities were observed in addition to dup(21). The majority 
had a near-diploid chromosome complement, with the 19 having a 
pseudodiploid karyotype, consistent with previous studies (Harewood et al, 
2003). None of the known established numerical or structural abnormalities were 
detected either by cytogenetics or FISH. Gain of one copy of a chromosome X 
was observed in nine patients, both male and female, an observation noted in a 
number of previous reports (Heerema et al, 2007;Heerema et al, 2000;Moorman et 
al, 2003). Deletion of ETV6 was observed by FISH in five patients with 
breakpoints of this region being involved in translocations found in four cases, 
whilst deletion of 11q23 was noted in six patients. 
  In a single case, 6783, a constitutional Robertsonian translocation, 
der(15;21), was detected. Although the incidence of Robertsonian translocations 
in the general population is 1 in 1000 (Jacobs, 1981), der(15;21) are particularly 
rare, accounting for only 3% of all reported Robertsonian translocations (Gardner 
& Sutherland, 2004). As follow up studies were not undertaken on this patient, it 
is not possible to determine if this was a de novo finding or an inherited one.  
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Patient 
ID 
G- banded 
Morphology  Karyotype 
3131 LM 
46,XY,t(1;16)(q23;p13),ider(21)(q10)dup(21)(q?)[3]/ 
51,idem,+X,+3,+10,+14,+21[3] 
5754 LM  46,XY,ider(21)(q10)dup(21)(q?)[6] 
5898 LM 
47,XY,+X,del(16)(q13),i(17)(q10),ider(21)(q10)dup(21)(q?)[3]/ 
47,idem,add(7)(p1)[3] 
6020 LM  46,XY,del(7)(q22q36),ider(21)(q10)dup(21)(q?)[cp3] 
6788 LM 
46,XY,add(13)(q?),ider(21)(q10)dup(21)(q?)[2]/ 47,idem,+14[1]/ 
48,idem,+8,+14[5] 
6957 LM  46,XX,ider(21)(q10)dup(21)(q?)[13] 
7045 LM 
47,XX,+X,del(9)(p?),-
10,del(11)(q13),ider(21)(q10)dup(21)(q?),+mar,[cp11] 
7829 LM  48,XY,+X,inv(1)(p13q?32),ider(21)(q1)dup(21)(q?),+mar[11] 
3956 LA 
45,XY,dic(8;16)(p1;p1),del(13)(q?14),dup(21)(q?)[6]/ 
46,idem,der(Y)t(Y;13)(q1;q?14),+dic(8;16)(p1;p1),del(13)(q?14)[2] 
4134 LA  46,XY,dup(21)(q?)[13] 
4178 LA  46,XX,del(7)(q22),t(14;22)(q32;q11),dup(21)(q?)[10] 
4623 LA  46,XX,dup(21)(q?)[11]/  47,idem,+X[1] 
6008 LA  46,XY,t(2;8)(p12;q24),del(9)(p?21),?del(13)(q1?),dup(21)(q?)[9] 
6783 LA 
43-
44,XY,del(5)(q11q13),der(15;21)(q10;q10)dup(15;21)(q10;q10),del(16)(q2
2),-20[cp5] 
6937 LA  46,XX,dup(21)(q?)[10] 
7219 LA  46,XY,dup(21)(q?),inc[3] 
7255 LA  45,XX,-21,+mar,inc[2] 
8743 LA  46,XX,t(7;9;17)(q22;p1?,p1?),del(11)(q23q2?5),dup(21)(?)[7] 
2776 R  47,XX,+X,der(21)r(21)(q?)dup(21)(q?)[3] 
3743 R 
45,XX,dup(8)(p?),-
11,der(15)t(11;15)(?;q24),der(21)r(21)(q?)dup(21)(q?)[2] 
3970 R 
47,XX,add(7)(q2),+10,der(21)r(21)(q?)dup(21)(q?)[7]/ 
47,idem,del(12)(p13)[4 
4405 R  45,Y,t(X;15)(q2?1;q2?4),dic(12;17)(p1;p1),der(21)r(21)(q?)dup(21)(q?)[4] 
4444 R  46,XY,der(21)r(21)(q?)dup(21)(q?)[3] 
5607 R  46,XY,t(8;11)(p?1;q21),del(11)(q?21),der(21)r(21)(q?)dup(21)(q?)[8] 
5674 R  47,XY,+X,dup(21)(q)[7] 
5809 R  45,XY,add(1)(p36),-2,add(4)(q35),-7,del(12)(p12),?del(16)(q?2),-
19,der(21)r(21)(q?)dup(21)(q?),+4mar,inc[cp6] 
7583 R  47,XY,+X,der(21)r(21)(q?)dup(21)(q?)[4] 
7650 R  47,XY,+9,der(21)r(21)(q?)dup(21)(q?) 
 
Table 3.5. G-banded karyotypes of 36 iAMP21 patients. 
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Patient 
ID 
G- banded 
Morphology  Karyotype 
    
3527 SA  45,XX,-7,del(12)(p12),dup(21)(q?)[5] 
4780 SA  45,XY,-11,del(12)(p1?2),der(20)t(11;20)(q?;q?),dup(21)(q?)[21] 
3745 SM  46,XY,der(21)dup(21)(q?)[4]/ 
46,idem,del(5)(q?),der(15)t(5;15)(q?;q?)[3]/ 47,XY,-18,+21,+22[1] 
4135 SM 
46,XX,t(12;16)(q24;p11),del(15)(q24q26),t(17;20)(p1?3;q11),der(21)dup(2
1)(q?)[6] 
4237 SM  46,XX,der(21)dup(21)(q?)[3]/  46,idem,del(16)(q1?)[7] 
4279 SM  46-47,XY,der(21)dup(21)(q?)inc[12] 
5655 SM 
46,XX,del(1)(q4?),del(6)(q1?5),del(7)(q2?2q3?1),der(21)dup(21)(q)[3]/ 
46,idem,add(6)(q2?)[12] 
6868 SM  47,XY,+X,-5,-9,add(20)(q),+21,der(21)dup(21)(q),+mar,inc[7] 
4316 n/a  46,XX[24] 
7828 n/a  46,XY[20] 
6009 n/a  50,XY,+X,+4,+21,+21[10] 
6899 n/a  46,XY[20] 
 
Table 3.5. (continued) G-banded karyotypes of 36 iAMP21 patients. Karyotypes 
for control patients 6009 (High hyperdiploid) and 6899 (normal) are also 
included. 
 
3.3  iAMP21- a distinctive genetic subgroup? 
3.3.1 Cryptic iAMP21 
3.3.1.1  Introduction 
  With the advent of new technologies to detect copy number change, 
oncogene amplification is becoming increasingly evident in a number of 
haematological disorders. In addition to ALL, a number of reports have observed 
amplification of regions on chromosome 21 in AML (Baldus et al, 2004) and MDS 
(Papenhausen et al, 2005;Andersen et al, 2004). In one study carried out in AML, 
detailed analysis by aCGH showed that this amplification did not include the 
RUNX1 gene but occurred at two different positions. One location was 
downstream of RUNX1 (38.7-39.1Mb) in a region that harbours the transcription 
factors ERG and ETS2, whilst the second target was located upstream, to a region 
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that harbours the APP gene (25-30Mb). Expression studies confirmed 
overexpression of both ERG, ETS2 and APP in these patients (Baldus et al, 2004). 
In more recent studies, it was noted that there was high expression of ERG in 
AML with cytogenetically normal karyotypes, which was associated with 
adverse risk (Marcucci et al, 2007). Over expression of APP, has however been 
found in a number of AML patients irrespective of their chromosome 21 
involvement. 
   As the majority of iAMP21 were identified by chance during FISH 
screening for the ETV6-RUNX1 fusion, it cannot be ruled out that we have 
selected a group of patients which may have a secondary rearrangement of 
chromosome 21 which has arisen from a smaller cryptic abnormality which may 
involve the over representation of ERG, similar to the one reported in AML. In a 
number of haematological disorders, variant translocations have been identified 
which occur as a secondary chromosomal change and at a lower incidence than 
the primary translocation. If this were so in iAMP21 patients, it is probable that 
the primary abnormality from which the dup(21) was derived would locate to 
chromosome 21 and would involve a cryptic copy number change.  
Using the information gained from studies described in the previous sections, a 
FISH study was designed to test this hypothesis, which was based on a number 
of assumptions: 
 
  The incidence of the primary abnormality would be higher than the 1.5 % 
incidence reported for iAMP21 (Harewood et al, 2003;Soulier et al, 2003) 
  No other prognostically significant abnormalities, such as the BCR-ABL1, 
ETV6-RUNX1 fusions, or MLL rearrangements would be present 
  The region involved would be adjacent to the RUNX1 locus, and would 
involve gain/amplification 
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  The karyotypic features would be similar in both groups namely: a modal 
chromosome number of between 40–50, with an abnormal karyotype but 
no obvious involvement of chromosome 21 
  Clinical features such as immunophenotype would be similar in both 
groups 
3.3.1.2  Methods  
  A four probe FISH screen was designed (Figure 3.9) to cover a ~10Mb 
region of chromosome 21 comprising two probes upstream (RP11-12M14 and 
RP11-8P19) of RUNX1 and two (RP1195I21 and RP110N12) downstream. In 
addition, the commercial chromosome 21 subtelomere probe was included to 
determine the status of this region in these patients, as well as the LSI TEL-AML 
ES®, (Vysis, UK) probe. The downstream probes spanned ERG and ETS2, to 
provide a direct comparison to the amplicon found in AML patients. 
 
30Mb 40Mb
RP11-12M14 RP11-8P19 RP11-110N12 AML1 RP11-95I21
RP11-476D17
ERG RUNX1 ETS
Centromere Telomere
30Mb 40Mb
RP11-12M14 RP11-8P19 RP11-110N12 AML1 RP11-95I21
RP11-476D17
ERG RUNX1 RUNX1 ETS ETS2
Centromere Telomere
30Mb 40Mb
RP11-12M14 RP11-8P19 RP11-110N12 AML1 RP11-95I21
RP11-476D17
ERG RUNX1 RUNX1 ETS ETS
Centromere Telomere
30Mb 40Mb
RP11-12M14 RP11-8P19 RP11-110N12 AML1 RP11-95I21
RP11-476D17
ERG RUNX1 RUNX1 ETS ETS2
Centromere Telomere
 
 
Figure 3.9 Genomic positions on chromosome 21 of FISH probes used to screen 
patients for copy number changes in regions adjacent to RUNX1. The red and 
green lines indicate the labelling of the probes with either Spectrum red or green, 
respectively. The TEL-AML ES® for AML1 (RUNX1) is shown in red. Probes run 
from left to right in a centromere to telomere direction. 
 
  A series of 30 childhood BCP-ALL patients with an abnormal karyotype 
with no evidence of MLL rearrangements, ETV6-RUNX1 or BCR-ABL1 fusions 
were selected from a search of the LRUKD karyotype database. The additional 
selection criteria were that the patients had a modal number of 40-50 
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chromosomes and no visible chromosome 21 abnormalities (Appendix 3, Table 
A3.6). These patients were screened using the probes described above using 
standard FISH procedures as outlined in section 2.3.2. 
3.3.1.3  Results 
  FISH was successful with at least four probes for all patients. In all cases 
tested a copy number of two was obtained for each of the probes employed 
(Appendix 3, Table A3.6). For each patient, the copy number at each probe 
location was the same. The results for all patients were consistent with their G-
banded karyotype (Appendix 3, Table A3.7). 
3.3.1.4  Conclusion 
  A small group of BCP-ALL cases, with no cytogenetic or RUNX1 FISH 
evidence of iAMP21, were screened by FISH to look for cryptic abnormalities of 
chromosome 21, particularly duplications/amplifications involving regions 
adjacent to the RUNX1 gene. No copy number changes were detected in these 
regions. From this data it was concluded that the iAMP21 abnormality does not 
represent a variant that has arisen from a cryptic duplication of chromosome 21. 
In addition no patients were identified with amplicons similar to those described 
in AML.  
3.3.2 Variant iAMP21 
3.3.2.1  Introduction 
  Screening of BCP-ALL patients using a combination of FISH and 
conventional cytogenetics to detect cases of iAMP21 (as outlined in section 3.1.) 
resulted in the discovery of two cases (4746, 5047) (Table 3.1) which were 
negative for the ETV6-RUNX1 fusion, with ≥ 5 copies of the RUNX1 gene. These 
cases did not strictly conform to the definition of iAMP21, and the additional 
RUNX1 signals detected did not correlate with gain of intact copies of 
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chromosome 21. As the studies previously undertaken in this project had 
established that RUNX1 was always present within the amplicon, it was 
important to characterise these two cases and determine whether they 
represented hidden or variant iAMP21.  
   It is possible that iAMP21 may haven arisen from further rearrangement 
of a structurally rearranged chromosome 21, such as i(21)(q10) , or that it may 
represent a secondary abnormality to i(21)(q10). If this were so, it is possible that 
there may be evidence of a cryptic copy number imbalance along the length of an 
apparently unrearranged i(21)(q10) chromosome.  
  To investigate this theory, as well as to establish whether the two cases 
outlined above represented hidden iAMP21, six patients previously identified as 
having an i(21)(q10) together with the above two cases with five RUNX1 signals, 
were screened with the same probes as outlined in section 3.2.1 and the results 
compared to those obtained from verified iAMP21 cases. 
3.3.2.2  Methods 
  Interphase FISH screening was undertaken on all eight cases following the 
method outlined in Section 3.2.1.  
3.3.2.3  Results 
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Patient  dup(21)    24.1 29.8 32.3 RUNX1  40 43.7  46.9 
     13J15  30N6  147H1  RUNX1  AF121782 88N2  21qTel 
4676  i(21)  4 5 5 5 5  4  4 
5003  i(21)  6.5 6.5 6.5 6.5 6.5  6.5  6.5 
5586  i(21)  4.5 4.5 4.5 4.5 4.5  4.5  4.5 
5612  i(21)  3 3 3 3 3  3  3 
7015  i(21)  4 4 4 4 4  4  4 
9410  i(21)  4.5 4.5 4.5 4.5 4.5  4.5  4.5 
                
4746  rea(21)  7.5 7.5 5  7  5.5  7  6.5 
5047  add(21)  Fail  4 4 5 Fail 1  1 
 
Table 3.6 Interphase FISH screening of six cases with i(21)(q10) and two 
potential iAMP21 variants. Columns represent probes and rows represent 
patients. The mean numbers of signals are given.  
 
  The results of interphase FISH screening undertaken in all eight cases are 
displayed in Table 3.6.  Successful results were obtained from all probes in six 
cases. Two probes failed in case 5047. In five of the cases with i(21)(q10), the copy 
number recorded for each probe was the same. In three patients (5003, 5586 and 
9410) two abnormal cell populations were noted, which indicated the presence of 
clonal evolution. For each of these cases, the number of signals in any one cell 
was the same for each of the dual probes employed, suggesting that a 
duplication of the isochromosome had occurred (Appendix 3, TableA3.8). In a 
single patient (4676) with an i(21)(q10), the number of signals observed for each 
probe, was variable with the average copy number for probes RP11-30N6, RP11-
147H1 ,RUNX1 and AF121782 being one single signal higher than the other 
probes. G-banded analysis (Appendix 3, Table A3.9) indicated that in addition to 
the i(21)(q10) a duplicated chromosome 21 was also present. G-banded review 
showed that the morphology of this dup(21) was not consistent with that of the 
dup(21) seen with iAMP21 patients. 
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3.3.2.4   Conclusion 
  Six patients with i(21)(q10) were investigated by FISH using probes 
located along 21q to determine whether copy number variation may be 
associated with this abnormality. No evidence of duplications or losses along 21q 
was found. In a number of cases two populations of cells were present and 
within each clone the copy number for all probes was the same and consistent 
with the number of 21q arms observed by cytogenetics. These findings suggest 
that i(21)(q10) chromosomes are distinct from the dup(21) seen in iAMP21 
patients. Had iAMP21 arisen from an isochromosome 21 it would have been 
expected that the observed copy number gain along the whole length of the 
dup(21) chromosome would have been two prior to amplification, thus in any 
one interphase cell the normal copy number would be three (the third signal 
represents the normal 21). Following amplification of the isochromosome, it 
would be expected that those regions not amplified or deleted would still have a 
copy number of two giving a total copy number in the interphase cell of three. 
BAC aCGH and iFISH (section 3.2) showed that the copy number in the regions 
proximal to RUNX1 (genomic position 15.1 – 20.0Mb) was consistent with a 
normal copy number namely two copies. Assuming that one copy represents the 
normal 21, and the other located on the dup(21) chromosome, it seems unlikely 
that all patients would lose a single copy in every one of these regions.  
  The FISH profiles obtained for patients 4746 and 5047 are similar to those 
reported for iAMP21 patients. It is noteworthy that patient 5047 showed loss of 
the subtelomeric region similar to the majority of iAMP21 patients. In both 
patients the karyotypes revealed the presence of a number of small marker 
chromosomes, which were composed of chromosome 21 material as confirmed 
by WCP 21. It is possible that these patients represent variant iAMP21 cases with 
an amplification of chromosome 21 which has arisen by a different mechanism. 
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3.3.3 Amplified der(15;21) 
3.3.3.1  Introduction 
   The results of interphase FISH and aCGH outlined in sections 3.2. 
revealed that patient 6783, had the smallest chromosome 21 amplicon. However, 
the cytogenetic morphology had shown that the dup(21) chromosome in this 
case (Figure 3.5) was amongst one of the largest in the study. This warranted 
further investigation.  
3.3.3.2  Method 
  A second, more detailed cytogenetic G-banded review was carried out on 
patient 6783, including both the diagnostic and remission sample. The findings 
from the remission sample prompted studies of stimulated peripheral blood to 
determine the constitutional origin of the chromosomal abnormalities observed. 
This was carried out by the regional cytogenetics laboratory. Chromosome 
painting with WCP 15 and 21 was carried out to confirm the cytogenetic findings 
and determine the chromosomal origin of the dup(21). 
  Prospective screening of new ALL patients for the presence of iAMP21 
identified a second case (11005) in which there were additional copies of the 
RUNX1 gene located on two copies of a dup(21) chromosome. Cytogenetic 
analysis revealed, that in addition to the clone with the dup(21) chromosomes, a 
second clone existed also with a Robertsonian der(15;21) as the only karyotypic 
change. As the clone with the two copies of dup(21) did not show this der(15;21), 
FISH was undertaken on both cases using WCP 15 and 21, to determine whether 
these dup(21) chromosomes were composed of material from both chromosomes 
15 and 21. 
  Oligonucleotide aCGH using the Agilent Human Genome CGH, 
Microarray Kits 185A and 244A was performed patients 6783 and 11005, 
respectively, following the protocol outlined in section 2.5. The profiles of 
chromosomes 15 and 21 were compared for both patients.  
  119Results 
3.3.3.3  Results 
  An additional cytogenetic review of 50 metaphases from case 6783 
showed no evidence of a normal diploid population, but a single metaphase was 
observed with a der(15;21)(q10;q10) as the sole karyotypic change. Review of a 
follow up bone marrow sample, taken when the patient was in complete 
remission, showed that der(15;21)(q10;q10) was present in all cells examined. 
Cytogenetic analysis of stimulated peripheral blood, undertaken by the regional 
cytogenetics laboratory confirmed this abnormality to be a constitutional 
Robertsonian translocation.  
  Metaphase FISH with WCP 15 and 21 carried out on the diagnostic 
sample, identified that the dup(21) was composed of both chromosome 15 and 21 
material (Figure 3.10). As the karyotype showed only one copy each of the 
normal chromosomes 15 and 21, it was assumed that the dup(21) must have 
arisen from the Robertsonian der(15;21) chromosome, and thus was described as 
der(15;21)dup(15;21). 
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Figure 3.10 Combined FISH and G-banding from patients with 
der(15;21)dup(15;21). a) and e) G-banded form of  chromosome 15, chromosome 
21 and der(15;21)dup(15;21) from patients 11005 and 6783. WCP 15 (green) and 
21 (red) on b) der(15;21) and c), f) and g) der(15;21)dup(15;21). d) RUNX1 exon 
probes from patient 11005 on the der(15;21)dup(15;21) chromosomes. 
 
  Metaphase FISH on case 11005 with WCP 15 and 21 (Figure 3.10), showed 
that the dup(21) chromosome was composed of both 15 and 21, implicating that 
in both of these cases (6783 and 11005) the dup(21) chromosomes had arisen from 
the der(15;21). 
  The array profiles for chromosome 21 and 15 are displayed in Figure 3.11. 
Both patients showed copy number imbalances along the lengths of both 
g 
b 
Case 11005  a 
c  d 
Case 6783  e 
f  g 
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chromosomes, comprising deletions, gains and amplifications. However the 
genomic profiles differed between the two patients. This is demonstrated by 
superimposing the two profiles in Figure 3.11. 
  The same 6.6Mb minimal CRA of chromosome 21 as defined in other 
iAMP21 patients (Section 3.2.3.) was also present in patient 6783, whilst the size 
of the amplicon in patient 11005 was larger at ~20Mb, extending from genomic 
position 19Mb to 40Mb. A deletion of the subtelomeric region ~ 6Mb in size was 
found in patient 11005. It extended from genomic position ~ 40Mb through to the 
telomere. 
  The array profiles of chromosome 15 for both patients were highly 
complex with numerous regions of deletion, gain and amplification. A minimal 
CRA ~ 9Mb in size, located between genomic positions 60.0 and 69.0Mb (bands 
15q21-q22), was common to both patients. Two common regions of deletion were 
recorded on chromosome 15. The first (~7Mb in size) was positioned between 
36.0 and 43.0Mb (band 15q13); whilst the second (also ~7Mb in size) was located 
between 51 and 57Mb (band 15q15-q21) (Appendix 3, Table A3.10). Patient 11005 
had a deletion which spanned from ~84Mb through to the telomeric region, 
whilst the same region in patient 6783 was gained.  
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11005  Combined 
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e  d  f 
Chromosome 21 
 
 
Figure 3.11 Oligonucleotide a CGH profiles of chromosome 15 and 
chromosome 21 from patients 6783 and 11005. a) b) Chromosome 15 profiles for 
6783 and 11005, respectively and c) combined. d) e) Chromosome 21 profiles for 
6783 and 11005, respectively and f) combined. Combined profiles illustrate 
common regions of deletion and amplification. 
Key Green = 6783; Brown = 11005. 
 
3.3.3.4  Conclusion 
  Two cases were identified with der(15;21)dup(15;21). Cytogenetic analysis 
of both cases determined that this abnormality was derived from a Robertsonian 
translocation, der(15;21)(q10;q10). In one patient this der(15;21) was confirmed to 
be constitutional in origin. This particular Robertsonian translocation is 
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extremely rare (Gardner & Sutherland, 2004), therefore the finding of two cases is 
extremely interesting. 
  High resolution aCGH carried out on these two cases confirmed the extent 
of involvement of both chromosomes 15 and 21 within the dup(21) marker. For 
each patient, unique profiles were obtained for both chromosomes with areas of 
deletion, amplification and gain being detected. The minimal CRA of 
chromosome 21 seen in iAMP21 patients was observed in patient 11005 and this 
region was contained within the amplicon of patient 6783. Patient 11005 also had 
a deletion of the subtelomeric region. Collectively, these results were consistent 
with the definition of iAMP21 for these patients.  
  The chromosome 15 profiles were also different between the two patients, 
with some common regions of deletion and amplification. Despite these 
differences, it is possible that the duplicated marker chromosomes had arisen via 
a common mechanism from a der(15;21) translocation. It was not possible to 
establish whether the der(15;21)dup(15;21) chromosome in patient 11005 had 
arisen from an acquired or a constitutional der(15;21). However, as only a single 
cell examined by both cytogenetic analysis and FISH was found with a normal 
karyotype it cannot be ruled out that the der(15;21) is a constitutional mosaic in 
this patient. Further studies are required to confirm this finding. 
3.4  Diagnostic Test 
3.4.1 Introduction 
  Treatment success rates in childhood ALL have progressively improved 
with time. Currently, five year event-free survival rates of >80% are achieved on 
a number of treatment protocols throughout the world (Pui & Evans, 
2006;Borowitz et al, 2008). The detection of genetic abnormalities associated with 
a poor prognosis is however essential in order to maintain the success of current 
risk adapted therapy by ensuring that high risk patients are treated 
appropriately. Moorman et al (2007b) established that patients diagnosed as 
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iAMP21 treated on the MRCALL97 treatment trial had a significantly inferior 
event free and overall survival compared with other ALL patients on the same 
trial. As a result patients diagnosed with this abnormality in the UK are now 
treated on the high risk arm of the current ALL2003 childhood treatment trial. In 
a recent study by Cooley et al (2007), it was noted that patients with loss of 
chromosome 21 have a poorer outcome than those with normal copy number for 
chromosome 21. This was a cytogenetic study only, but based on the karyotypes 
published in this paper, it is likely that patients with iAMP21 were included, 
hence having an impact on the overall outcome of the patient group.  
  To date, characterisation of iAMP21 using classical cytogenetics and FISH 
(as outlined in previous sections) as well as other molecular methods to look for 
copy number changes and gene expression profiling (Strefford et al, 
2006;Kuchinskaya et al, 2007), have failed to identify a putative target gene or 
gene fusion initiating leukaemogenesis in these patients. Consequently, the only 
methods for detection of iAMP21 patients are those that accurately detect their 
distinctive genomic profiles. Although aCGH could potentially fulfil this role, it 
is an expensive option as a routine diagnostic test. Thus, FISH, using probes 
directed to the RUNX1 locus, remains the most reliable method. Although 
iAMP21 may be reliably defined by this method, it depends on the presence of 
metaphases for the definitive diagnosis. A significant number of ALL samples 
fail cytogenetic analysis (Harrison et al, 2005), which is frequently a reflection of 
the lack of metaphases. In interphase it is particularly difficult to distinguish 
iAMP21 patients from those having gain of chromosome 21 or i(21)(q10). The 
best way to differentiate between the different abnormalities when no 
metaphases are present would be to use a test that precisely detects the copy 
number of chromosome 21; for example a combined FISH test consisting of a 
RUNX1 probe together with a chromosome 21 centromeric and telomeric probe. 
However, the centromeric region of chromosome 21 is problematic as it has 
repetitive sequences in common with chromosome 13. This results in cross 
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hybridisation when using FISH probes, making accurate enumeration difficult. 
Although these tests would be definitive for the detection of chromosome 21 
copy number, they would not provide an unequivocal test for the detection of 
iAMP21.  
  Coupled with this dilemma is the fact that a number of centres outside the 
UK do not employ FISH for the detection of chromosomal abnormalities, but rely 
on molecular based techniques, for example using RT-PCR for the detection of 
the ETV6-RUNX1 fusion will fail to find iAMP21. It is thus paramount to design 
a diagnostic test which will accurately identify iAMP21 patients using either a 
complementary FISH or molecular technique.  
  Based on the FISH and aCGH data (section 3.2) (Kuchinskaya et al, 
2007;Strefford et al, 2007), a diagnostic test was designed making the following 
assumptions:  
 
  RUNX1 would define the level of amplification within the CRA 
  DNA copy number distal to the CRA at the subtelomere will always be 
lower than RUNX1 
  DNA copy number proximal to the CRA will be normal, gained or deleted 
but never amplified to the same extent as RUNX1 
 
Thus by quantifying the DNA copy number as a ratio difference between three 
targets, one either side of the CRA and one within, it should be possible to 
definitively diagnose iAMP21, as these patients would be the only group with 
the highest copy number within the CRA. 
  Two quantitative molecular techniques, Q-PCR and MLPA, in addition to 
a diagnostic FISH test were designed and evaluated in order to establish their 
relative abilities to accurately identify iAMP21 and distinguish these patients 
from those with other abnormalities involving chromosome 21.  
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3.4.2 Methods 
3.4.2.1  FISH 
  All patients involved in the evaluation of the FISH procedure had been 
previously screened with the commercial LSI TEL-AML ES® probe to: 
 
  exclude the presence of the ETV6-RUNX1 fusion  
  determine the RUNX1 copy number   
 
  From this screen, patients were selected who had been identified as ETV6-
RUNX1 negative with ≥ 5 RUNX1 signals. Two dual colour FISH tests, one with 
an upstream probe located close to the centromere and one with a 21q 
subtelomere probe, in association with RUNX1 provided the second part of the 
diagnostic test. A comparison of the copy number obtained for all three probes 
was then undertaken and the ratio of the upstream probe compared to RUNX1 
and the down stream probe compared to RUNX1 was calculated. It was 
hypothesised that those patients who were iAMP21 positive would have a ratio 
of < 1 for each site. In order to validate the test, the FISH procedure and scoring 
was carried out blind by an independent technician.  
3.4.2.1.1  Probe selection 
  Two BAC probes RP11-213G23 (H) (genomic position 15.3Mb) and Probe 
RP11-135B17 (I) (genomic position 46.8Mb) were chosen to represent the 
proximal and distal probes to the RUNX1 target. (Probe I is a new subtelomeric 
probe, selected to ensure consistency, because the exact genomic location of the 
commercial subtelomeric probe used in previous studies is not fully known). 
Probe RP11-17O20 (J) (genomic position 35.3Mb) was selected as the RUNX1 
target probe. Previous screening of fixed cell suspensions from 20 iAMP21 
patients had established that both probes H and I were not amplified.   
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3.4.2.1.2  FISH experiment 
  Two, dual colour, dual probe experiments were undertaken with the 
RUNX1 probe, (labelled with Spectrum green) being combined with one of each 
of the other probes (labelled with Spectrum red). Copy number was determined 
in 50 abnormal cells for each probe and the modal number of signals found for 
each probe used to calculate the ratio. This FISH analysis was undertaken by 
Kerry Barber, LRCG. 
3.4.2.1.3  Patients 
  FISH was performed blind on a total of 30 patients including iAMP21 
patients (n=8), gain of chromosome 21 as the sole abnormality (n=6 ), high 
hyperdiploidy (n=5), tetraploidy (n=1), isochromosome 21 (n=4), possible 
variants of iAMP21 (n=3), normal (n=1) ALL patients with no detectable 
chromosome 21 abnormalities (n=1).  
3.4.2.1.4  Results 
  The results of FISH screening are displayed in Table 3.6. In a single patient 
(7588), FISH failed, as the distribution and quality of the signals were such that it 
was not possible to accurately count the number of signals at each probe location. 
Seven of the eight iAMP21 patients were correctly identified based on the ratio 
assessment.  
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Patient H RUNX1   I Ratio  A 
H:RUNX1 
Ratio B 
I:RUNX1 
iAMP21 
Chromosome 
21  
Abnormality 
4894 3  3  3  1  1  No  21 
7214 3  3  3  1  1  No  21 
8274 3  3  3  1  1  No  21 
11463 3  3  3  1  1  No  21 
11734 3  3  3  1  1  No  21 
7251 4  4  4  1  1  No  Tetraploid 
6786 4  4  4  1  1  No  Heh 
9180 4  4  4  1  1  No  Heh 
9453 4  4  4  1  1  No  Heh 
9488 4  4  4  1  1  No  Heh 
10192 4  4  4  1  1  No  Heh 
5047 2  4  1  0.5  0.3  Yes  iAMP21 
5754 3  7  1  0.4  0.1  Yes  iAMP21 
10444 1  7  1  0.1  0.1  Yes  iAMP21 
10542 1  7  1  0.1  0.1  Yes  iAMP21 
11056 2  5  1  0.4  0.2  Yes  iAMP21 
11061 2  7  1  0.3  0.1  Yes  iAMP21 
11116 1  5  5  0.2  1  No  iAMP21 
11158 3  6  1  0.5  0.2  Yes  iAMP21 
5612 3  3  3  1  1  No  iso(21) 
4247 2  3  3  0.7  1  No  iso(21) 
11200 3  3  3  1  1  No  iso(21) 
7558 Fail  Fail  Fail  Fail Fail  Fail iso(21) 
5586 5  5  5  1  1  No  iso(21) 
9859 2  2  2  1  1  No  Normal 
4676 5  5  5  1  1  No  Unknown 
4746 1  6  6  0.2  1  ?  Unknown 
9010 1  3  1  0.3  0.3  ?  der(9)ins(21) 
 
Table 3.6 Interphase FISH screen of ALL patients with probes designed to 
detect iAMP21. Columns represent probes and rows represent patients.  
H = RP11-213G23 clone, genomic position 15.3 Mb (proximal to RUNX1), 
I = RP11-135B17, genomic position 46.8 Mb (distal to RUNX1). 
Patients are ordered according to chromosome 21 abnormality. Modal copy 
number is recorded in the boxes. The interpretation is recorded in the iAMP21 
column, with Yes = iAMP21 and No= non iAMP21. The true abnormality is 
given in the final column. 
21= Gain of chromosome 21; Heh= high hyperdiploid; iso(21) = i(21)(q10) 
iAMP21= intrachromosomal amplification of chromosome 21 
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  In one iAMP21 case (11116) the observed ratio did not reach the expected, 
thus it was recorded as iAMP21 negative. A review of the RUNX1 signal 
distribution in interphase in this patient, was however consistent with the 
clusters of signals associated with iAMP21.  
  In another case (9010) the ratios of the proximal and distal probes were 
consistent with that of iAMP21. However, enumeration of signals with the 
commercial TEL-AML1 probe had shown that the modal copy number for 
RUNX1 was 3, (range 3-4). Metaphase FISH demonstrated that two of the signals 
were on a single chromosome, confirmed to be a der(9)t(9;21)(p1;q?)dup(21)(?) 
chromosome. This patient had been included in the blind test to highlight the 
importance of having ≥ 5 signals to indicate the presence of iAMP21. The scorer 
had noted that, although the ratio fulfilled the criteria for diagnosis of iAMP21, 
the overall number of RUNX1 signals was too low.  
  Two patients (4247, 4746) showed ratios similar to those of the iAMP21 
patient (11116). These results were discrepant with the expected ratios in patient 
4247 for the upstream probe. In case 4676, the karyotypic origin of chromosome 
21 had not been established. For the other cases the ratios of both A and B were 
recorded as one. This highlighted that the copy number in these areas is equal 
along the length of the chromosome. 
3.4.2.1.5  Conclusion 
  Screening 30 ALL cases with a probe set specifically designed to detect 
iAMP21 patients, demonstrated that in the majority of cases results were 
concordant with the expected outcome.  Seven of eight iAMP21patients were 
correctly identified. A discrepant result was noted in a single case, in which the 
number of signals in the subtelomeric region was the same as the RUNX1 probe. 
Although a previous case of iAMP21 (6788, section 3.2.3.) had been noted with 
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amplification of the subtelomeric region, the level of amplification in that case 
was lower than that recorded for RUNX1. Patient 11116 had a failed cytogenetic 
result, thus it cannot be ruled out that additional copies of chromosome 21 may 
account for some of the additional RUNX1 signals. In a single patient the ratios 
were neither consistent with iAMP21 nor with the karyotype. This case may 
represent a variant iAMP21. In all cases where the chromosome 21 status was 
known, the results were as expected, consistent with the predicted outcome. This 
demonstrated that, using this approach, it was possible to distinguish iAMP21 
patients and differentiate them from patients with high hyperdiploidy and 
i(21)(q10).  
3.4.2.2  Polymerase chain reaction (PCR) 
  In a non peer reviewed abstract Haas et al (2005) designed a DNA- based 
real-time polymerase chain reaction test to identify iAMP21 patients. The test 
was based on the comparative quantification of three regions, using two probes 
located to chromosome 21 and one to chromosome 11. By comparing the level at 
each region they were able to delineate and discriminate between patients with 
iAMP21 and those with gain of chromosome 21, due to either having an 
isochromosome 21, trisomy 21 or a high hyperdiploid karyotype with additional 
copies of 21. In order to test this model on the patients in this study, a 
quantitative DNA based RT-PCR (Q-PCR) test was designed. Using the 
hypothesis outlined in section 3.4.1, three target genes were selected on 
chromosome 21. STCH located at genomic position ~14.6Mb was selected as the 
centromeric upstream target, RUNX1 as the target within the amplicon and 
PRMT2 located at genomic position ~46.8Mb as the telomeric target. CYP27C1 on 
chromosome 2, genomic position ~12.7Mb was selected as the reference gene/ 
house keeping gene that the relative ratios would be obtained from. This gene 
was chosen as karyotype analysis of iAMP21 and high hyperdiploid karyotypes 
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(Robinson et al, 2007;Heerema et al, 2007) have shown that it is not involved in 
copy number changes in ALL.  
  By comparing the relative ratios of these genes in our samples to those of 
normal DNA, it should be possible to distinguish iAMP21 patients from those 
with gain of chromosome 21 as they would show a different pattern of gain 
along the length of chromosome 21 in a similar manner to the diagnostic FISH 
test (Section 3.4.2).  
3.4.2.2.1  Methods 
  The Multiplex Q-PCR test was conducted as described in section 2.6. 
Genomic DNA from three iAMP21 patients (6996, 6788 and 7045), three with 
high hyperdiploidy and 3 or 4 copies of chromosome 21 (7290, 4073, 11002) and a 
single ALL patient with gain of chromosome 21 as the sole abnormality (4381) 
were initially investigated. Genomic DNA from six normal individuals was also 
tested. 
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3.4.2.2.2  Results 
0 
1 
2 
3 
4 
5 
6 
7 
8 
6996 
iAMP21 
6788 
iAMP21 
7290 
HeH
7045
iAMP21
4381
+21c
4073 
HeH
11002 
HeH 
WT 
STCH
RUNX1
PRMT2
 
Figure 3.12 Q-PCR of DNA levels for STCH, RUNX1 and PRMT2 in seven ALL 
patients. 2^-DDCt recorded for each DNA target in each patient are plotted 
adjacent to each other.  
  
  The fold change (2^-DDCt) obtained for each gene from all seven patients 
are displayed in Figure 3.12 (Appendix 3, Tables A3.11–A3.13). In two patients 
(6788 and 6996) no fluorescence was detected following 40 cycles of amplification 
for the RUNX1 locus. In addition patient 6996 failed to give a result for the 
PRMT2 downstream target gene. Thus no interpretation of the results for this 
patient was possible. 
  The results obtained from the three high hyperdiploid cases and the 
patient with a constitutional gain of chromosome 21 (+21c) was unexpected. Fold 
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change differences indicated that in all four patients there was a lower level of 
the downstream target gene PRMT2 in comparison to RUNX1 and STCH.  
  The level of RUNX1 and STCH was higher in all four cases compared to 
that of the wild type, consistent with the cytogenetics, however it was expected 
that the level of all three genes was the same. Patient 7045 showed the expected 
pattern, with a higher level of RUNX1 in comparison to both the upstream target 
STCH and the downstream target PRMT2.  
  An assessment was made of six normal individuals to investigate whether 
the unexpected results were due to an error in the design of the PCR reaction or a 
true reflection of copy number change in these patients. These results are 
displayed in Figure 3.13. As with the previous experiment, unexpected results 
were obtained from all cases. Fold change differences indicated that the relative 
levels for all three genes were different in all samples. In particular the level of 
RUNX1 appeared to be lower in all patients than either STCH or PRMT2. 
3.4.2.2.3  Conclusion 
  Results obtained from both the normal control and test samples appeared 
to be inaccurate. This suggested that the PCR reaction was not sufficiently 
optimised to detect the copy number changes with the sensitivity required for 
the test. Primer and probe design is crucial to the success of any Q-PCR reaction. 
Our results indicated that there were problems with the test design. Initial 
calculations had assumed that the PCR efficiency for all primers was equal and 
100%. In order to eliminate this error the primer efficiency for each target gene 
was adjusted using the Light Cycle Q Software. 
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Figure 3.13 Q-PCR of DNA levels for STCH, RUNX1 and PRMT2 in six normal 
controls. 2^-DDCt recorded for each DNA target in each control are plotted 
adjacent to each other. For each target the standard deviation is shown by the 
vertical line. 
 
  The results obtained (Figure 3.13) (Appendix 3, Tables A3.14–A3.16) did 
not correct any of the differences seen initially. This indicated that the primer 
efficiencies were too different between the target genes to make the relative 
quantification compatible. To demonstrate this further, a comparison was made 
between STCH and PRMT using RUNX1 as the calibrator (Appendix 3, Figure 
A3.3). In theory, as each sample has the same copy number for chromosome 21 at 
the start of the reaction, they should have equal concentration at the end. The 
results clearly indicated that both STCH and PRMT2 were lower than RUNX1. 
This implied that the RUNX1 primers did not have the same PCR efficiency as 
the other target genes. Hence, this explained the low levels of RUNX1 seen in the 
normal samples. In the only other previously reported RQ-PCR test for iAMP21 
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(Haas et al, 2005), the primer design has not been published; thus it was not 
possible to compare results. 
  In addition to primer design, the test must be robust enough to deal with 
differences in DNA quality. Discrepancies were noted between the control 
patient and wild type DNA indicating that both the quantity and quality of the 
patient genomic DNA may have been poor. Overall this test failed to generate a 
robust result that was able to detect genomic DNA levels of STCH, RUNX1, 
PRMT2 and CYP27C1 accurately. Further work is required to optimise the PCR 
reaction in order to ensure that the reactions are run at optimal conditions with 
equal primer efficiency. Due to time constraints this was not possible and further 
work on the development of a Q-PCR diagnostic test has ceased.  
3.4.2.3  Multiplex ligation dependent probe amplification  
3.4.2.3.1  Introduction 
  Multiplex ligation dependent probe amplification (MLPA) is a recently 
described method for detecting gross deletions and duplications of DNA 
sequences (Schouten et al, 2002). The technique allows for the simultaneous 
detection of different nucleic acid sequences in a single PCR reaction (section 
2.7), which can then be quantified. Designing an MLPA assay with a selection of 
target sites along the length of chromosome 21, including areas either side of the 
CRA as well as within would allow for the identification of iAMP21 due to their 
distinct chromosome 21 profiles, as highlighted in section 3.2. 
  To evaluate the efficiency of MLPA in the identification of iAMP21 
patients, a test was developed using two MLPA probe pairs targeting RUNX1 
and PRSS7 (an upstream gene located at 18.5MB) which were combined with the 
commercially available telomere probe mix (P036B, MRC Holland, Amsterdam) 
as outlined in section 2.7.1. By comparing the relative amounts of DNA at each 
site, iAMP21 patients were accurately identified. 
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3.4.2.3.2  Methods 
  MLPA was performed on genomic DNA from a total of 33 patients 
including iAMP21 (n=16), gain of chromosome 21 as the sole abnormality (n=4 ), 
high hyperdiploidy (n=6), hypodiploidy (n=1), isochromosome 21 (n=1), variant 
iAMP21 (n=3), ALL patients with no detectable abnormalities (n=2).  
  The MLPA work was performed blind by Dr D Bunyan, Wessex Regional 
Cytogenetic Unit. The results obtained were compared to the karyotype and 
RUNX1 FISH. 
3.4.2.3.3  Results 
  The MLPA screening results for the four locations on chromosome 21, 
from all 33 patients are displayed in Table 3.7. Patients defined as iAMP21 
showed variable copy number at each of the four sites. For all 16 iAMP21 cases 
the highest level was recorded at the RUNX1 locus. In 12 of these cases a deletion 
of the 21q subtelomere was found, consistent with the results from the FISH 
diagnostic test (section 3.5.5.3.1). In three patients (6783, 4279 and 6788) the 
results were discrepant with the FISH findings. In patient 6783, FISH had shown 
the presence of two copies of the 21q subtelomere in comparison to the three 
observed by MLPA. In patient 4279, only a single copy had been recorded for 
this location by FISH compared to the two copies seen with MLPA (a normal 
copy number for chromosome 21 was observed by conventional cytogenetics). In 
patient 6788, four copies of the 21q subtelomere had been detected by FISH, 
whilst MLPA had only detected three copies. Of the 11 cases with high 
hyperdiploidy, hypodiploidy and sole gain of chromosome 21, the copy number 
in the majority of cases was consistent with the cytogenetics. As expected the 
level was the same at all four locations. One exception to this was case 4073 in 
which only two copies of the 21q subtelomere was detected instead of the 
expected three (one on each of the three chromosomes 21). As no FISH with 
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subtelomeric probes had been carried out, it was not possible to confirm this 
unexpected gain. In two high hyperdiploid cases (12025 and 7558), the copy 
number recorded for RUNX1 was lower and higher (3 and 6), respectively, than 
that recorded for both the subtelomeric region and PRSS7.  
  A comparison between the RUNX1 copy number detected by FISH and 
MLPA illustrated that there were a number of discrepant results between the two 
techniques.  
  In fourteen of the 16 iAMP21 cases the results were higher with FISH than 
MLPA. In the majority of cases this differed by only one or two copies with most 
of the FISH results being higher than those from MLPA. 
  Abnormalities detected in patients for subtelomeric regions other than 
chromosome 21 are shown in Appendix 3, Tables A3.17-A3.18. Cases with gain 
of chromosomes due to the presence of a high hyperdiploid karyotype or gain of 
single chromosomes were successfully detected by subtelomeric MLPA. In the 
majority of cases these gains were consistent with the cytogenetics. A small 
number of cases had discrepant results, when compared to the cytogenetics. As 
no FISH with the relevant subtelomeric probes had been carried out, it was not 
possible to determine if the unexpected gains or losses were true.  
  In the iAMP21 patients, no consistent gain or loss of any subtelomeric 
region, other than chromosome 21, was observed. Screening with 21p 
subtelomeric probes showed a gain in five patients (6783, 6996, 7219, 8983,11706), 
whilst in one patient (4405) a deletion had occurred.  
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   Copy Number    
Patient 
ID 21p  PRSS7 
RUNX1 
(FISH)  RUNX1  21q 21qFISH  Code 
3043  3  3 3 3  3 NK  21 
4073  3  3 3 3  2 NK  21 
4184  3  3 ND 3  3 NK  21 
4318  3  3 ND 3  3 NK  21 
7653  3  3 3 3  3 NK Ho 
4642  3  3 ND 3  3 NK  HeH 
11102  3  3 4 3  3 NK  HeH 
7290  4  4 4 4  4 NK  HeH 
9525  4  4 4 4  4 NK  HeH 
12025  4  3 4 3  4 NK  HeH 
7558  5  6 4 6  5 NK  HeH  i(21) 
4405  1  3 8 7  1 1  iAMP21 
6783  3  2 5 4  3 2  iAMP21 
6788  2  2 4.5 5  3 4  iAMP21 
6996  4  5 10.5 6  1 1  iAMP21 
7045  2  2 6.5 5  1 1  iAMP21 
7093  2  3 7 5  1 1  iAMP21 
7219  3  3 7 6  1 1  iAMP21 
7619  4  4 8 7  1 NK  iAMP21 
7732  2  3 5 4  1 1  iAMP21 
7774  2  2 5 3  2 NK  iAMP21 
8743  2  2 5 4  1 1  iAMP21 
8983  3  3 7 5  1 1  iAMP21 
9028  2  3 8 6  1 1  iAMP21 
11005  2  3 7 7  1 1  iAMP21 
11706  3  3 9.5 6  1 1  iAMP21 
4279  2  2 5 3  2 2  iAMP21 
10958  2  2 2 2  2 NK  Normal 
12377  2  2 2 2  2 NK  Normal 
4676  4  5 5 5  4 5 i(21) 
4247  2  2 3 3  3 3 NK 
4746  1  4 7 4  6 6 NK 
9101  1  1 4 3  1 1 NK 
Key  Del  Nor  Gain  Amp          
 
Table 3.7 MLPA and FISH data measuring the copy number of the p and q 
subtelomeric regions and PRSS7 and RUNX1 on chromosome 21. iAMP21= 
iAMP21, 1= Gain of chromosome 21 as the sole abnormality, HeH = High 
hyperdiploidy, Ho= Hypodiploidy, i(21)= Isochromosome 21, NK= undefined 
abnormality in chromosome 21. MLPA copy number changes are recorded in 
coloured columns whilst the FISH data recorded as the mean is shown in clear 
columns.  
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Key: D=deletion (1 copy); N= Normal (2 copies), G=Gain (3-4 copies); A= 
Amplification (> 5 copies). 
3.4.2.3.4  Conclusion 
  The results obtained from screening a number of ALL patients to look for 
copy number changes along the length of chromosome 21, clearly demonstrate 
the power of MLPA in detecting copy number change. In all 16 iAMP21 patients 
the profiles obtained were consistent with those previously described for 
iAMP21 patients and distinct from those seen in the other groups. The test 
carried out blind, clearly validated the test design and illustrated that this 
technique was able to differentiate between those cases defined as iAMP21 and 
those which were not. 
   Unlike the other studies outlined in this thesis, this technique provided 
data on the status of the 21p subtelomere in iAMP21 patients. In 31% (5/16) there 
was gain of the 21p subtelomere. Previous studies to characterise iAMP21 using 
a variety of techniques (section 3.2) had not investigated 21p. In four of these 
cases a direct comparison with the karyotype was not possible, as conventional 
cytogenetics had either failed or the result was normal. In one case with 
der(15;21)dup(15;21) (6783) (Section 3.3.3.), there was no evidence of an 
additional chromosome 21 in the karyotype. Thus, it was concluded that the 
gains of both the 21p and 21q subtelomeres were located within the 
der(15;21)dup(15;21) chromosome in this case. These results provided further 
evidence for the complexity of this abnormality.  
  Discrepant results were noted between FISH and MLPA data regarding 
accuracy of copy number change. This was probably due to comparing results 
from genomic DNA and interphase FISH. The interphase FISH scoring excluded 
the normal cell population. DNA from the normal cell population is included 
within the total genomic DNA used in the MLPA assay and will have the effect 
of reducing the relative copy number gain in some cases.  
 Discussion 
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4 Discussion 
  Genetic aberrations are a key feature of malignancy where they result in 
the altered expression and function of genes residing within those regions of the 
genome where they occur. In haematological malignancies abnormalities 
comprise:  
 
  Chromosomal translocations or other structural rearrangements which 
result in the formation and overexpression of oncogenic fusion genes  
  Copy number changes including deletions /monosomy which can result 
in loss of tumour suppressor genes or duplications /trisomy which lead to 
overexpression of oncogenes 
 
  These aberrations contribute to the development of leukaemia by altering 
the regulatory processes that control cellular function, which in turn results in 
changes in proliferation, differentiation and resistance to apoptosis, as described 
in the introduction (Section1.1). Individual genetic abnormalities alone are 
usually insufficient to drive the leukaemic phenotype but require the co-
operation of additional aberrations, for example in genes encoding the principal 
regulators of B lymphocyte development and differentiation, such as mutations 
in PAX 5 present in 40% of pre-B -ALL (Mullighan et al, 2007).  
  Current treatment protocols are based on a risk-adapted strategy, 
whereby the intensification of therapy is tailored to risk of relapse as indicated 
by certain clinical features including age, WBC at diagnosis, gender, 
immunophenotype, as well as the presence of specific genetic abnormalities. This 
approach has resulted in overall survival rates of over 80% in childhood ALL 
and 40% in adults (Pui & Evans, 2006). Increased intensification of such 
treatments is unlikely to effect higher rates of cure, but will increase treatment 
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related toxicity both in the short and long term. In order to achieve further 
improvements in response to treatment, it is thus important to develop new 
treatment strategies based on targeted therapies which will act against the 
specific genetic abnormalities that are crucial to the survival of the leukaemic 
clones. A number of recurrent genetic subtypes have been described in ALL, 
accounting for approximately 75% of cases (Johansson et al, 2004). With the 
development of new technologies, novel genetic subgroups are being identified. 
The accurate characterisation of these novel abnormalities is essential in order to 
further increase our understanding of the mechanisms involved in the disease 
biology as well as providing the basis for improved clinical management and the 
identification of therapeutic targets.  
4.1  iAMP21 Characterisation 
   The application of a combination of cytogenetic techniques, including G-
banding, FISH and aCGH has successfully enhanced our understanding of the 
iAMP21 abnormality. From the results of initial investigations using aCGH and 
FISH, it was apparent that this abnormality, previously described as RUNX1 
amplification (Harewood et al, 2003;Soulier et al, 2003;Strefford et al, 2006), 
spanned a large region of 21q. In all patients gain, amplification and deletion of 
chromosome 21 was established. Detailed analysis of the results illustrated that 
the abnormality was highly complex, with each patient having a unique genomic 
profile, with regards to the extent of 21q involvement, the level of amplification 
and the size of the amplicon. Despite this variability, a minimum CRA located 
between genomic positions 32.3 and 40.0Mb (21q22.1-21q22.2), which included 
the RUNX1 gene, was identified in 100% (10/10) of cases. Studies with high 
resolution oligonucleotide aCGH refined the minimal CRA to a region of ~6Mb 
in size between genomic positions 33.2-39.8Mb and demonstrated that there was 
a ‘step wise profile’ of duplication, gain, amplification and deletion running in a 
centromeric to telomeric direction (Strefford et al, 2006;Kuchinskaya et al, 
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2007;Strefford et al, 2007). These findings were confirmed in another recent study 
by Kuchinskaya et al (2008), where a similar pattern of gain, amplification and 
deletion using similar techniques was observed. However, they were, unable to 
confirm the CRA. Instead, they identified an amplicon that was 15~30Mb in size 
located between genomic positions 14.5 and 46.5Mb, spanning a large region of 
chromosome 21. 
  FISH analysis of a larger group of iAMP21 patients, established that the 
highest copy number for all patients occurred at the RUNX1 locus, confirming 
the aCGH data. As patients were selected for study based on their increased 
RUNX1 copy number, it could be argued that this result was not unexpected and 
was a reflection of selection bias. The extent of involvement of chromosome 21 in 
iAMP21 became apparent following BAC aCGH analysis. Although RUNX1 
copy number gain was known prior to the onset of this study, its involvement 
within the CRA was unknown. The results obtained from the oligonucleotide 
aCGH (a more sensitive technique than BAC aCGH) illustrated that the level of 
amplification was similar over the length of the amplicon. As RUNX1 was 
located within the amplicon, this justified the choice of RUNX1 as representative 
of the CRA. 
FISH studies, carried out on both interphase and metaphase cells, 
provided further evidence that the abnormality was highly complex, involving 
large regions of 21q, with each patient having a unique chromosome 21 profile in 
relation to the level of amplification and size of amplicon. The variability seen at 
this level supported the differences observed between patients in the G-banded 
morphology of the dup(21). An unexpected result from the initial investigations 
was the detection of a minimum CRD observed in 70% (7/10) of patients. This 
CRD was ~ 3.5Mb in size and included the subtelomeric region of chromosome 
21. Further work demonstrated that this CRD occurred in a larger proportion of 
cases at an incidence of 76% (35/45). 
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  The amplification of a genomic region is thought to represent selection of 
a region where the expression of gene(s) promotes growth of the tumour. 
Albertson et al (2006) emphasised that mapping of amplicons should identify 
candidate oncogenes within them. However, proving that a gene is the important 
target within an amplicon is problematic, as several genes map to the amplified 
region. In order to identify the significant genes, studies are usually undertaken 
to determine whether the candidate oncogene is expressed in the tumour and 
whether expression is enhanced when the gene is amplified. Gene expression 
analysis carried out on eight of the iAMP21 patients in a separate study, 
demonstrated that 10% of the top 150 significantly overexpressed genes were 
located within the CRA. However, analysis was unable to identify any one gene, 
including RUNX1, which was significantly differentially expressed in these 
patients (Strefford et al, 2006). It was noted that RUNX1 was equally 
overexpressed in ETV6-RUNX1 fusion positive and iAMP21 patients. This may 
be due to the failure of the expression profiling platform to distinguish these two 
groups or to the gain of chromosome 21, which is often seen as a secondary 
change in ETV6-RUNX1 positive ALL. Mikhail et al (2002) also found increased 
RUNX1 expression in four cases with iAMP21. However, this overexpression 
was not exclusive to patients with this abnormality. As reviewed by Myllykangas 
and Knuutila (2006) the overexpression of genes within amplified regions is 
variable in different cancers and frequently it is difficult to separate those driving 
genes (amplified and overexpressed) from bystander genes. In a number of 
studies it has been suggested that the co-amplification of genes within an 
amplicon is responsible for driving the disease, for example the co amplification 
of activated genes associated with HER2 amplification in breast cancer 
(Kauraniemi & Kallioniemi, 2006;Arriola et al, 2008). It is possible that it is the co-
amplification of a number of genes within the iAMP21 amplicon that is 
important in this subgroup of patients, rather than any one single gene within 
the amplicon.  
  145Discussion 
The minimum size of the CRA in iAMP21 was established from the results 
of BAC aCGH and FISH data of a single patient. Subsequent investigations 
revealed that in this patient the abnormal chromosome 21, later described as a 
variant iAMP21, had arisen from a Robertsonian t(15;21) translocation. Although 
the amplification of 21q in this patient was verified, it is uncertain whether it 
should have been regarded as a typical iAMP21 and thus used to define the CRA 
of the entire patient group. If this patient is excluded then the size of the CRA 
becomes ~10Mb in size. Thus it is possible that the lack of identification of over 
expression of a single gene in the CRA is a reflection of defining the amplicon 
based on the results from a single patient. By removal of this patient from the 
expression analysis, it may be possible that the overexpression of other genes 
within this region would be identified. To the contrary, as the size becomes 
relatively large, it may emerge that the co- expression of a number of genes 
becomes important.  
  In the same study, high resolution array analysis of single-nucleotide 
polymorphisms (SNP) was undertaken on samples from three iAMP21 patients 
from the same series. The results confirmed the regions of copy number change 
and showed loss of heterozygosity (LOH) within the minimal CRA. As gain in 
copy number may mask LOH, no conclusions could be drawn as to whether the 
LOH was due to copy number neutral LOH (CNNLOH), otherwise known as 
acquired isodisomy or acquired uniparental disomy (UPD). This phenomenon 
has been seen in 20% of AML (Raghavan et al, 2005), where it is frequently 
associated with gene mutations such as FLT3 (Griffiths et al, 2005). A recent study 
of 399 childhood ALL patients using high resolution 50K SNP chip analysis 
failed to detect any cases of CNNLOH involving copy number changes along 
chromosome 21, from which it was concluded that it is a rare event in childhood 
ALL (Kawamata et al, 2008). Thus, the presence of LOH as found in the three 
cases of iAMP21 should be further investigated. 
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4.2  Breakage–Fusion -Bridge 
  The combined technical approach employed to characterise iAMP21 
provided evidence to imply that this abnormality had arisen from a distinct 
mechanism. A disadvantage of aCGH and interphase FISH is that neither 
technique is able to provide any information on the location in situ of the copy 
number alterations detected. The results obtained from the detailed 
characterisation of metaphases, using mBAND and BAC probe FISH mapping, 
provided evidence of inversions, duplications, amplification and deletions. These 
findings combined with the observation that each patient had a distinct genomic 
profile suggest that the dup(21) may have arisen from a series of chromatid 
breaks and reunions, such as those found in the Breakage-Fusion-Bridge (BFB) 
model. This mechanism was first described in maize by McClintock in 1941 
(1941). It proposes that, after an initiating event, a double stranded DNA break 
(DSB) occurs, generating an unstable chromosome with two broken sister 
chromatids. Following replication of this chromosome, the sister chromatids, 
which are in close proximity, fuse together at their ends to form a dicentric 
chromosome. As a result of this fusion, the two sister chromatids cannot easily 
separate from one another in the subsequent anaphase. Thus as the two 
centromeres pull apart to opposite poles, a chromatin bridge is produced which 
eventually ruptures under tension. This leads to the generation of another 
unstable chromosome which contains an inverted repeat. This process defines 
the BFB cycle. Subsequent to DNA replication in the next cell cycle, this BFB 
cycle is repeated. These “chromosome end-to-end fusion” cycles may continue 
for generations and, as the fused chromosomes do not always break exactly at 
the site of fusion, it follows that one daughter cell will receive a chromosome 
with an inverted repeat while the other chromosome will have a terminal 
deletion. In this way it is possible to generate complex chromosomes with 
extensive intrachromosomal gains, amplifications and deletions organised as 
inverted repeats (Figure 4.1). The process is repeated until the chromosome 
  147Discussion 
becomes stabilised by the gain of a teleomere. In this way it is possible to 
generate a chromosome with highly complex intrachromosomal rearrangements. 
 
A double-strand DNA break results in loss of a
telomere and the formation of an unstable 
chromosome 
Following replication the two sister chromatids 
fuse to form a dicentric chromosome
During anaphase the dicentric pulls apart 
resulting in breakage of the fusion bridge and 
production of an unstable chromosome with an 
inverted repeat
This process is repeated until the chromosome 
becomes stabilised by gaining a telomere. In this 
way it is possible to generate a chromosome 
with ladder like amplification.
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Breakage event
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chromosome 
Following replication the two sister chromatids 
fuse to form a dicentric chromosome
During anaphase the dicentric pulls apart 
resulting in breakage of the fusion bridge and 
production of an unstable chromosome with an 
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becomes stabilised by gaining a telomere. In this 
way it is possible to generate a chromosome 
with ladder like amplification.
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KEY
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Figure 4.1 The Breakage Fusion Bridge Cycle. Adapted from Robinson et al 
(2007). 
 
  The variation in the size of the amplicon found in the iAMP21 patients 
using both aCGH and FISH, together with the ladder like distribution of RUNX1, 
and the varied morphology of the dup(21) between patients are consistent with 
this abnormality having arisen through a BFB mechanism. Although no evidence 
of anaphase bridges were found in this study due to the lack of visible anaphase 
cells, the work carried out by Kuchinskya et al (2007) demonstrated the presence 
of anaphase bridges containing chromosome 21 material, thus providing 
confirmation of the hypothesis.  
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  In the review by Albertson (2006) it was described that amplified DNA 
can be visualised cytogenetically in three main ways, all of which may arise from 
the BFB mechanism: 
 
1.  Homogeneous staining regions, defined as an area on a chromosome 
with uniform staining frequently harbouring multiple copies of 
amplified DNA, often organised in a head–to–tail or inverted repeat 
fashion 
2.  Insertions, where the amplified region is inserted into other 
chromosomes throughout the genome 
3.  Double minutes defined as extra chromosomal amplified DNA 
visualised as acentric chromosomal fragments 
 
  In iAMP21 patients the amplified DNA was located on the dup(21), 
defining this abnormality as intrachromosomal amplification. Usually, this type 
of amplification is associated with the presence of HSR. However, both the 
morphology and staining pattern was extremely heterogeneous and a more 
appropriate description of the amplified regions would be an “abnormal staining 
region”. This may reflect the complexity of the mechanisms involved in the 
generation of such regions or that the chromosomes may have been generated 
from ring chromosomes. Gisselsson et al (2000) observed that ring chromosomes 
may successfully undergo cell division utilising a BFB type of mechanism. As a 
ring chromosome may break at any point between the centromeres, it can give 
rise to daughter cells which differ from each other as well as from the mother 
cell.  
  A frequent observation throughout this study was the variability in copy 
number noted by FISH at those locations where amplification may have 
occurred. This range in copy number may have been a reflection of difficulties 
encountered in enumerating signals or it may have been a true reflection of inter-
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cell differences. It is possible that a number of populations exist within the same 
patient samples, each with distinct amplicons.  
  The BFB model requires, as an initiating event, a DNA DSB (Gisselsson et 
al, 2000;Murnane, 2006). A number of mechanisms have been proposed, 
including errors in DNA repair and replication, loss or dysfunction of telomeres 
(Murnane, 2006;Bailey & Murnane, 2006) and breaks within regions of homology 
such as fragile sites (Arlt et al, 2006). The results from this study indicated that 
the most likely mechanism was loss of telomere.  
4.2.1 Loss of Telomere 
  Telomere loss is a known initiating event of the BFB mechanism  
(Gisselsson et al, 2001;Lo et al, 2002;Murnane & Sabatier, 2004;Sabatier et al, 
2005;). Telomeres are DNA-protein complexes that contain short repeat 
sequences added onto the ends of chromosomes by telomerase. They have a 
number of functions including protecting the ends of chromosomes and so 
preventing chromosome end to end fusion. The telomeric DNA sequences 
consists of tandem 5'-TTAGGG-3' repeats with a single-stranded G-rich 3' 
overhang of about 50-210 bases (Maser & Depinho, 2004). The single-stranded 3'-
end overhang invades the duplex telomeric DNA repeats to form a large duplex 
telomere loop (T-loop) and a smaller single-stranded displacement loop (D-loop) 
(Maser & Depinho, 2004;Cheung & Deng, 2008). This configuration, together 
with a number of telomere-associated proteins, creates the telomere cap which in 
addition to protecting the chromosome end, distinguishes it from a DSB.  
  Loss or dysfunction of telomeres can occur in a number of different ways. 
Studies into these mechanisms, as reviewed by (Murnane, 2006) have shown that 
changes in expression of the proteins involved in the regulation of telomerase (an 
enzyme that controls telomere length by adding the TTAGGG sequence repeats 
to the 3' end of DNA in the telomere), including the Mre-11-Rad50-Nbs1 
complex, have resulted in increased chromosome fusions. Equally the loss of 
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‘capping function’ has been found in cells with disrupted expression of telomere-
associated proteins such as TRAF2, Ku and DNAs-PKcs (Murnane, 2006). DSB 
can result in the indirect loss of a telomere by deleting regions upstream of the 
telomere, or direct loss as a result of breaks within the telomeres themselves. As 
telomeres are similar to fragile sites, in that they have repetitive DNA, they are 
prone to DSB due to stalled replication forks (Murnane, 2006). 
  In this current study, loss of the chromosome 21q subtelomeric region was 
demonstrated in 77% of iAMP21cases. As the FISH probe used to detect specific 
subtelomeric sequences are designed to hybridise to regions adjacent to the 
repetitive telomeric sequence present on all chromosomes, it was hypothesised 
that in the iAMP21 patients, the 21q telomere had been deleted and that this loss 
initiated the BFB cycles observed in these patients.   
  FISH screening and oligonucleotide aCGH (Strefford et al, 2006) analysis 
of these cases demonstrated that the subtelomeric deletions were always adjacent 
to the amplicon. This finding is consistent with the loss of material near to the 
point of chromosome breakage, followed by the concomitant amplification of 
sequence centromeric to the breakpoint. This provides further evidence that BFB 
is initiated in iAMP21 patients by loss of telomere. In those cases with no 
subtelomeric probe deletion, it is possible that deletion may have occurred in a 
region distal to the subtelomeric probe. One patient (6788) demonstrated that 
there was an amplification of subtelomeric DNA, consistent with breakage 
occurring in the adjacent region, followed by amplification in a fashion similar to 
that observed in mouse embryonic stem cells (Lo et al, 2002).  Similarly in patient 
3131, detailed mapping showed the telomeric probe to be located to an 
unexpected region, indicating that a break had occurred in a region distal to this 
probe. In another four patients (7255, 3743, 3527, 4780), a normal copy number 
was observed for the subtelomeric probe. However, in these cases it was not 
possible to confirm the location of this probe in metaphase, thus it cannot be 
ruled out that an additional copy of chromosome 21, with an intact telomeric 
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region was present (as seen by conventional cytogenetics in patients 3131 and 
3743) or that the deletion was distal to this probe.  
  Although the data indicated that the loss of a telomere may be the 
initiating event in the majority of iAMP21 patients, it is possible that in those 
patients with no evidence of subtelomeric loss that the BFB cycles may have 
alternatively arisen from defects in telomere function, or that the process may 
have been initiated by other events.  
  Previous studies have demonstrated amplification of genes at a distance 
from the telomere, indicating that alternative mechanisms do exist. Ciullo et al 
(2002) noted that overexpression of the PIP gene in breast cancer was initiated by 
activation of the fragile site, FRA7, on chromosome 7. Similarly, Miller et al (2006) 
found evidence that MET, which is up-regulated in oesophageal cancer, maps to 
the fragile site, FRA7G. Although no fragile sites have been detected on 
chromosome 21, Hattori et al (2000) found evidence of duplications of sequences 
of chromosome 21 which may be susceptible to DSB. Tanaka et al (2005;2007) 
noted that a critical event in the initiation of gene amplification was the 
formation of a large DNA palindrome, following the initial DBS break. They 
showed that DNA inverted repeats marked the borders between those regions 
which were amplified and those which are not. This indicated that the sites of 
such repeats may be important for the initiation of amplification. Similarly, 
Kolomietz et al (2002) highlighted that Alu repeat clusters, which have a high 
density of repetitive DNA, may be hot spots for DSB, and subsequent 
amplification.  
  Despite having no direct evidence that BFB initiated by loss of a telomere 
resulted in the generation of iAMP, the circumstantial evidence from this study 
indicated that this was the most plausible mechanism. 
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4.2.2 Termination of BFB 
  The BFB cycle ends, primarily, when the unstable chromosome stabilises 
by acquiring a new telomere. Acquisition of a new telomere, as reviewed by 
Murnane and Sabatier (2004), has been proposed to occur through a number of 
possible mechanisms including direct addition by telomerase, a recombination-
based mechanism of alternative lengthening of telomeres, non reciprocal- 
translocations, break-induced replication, and the formation of dicentric, 
isochromosome or ring chromosomes. 
  The ‘de novo’ addition of repeat telomere sequences by telomerase has 
been observed in humans with genetic diseases that result from terminal 
deletions (Varley et al, 2000) as well as in tumour cells (Murnane & Sabatier, 
2004). In childhood ALL, raised levels of telomerase (hTERT) (Cogulu et al, 2008) 
has been detected in pre-treatment samples compared to remission ones, 
indicating an increase in telomere synthesis associated with disease. A further 
mechanism of telomere acquisition is breakage-induced-replication (BIR) 
(Watanabe & Horiuchi, 2005), where the broken end of a chromosome with 
telomere loss invades a region of homology and initiates replication at that point 
by duplication. Telomeres can also be acquired in mammalian cells through the 
capture of the ends of other chromosomes as a result of nonreciprocal 
translocations. 
  The mechanism by which the telomeres are restored has an impact on the 
stability of the genome as a whole. Sabatier et al (2005) found that one of the most 
common methods of acquisition is through translocation, which can be either 
reciprocal or nonreciprocal (NRT), with loss of DNA from a donor chromosome, 
or through duplication, where DNA is retained on the donor chromosome. NRT 
result in the stabilisation of the recipient chromosome at the expense of the donor 
chromosome, which will now become unstable due to loss of its telomere. As a 
consequence, this chromosome undergoes further translocations with other 
chromosomes, resulting in the generation of complex karyotypes with numerous 
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translocations, amplifications and dicentric chromosomes. This chain of events 
will progress until there is acquisition of telomere through some mechanism 
other than non reciprocal translocation. In contrast, duplications do not result in 
further instability as the donor chromosome does not lose its telomere, but this 
mechanism will generate allelic imbalance. Thus, partial duplication of 
chromosome arms is observed in the karyotype. 
  Both complex and simple karyotypes were detected in the iAMP21 
patients in this study. The finding of complex karyotypes in some patients has 
provided further evidence of the BFB mechanism being initiated by of loss of 
telomere. However, in a number of patients dup(21) was the sole visible 
abnormality. Gisselsson et al (2000) suggested that complex karyotypes (≥ 5 
chromosomal aberrations) arise following BFB events in highly malignant 
tumours, whilst in less malignant tumours BFB events can give rise to 
chromosomal abnormalities that may be limited to ring chromosomes and 
telomeric associations. In a number of patients in this study (ten), a ring 
chromosome 21 with duplicated regions was present, consistent with this 
observation. 
  It is noteworthy that the level of RUNX1 amplification in the iAMP21 
patients ranged from 5 to 14 copies, with a median of 9. This may be an 
indication that the abnormality becomes stabilised relatively quickly. The results 
observed by conventional cytogenetic analysis and PNA telomere FISH 
demonstrated that in those iAMP21 cases examined, telomeres were present on 
the dup(21) chromosomes. It is possible to hypothesise that in these patients 
either a non-reciprocal translocation involving the telomere of another 
chromosome or a translocation involving duplication has occurred. In the 
iAMP21 cases it appears that the dup(21) has stabilised, although how this occurs 
remains unresolved. 
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4.2.3 Cell Cycle Checkpoint 
  Until a chromosome is able to stabilise via acquisition of a telomere, it 
follows that cells undergoing BFB cycles enter into their next mitosis with a 
chromosome lacking a telomere. In normal cells this would initiate cell cycle 
arrest via the ATM/p53 signalling pathway. Therefore it seems likely that cells 
undergoing BFB cycles will have abnormalities of the genes involved in these 
pathways. Studies in AML and MDS with amplification of MLL and RUNX1 
have linked these findings to mutations in p53 (Andersen et al, 2004;Andersen et 
al, 2001). Similar studies have not been undertaken in patients with iAMP21 to 
investigate the presence and mutation status of genes such as ATM or p53. High 
density oligonucleotide aCGH of patients with iAMP21 did not highlight a 
particular association with deletions of these genes, thus the presence of 
mutations cannot be excluded. It is of note that in a number of patients, deletions 
of the long arm of chromosome 11 were observed by cytogenetics, indicating a 
possible link with loss of the ATM gene, which is located at 11q21. Further 
studies need to be conducted in order to establish the involvement of these two 
genes in iAMP21 patients.  
4.3  iAMP21-a distinct genetic subgroup 
  Recurrent abnormalities of chromosome 21 are frequently found in a 
number of haematological malignancies. The two largest genetic subgroups in 
childhood ALL (high hyperdiploidy and those with the ETV6-RUNX1 fusion) 
contain either numerical and/or structural rearrangements of this chromosome, 
which together have an estimated frequency of approximately 50% (Pui, 2000). 
  In childhood ALL, iAMP21 has been observed as a rare cytogenetic 
subgroup in 1.5 -2% of patients. This abnormality is associated with distinct 
clinical features including a higher incidence in older children, a low presenting 
WBC count, a pre-B immunophenotype and a poor prognosis (Robinson et al, 
2003;Moorman et al, 2007b). As this abnormality was originally identified by 
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chance it was important to establish that it represented a primary genetic 
aberration rather than a secondary one, to an as yet, unidentified abnormality.  
Whole genome analysis using aCGH and conventional cytogenetics failed 
to detect any other consistent genetic aberrations in these patients, providing 
evidence that the dup(21) was the primary event. These results however do not 
rule out the possibility that the dup(21) chromosome may have arisen as a 
secondary event to a cryptic abnormality on chromosome 21. Kempski et al 
(1997;1998) noted cryptic chromosomal rearrangements including deletions and 
inversions of chromosome 21 in myeloid disorders, whilst Mikhail et al (2002) 
showed RUNX1 amplification on an apparently normal chromosome 21. 
Coupled with these observations, evidence of the intrachromosomal 
amplification of chromosome 21 (outlined in section 3.3.1) has been reported in 
both AML and in MDS (Viguie et al,2002;Baldus et al, 2004;Papenhausen et al, 
2005;Herry et al, 2006). Studies of de novo AML found that in these myeloid 
disorders, the amplification was linked to the transcription factors ERG and EST2 
(Baldus et al, 2004). Although no evidence of overexpression of these genes was 
found in iAMP21 patients (Strefford et al, 2006), their CRA included both of these 
genes. In an attempt to establish whether iAMP21 had arisen from a cryptic 
abnormality of chromosome 21 involving these genes or other genes in regions 
neighbouring RUNX1, an investigation was undertaken on a group of patients 
with karyotypic features similar to the iAMP21 cases but without any visible 
abnormalities of chromosome 21. As there was no evidence of abnormalities in 
these regions, it was concluded that iAMP21 had not arisen as a secondary 
change to a cryptic abnormality on chromosome 21.  
In AML, amplification of chromosome 21 appears to be distinct from that 
of iAMP21 found in ALL. The amplified genes in AML have been identified as 
ERG and ETS, not RUNX1 (Baldus et al, 2004). A comparison of the dup(21) 
morphology between the two diseases also provides evidence that it is different. 
The morphology of dup(21) in the AML appears uniform and more recognisable 
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as a rearranged chromosome 21 (Viguie et al, 2002;Fisher et al, 2003;Podgornik et 
al, 2007). Although, it is possible that in both disorders the dup(21) may have 
arisen by similar mechanisms, the initiating event may be different, resulting in 
the generation of different amplicons.  
  Having established that iAMP21 was not secondary to a cryptic 
chromosome 21 abnormality, it was important to exclude that it had not arisen 
from a visible structural abnormality of chromosome 21. The discovery that in 
two cases iAMP21 had arisen from a Robertsonian der(15;21) translocation raised 
the question as to whether the dup(21) may have arisen from an i(21)(q10). 
Screening a small group of i(21)(q10) patients failed to identify any unexpected 
copy number changes along the length of either chromosome arm, indicating 
that they were distinct from iAMP21.  
  The results from all studies point to iAMP21 representing a distinct 
genetic subgroup in ALL. However, two reports have linked RUNX1 
amplification to the ETV6-RUNX1 fusion. In one report, the clone of cells with 
amplification of RUNX1 was separate from the one with ETV6-RUNX1 fusion 
(Ma et al, 2001). The additional RUNX1 signals were not present on a single 
abnormal dup(21), but located to a number of marker chromosomes. In the 
second case, in addition to the RUNX1 amplified cells being a distinct ETV6-
RUNX1 negative population, 5.5% of the ETV6-RUNX1 positive cells also had 
RUNX1 amplification (Niini et al, 2000). Gain of additional copies of RUNX1 is a 
frequent secondary finding in ETV6-RUNX1 positive ALL, with the additional 
copies usually corresponding to either gain of chromosome 21, gain of the 
derivative chromosome 21, or gain of the derivative chromosome 12. Although 
both reports clearly provide evidence of amplification similar to iAMP21in 
interphase cells, the G-banded morphology is different from iAMP21. Without 
screening cells from these reported patients with the probes used in this study, it 
is not possible to determine whether the amplification is similar to that described 
in this study or different. It is of note, that in both cases the majority of cells with 
  157Discussion 
amplification occurred in a population distinct from the one with ETV6-RUNX1 
fusion, suggesting that the amplification had arisen independently, rather than 
as a secondary event to the ETV6-RUNX1 fusion. Further studies are required to 
establish whether these cases can be linked in any way to the iAMP21 genetic 
subgroup.  
4.4  Variant iAMP21 
  A number of variant translocations, in which one gene characteristically 
involved in a common translocation is fused to a different partner gene, have 
been described in haematological malignancies. The fusion proteins resulting 
from these variant translocations have a similar structure and function to those 
from the common translocation and so exert the same effect at a molecular level. 
Four cases were identified in this study with copy number changes characteristic 
of iAMP21, but which could not be strictly defined as such. Detailed analysis 
revealed that two of these cases had arisen from a Robertsonian der(15;21) 
translocation. In both cases the der(15;21) chromosomes had features consistent 
with having arisen as a result of BFB, with the derivative chromosome containing 
both chromosomes 15 and 21 material distributed along the length of the 
der(15;21). As iAMP21, there was evidence that the initiating event may have 
been loss of a telomere, with one case (11005) having loss of a 21q subtelomere 
whilst the other (6783) had loss of a 15q subtelomere. These two cases may 
represent variant iAMP21 which have arisen by a common mechanism to 
generate a derivative chromosome with features consistent with the iAMP21 
abnormality. Niini et al (2000) described RUNX1 amplification in one case in 
which copy number changes on the long arm of chromosome 15 were also 
observed using comparative genomic hybridisation. In the study by Cooley et al 
(2002), two cases with a missing chromosome 21 also had loss of chromosome 15 
and a further case with an add(21) had a clone with a dic(15;21). It is possible that 
chromosome 15 may be involved in leukemogenesis in iAMP 21 patients. 
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Heerema et al (Heerema et al, 2002) noted that 1% of childhood ALL had 
breakpoints in 15q13~15, a finding consistent with the CRD seen on chromosome 
15 in the two patients with der(15;21)dup(15;21). The RAD51 gene is located in 
this region, which is known to be involved in homologous recombination and 
repair of DNA. It is possible that in these cases deletion of RAD51 has 
contributed to the abnormality. Further studies are required to determine 
whether this chromosome and/or gene are involved in iAMP21 patients. 
   In the remaining two cases, chromosome 21 material was found in 
locations other than on the dup(21). In one case (4746), a t(20;21) translocation 
had been detected by both G-banding and FISH, together with three copies of a 
rearranged chromosome 21. It is possible that in this case the additional copies 
arose from a duplication of the reciprocal partner chromosome from this 
translocation. Alternatively, amplification may have been generated by BFB 
cycles followed by stabilisation of the abnormal chromosome 21 by insertion into 
other chromosomes (Albertson, 2006). Lastly, in patient 5047, the distribution of 
RUNX1 signals was not consistent with iAMP21, as four marker chromosomes, 
each containing chromosome 21 material were identified. In these cases it is 
possible that because they have a genomic profile similar to that of iAMP21, that 
they represent variant or masked cases. However, as it has not yet been 
established at the molecular level that these cases are linked, it is not appropriate 
to definitively define them as iAMP21, thus they remain a diagnostic dilemma.  
4.5  Diagnostic Test 
  The success of risk adapted therapy relies on the accurate detection of 
patients with features associated with a poor prognosis. Moorman et al ( 2007b), 
established that the iAMP21 subgroup was linked to a poor prognosis and 
patients on the UKALL97 treatment trial, had a significantly inferior 5 year 
overall survival compared to other groups on the same treatment trial. To date, 
there is no supporting evidence from alternative treatment protocols with long 
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term follow up, of the association between iAMP21 and a poor prognosis, as for 
the most part these patients have remained undetected. The majority of other 
groups do not routinely use FISH techniques, but rely instead on other molecular 
techniques to identify the significant genetic subgroups.  
  As outlined in section 3.1.1, currently FISH provides the only reliable 
method to identify these patients. Although this was the original method used to 
define the subgroup, in the absence of metaphases it can be difficult to 
distinguish them from ALL patients with other numerical abnormalities of 
chromosome 21. It was thus of paramount importance to design a test which 
would accurately diagnose iAMP21 patients using complementary FISH or 
molecular based techniques. 
  The results from this study have illustrated that iAMP21 has a distinct 
profile in relation to copy number changes along the length of chromosome 21. 
These differences were exploited to design a diagnostic test based on the 
comparative quantification of three regions along the length of chromosome 21 
(section 3.2). Blind testing validated that in principal this technique (MLPA) was 
equally effective distinguishing cases of iAMP21 from those with numerical 
abnormalities of chromosome 21. Ideally a diagnostic test should identify all 
individuals with the particular abnormality without any risk of false positive or 
false negative results. In this study, although no false negative cases were 
identified, cases with copy number changes involving RUNX1 were difficult to 
distinguish from those with iAMP21, and so might be classified as false positive. 
The selection of only a single location within the CRA may have been responsible 
for this limitation. By using alternative as well as additional probes within this 
region, it should be possible to improve this test to accurately distinguish 
iAMP21 cases from those with numerical abnormalities of chromosome 21. 
However one other limitation of this test is its inability to detect other genetic 
rearrangements arising from balanced translocations, such as BCR-ABL1 or 
ETV6-RUNX1 fusions, thus it cannot be described as a definitive test. 
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4.6  Future Studies 
  The current definition of iAMP21 requires the presence of ≥ 5 copies of the 
RUNX1 gene. Although the results of this study validated that this was an 
appropriate selection criteria, it is biased against those cases where the copy 
number is ≤ 4. It is possible that cases with similar profiles exist which have a 
lower RUNX1 copy number than that currently used to define the abnormality. 
FISH screening with the TEL-AML1 ES® probe (Vysis, UK) in large series of 
patients, have identified a number of ETV6-RUNX1 negative cases, with 3 – 4 
copies of the RUNX1 gene (personal communication: Professor CJ Harrison, 
LRCG). Conventional cytogenetic analysis did not always establish in these 
cases, if this was due to the presence of an additional copy of chromosome 21, a 
rearrangement of the RUNX1 locus or copy number changes within the 
chromosome 21. Screening these patients with an improved iAMP21 FISH 
diagnostic test (Section 3.4.2.1) should establish whether they have similar 
genomic profiles to those seen in iAMP21. Any cases identified in this way to 
have low level copy number changes along chromosome 21 would undergo 
further studies similar to the ones outlined in the characterisation of iAMP21 
(Section 3.2), in an attempt to precisely define this abnormality.  
4.6.1  RUNX1  
  Since the first description of iAMP21 in which Le Coniat et al (Le Coniat et 
al, 1995) linked this abnormality to RUNX1, there has been speculation about the 
involvement of this gene in the abnormality. Mutations of RUNX1 have been 
found in a number of cases of AML and MDS (Busson-Le Coniat et al, 
2001;Penther et al, 2002;Owen et al, 2008;Niebuhr et al, 2008), however sequence 
analysis failed to detect such mutations in the significant regions of the gene in 
childhood ALL patients with amplification of RUNX1 (Greaves et al, 2003;Hong 
et al, 2008). It has been hypothesised that mutations and translocations in this 
gene are the initiating event in the leukaemias in which they occur. Evidence 
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supporting this theory in ALL comes from studies which have demonstrated that 
the ETV6-RUNX1 fusion occurs in a pre-leukaemic clone which requires a second 
hit to bring about overt disease (Pui & Evans, 2006). This gene remains a 
potential candidate for leukaemogenesis in these cases, due to its essential role in 
haematopoiesis, therefore further studies are required to determine its mutation 
status in a larger group of patients, as well as to exclude the presence of any 
fusion gene involving RUNX1. Currently FISH has been the only technique used 
to exclude a fusion and it may be possible that a break has occurred within a 
region that is too small to be detected by FISH. An investigation into exon copy 
number with MLPA may provide a means to further investigate this.  
4.6.2 SLC19A1  
  Recent studies in the pharamacogenetics of ALL (Cheok & Evans, 2006) 
have provided evidence of potential mechanisms for the development of drug 
resistance. By identifying the genetic determinants of such drug resistance it may 
be possible in the future to tailor treatment to individuals and so reduce the 
toxicity and increase the efficacy of treatment in ALL. One of the potential causes 
of the development of drug resistance in ALL is alterations in the genes involved 
in metabolism, such as drug transporters or drug targets (Ganapathy et al, 2004).  
  Folate is an essential co-factor in purine and pyridine synthesis and 
methotrexate its structural analogue inhibits a number of specific steps in DNA 
synthesis (Figure 4.2). The main mechanism by which methotrexate and natural 
folate enter cells is through the reduced folate gene or SLCA19I located on 
chromosome 21 (Pui & Evans, 2006).   
  In high hyperdiploid ALL with gain of chromosome 21, increased 
expression of SLC19A1 has been shown in association with greater accumulation 
of methotrexate polyglutamates (Chango et al, 2000). This increase in expression 
is associated with an improved outcome in those children treated with low dose 
methotrexate and it has been proposed as a mechanism to explain the good 
  162Discussion 
prognosis associated with this specific subgroup. Mutations in this gene have 
been found in tumour cell lines leading to disrupted methotrexate transport and 
subsequent drug resistance (Laverdiere et al, 2002). Although genetic mutations 
have not been identified in primary ALL cells, a common polymorphism of this 
gene has been associated with increased relapse in ALL. In a study of childhood 
ALL patients homozygous for the 80A polymorphism (Kager et al, 2005;Ge et al, 
2007) it was noted that the methotrexate levels in plasma were higher than those 
patients without the polymorphism and that their prognosis was worse. The 
authors suggested that this was a direct consequence of decreased uptake of 
methotrexate.  
 The  SLC19A1gene is located on chromosome 21 at genomic position ~45.7 
Mb. In a number of iAMP21 patients this region was located within the CRD 
identified from the aCGH and FISH studies. As studies in folate pathway gene 
expression have noted that expression differs in different subtypes of ALL 
(Cheok & Evans, 2006) it is possible to hypothesise that the poor outcome 
observed in these patients may be a direct consequence of either deletions 
and/or mutations of this gene. Further studies should be undertaken in iAMP21 
patients to investigate the expression level of SLC19A1as well as the presence or 
absence of the G80A polymorphism.  
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Figure 4.2 The folate pathway. Methotrexate enters the cell via SLC19A1, and 
inhibits the dihydrofolate reductase, which results in the depletion of cellular 
folates. Adapted from Cheok (2006). 
 
  Currently there have been no reports of relapse in the iAMP21 patients 
being treated on regimen C of the UK treatment trial ALL2003 (personal 
communication: Dr AV Moorman, LRCG). Similarly the initial results from the 
Berlin-Frankfurt-Münster (BFM) ALL treatment trials, indicate that iAMP21 
patients fare better (personal communication: Dr AV Moorman, LRCG). 
Although these are preliminary results it is possible that it may be due to the 
more intensified therapy which includes methotrexate given in both of these 
trials which may over come the deleterious effect of the deletions /mutations in 
SLC19A1. Further studies into the efficacy of these treatment trials may provide 
evidence in support of this hypothesis. 
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4.6.3 Screening of relapse samples 
  The results from this study have identified a small CRA in all iAMP21 
patients. However, despite extensive studies, no putative target gene has been 
identified, located within this region or elsewhere in the genome, to be the causal 
event driving leukaemogenesis in these patients. Detailed analysis of patient 
karyotypes coupled with high resolution genome aCGH also failed to identify 
any single common abnormality, other than dup(21) that may be the driving 
mechanism. A direct comparison between diagnostic and relapse samples from 
iAMP21 patients may confirm whether the dup(21) is the primary change in 
these patients. In addition to this a comparison between the two samples would 
determine if the dup(21) chromosome has remained stable or continued to 
evolve. It is proposed that a study be undertaken on relapse samples using a 
combination of techniques including, interphase FISH, conventional cytogenetics 
and oligonucleotide aCGH and the results compared to those of the diagnostic 
samples. 
4.7  Conclusions 
  Investigations using FISH, aCGH and G-banding have established 
that iAMP21 is a highly complex genetic abnormality involving large 
regions of chromosome 21 
  It is characterised by the presence of a highly complex 
rearrangements along the duplicated chromosome 21, involving 
numerous chromosomal breaks, giving rise to a chromosome with 
deleted, duplicated, inverted and amplified regions 
  iAMP21 appears to be a primary cytogenetic change and not a 
secondary abnormality 
  The abnormality can be distinguished from other numerical 
abnormalities of chromosome 21 by exploiting the unique pattern of 
gain, amplification and deletion seen in these patients 
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  Variant cases may exist, however further work is required to 
characterise them more fully 
  The abnormality may be driven by a BFB mechanism, potentially 
initiated by loss of a telomere: an unusual mechanism in ALL 
  Patients with iAMP21 appear to be distinct from other genetic 
subgroups associated with ALL 
  The initiating mechanism has not yet been elucidated. This discovery 
would assist in more accurate diagnosis and provide further insight 
into the understanding of other rare subgroups of ALL 
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  168Table A1.1 Karyotypes and clinical details of previously reported patients with iAMP21. 
 
Case No 
in study 
Sex 
/Age 
(years) 
WBC 
109/L 
Karyotypes 
Number 
of 
RUNX1 
signals 
by FISH    
3  F/11  NA  46,XX,-21,+mar  5  1 
1  M/15  4.3  46,X,-Y,add(21)(q22),+mar1 [8]/46,XY[12]  4–5  1 
2  M/6  4.9  53,XY,+X,+Y,inv(3),add(4),+9,+17,+21,+21,+add(21)(q22)  4–5  1 
1  F/10  1.4  46,XX,der(21)[2]  4–5  2 
2  M/11  5.9  47,X,+X,inv(Y)(p11.2q12),+10,-20,der(21)[20]  6  2 
1  F/15  NA  46,XX,add(1)(p?),del(6)(q25)  >4  3 
38  M/2.9  NA  46,XY  4–5  3 
39  F /3.4  NA  46,XY  >4  3 
10  F/12  7.1  48,XX,+X,+10,del(11)(q23),qdp(21)(q11q22)[13]/46,XX[7]  5  4 
9  F/8  0.9  47,XX,+X,del(21)(q22),der(21)[12]/46,XX[4]  5-10  5 
1  M/12  4.3  46,XY,del(18)(p11),der(21)  10–15  6 
2  F/5.6  26.3  48,XX,-20,+der(21),+2mar  6  6 
44  M/13  7.6  46,XY,i(9)(q10),-16,+mar (trp 21q using SKY)  4  7 
64  M/14  14.5  46,XY  6–15  7 
3  M/17  1  46,XY,add(1)(q25),add(21)(q21) [6]/46,XY[14]  8  8 
4  F/19  10.1  46,XX,del(7)(p14p21),-21,+mar[10]/46,XX[2]  6–8   8 
1 F/11  18  46,XX,del(8)(q?),+13,-19,add(21)(p)[5]  >10    9 
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Case No 
in study 
Sex 
/Age 
(years) 
WBC 
109/L 
Karyotypes 
Number 
of 
RUNX1 
signals 
by FISH    
11  F/13  2.8  46,XX,-21,+mar[9]/46,XX[2]  5–10   9 
5  M/14  2.2  46,XY,inv(7)(p?15q?21),-21,+mar[2]/46,XY[4]  5–7  9 
6  M/12  15.1  46,XY,-21,+mar[8]  5–7   9 
7  F/13  3.8  46,XX,del(7)(q22q35),del(11)(p12),add(21)(p11.2) [9]/46,XX[5]  5  9 
8  F/15  9.9  46,XX,trp(21)(q11.2q22)[13]/46,XX[7]  4  9 
11  F/13  6.6  47,XX,?add(4)(q31),del(7)(q3?2),i(21),+mar[5]/46,XX[10]  5  9 
12  M/5  7.2  56,XY,+X,+Y,+6,+10,+14,+17,-19,+21,+22,+mar1,+mar2, +mar3[5]/46,XY[18]  5–10   9 
13  F/6  3,1  54,XX,+X,+6,+9,+14,+17,+18,+2mar[12]  4–10   9 
14  M/11  NA  46,XY[30]  3–10   9 
15  F/11  1.6  Failure  >10   9 
16  M/7  NA  Failure  4–10   9 
1  F/15  NA  46,X [20]  15–20   9 
65  F/8  2  Failure  6–15  9 
2423 M/10  2 48,XY,+X,+14,ider(21)(q10)dup(21)(q?)  6+  10 
2776 F/7  17  47,XX,+X,der(21)r(21)(q?)dup(21)(q?)  4-6  10 
3131 M/11  11  46,XY,t(1;16)(q23;p13),ider(21)(q10)dup(21)(q?)/51,idem,+X,+3,+10,+14,+21 6+  10 
3368 M/20  6 46,XY,del(7)(p1?5),t(8;22)(q1?1;q13),dup(21)(q?)  5+  10 
3527 F/13  3  45,XX,-7,del(12)(p12),dup(21)(q?)  5+  10 
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Case No 
in study 
Sex/ 
Age 
(years) 
WBC 
109/L 
Karyotypes 
Number 
of 
RUNX1 
signals 
by FISH   Ref 
3956 M/7  3 
45,XY,dic(8;16)(p1;p1),del(13)(q1?4),dup(21)(q?)/46,idem,t(Y;13)(q1;q1?4),         
+dic(8;16)(p1;p1)*  4-7  10 
3970  F/12 2  47,XX,add(7)(q2?),+10,der(21)r(21)(q?)dup(21)(q?)/47,idem,del(12)(p13)  6-10  10 
4134 M/8  4  46,XY,dup(21)(q?)  5+  10 
4135 F/14  1  46,XX,t(12;16)(q24;p11),del(15)(q24q26),t(17;20)(p1?3;q11),der(21)dup(21)(q?) 6+  10 
4178 F/14  3  46,XX,del(7)(q22),t(14;22)(q32;q11),dup(21)(q?)*  7+  10 
4237 F/13  3  46,XX,der(21)dup(21)(q?)/46,idem,del(16)(q1?)  6-8  10 
4279 M/5  8  47,XY,-12,der(21)dup(21)(q?),+mar1,+mar2  4-9  10 
4405 M/8  3  45,Y,t(X;15)(q2?1;q2?4),dic(12;17)(p1;p1),der(21)r(21)(q?)dup(21)(q?)  5-8  10 
4444 M/9  2  46,XY,der(21)r(21)(q?)dup(21)(q?)  6+  10 
4623 F/6  14  46,XX,dup(21)(q?)/47,idem,+X  4-7  10 
5601 F/14  1  46,XX,del(9)(p22),dup(21)(q?)  4-6  10 
5607 M/8  4  46,XY,t(8;11)(p2?1;q21),der(21)r(21)(q?)dup(21)(q?)/47,idem,+X*  4-6  10 
5754 M/9  2  46,XY,ider(21)(q10)dup(21)(q?)*  4-6  10 
2848 M/5  2  46,XY,  dup(21)(q?)  5-7  10 
3382 M/11  6 46,XY,i(9)(q10),del(11)(q2?1),der(21)dup(21)(q?)  5 11 
3767 F/10 1.1  46,XX,dup(21)(q?)  5  11 
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Case No 
in study  
Sex/Age 
(years) 
WBC 
109/L 
Karyotypes 
Number 
of 
RUNX1 
signals 
by FISH    
4414 M/7 
9 
45,XY,t(6;19)(p21;p13),der(7)t(7;15)(p1;q1),del(11)(p13), 
-15,del(16)(q2),ider(21)(q10)dup(21)(q?)  4-6  11 
1  M/8  29.8 44~46,XY,del(1)(q32),-5,-9,-21,-21,add(21)(q22),+mar1,inc[7]/46,XY[3]  4  12 
2  F/9  2.6 46,XX,del(6)(q24),add(21)(q22)[4]/46,XX[7]  4-5 12 
3  M/10  1.9 46,XY,add(21)(q22)[9]/46,XY[1]  3-6 12 
4  F/8  2.4 46,XX,add(21)(q22)[18]/46,XX[2]  4-7 12 
5  F/10  11.6 45,XX,t(3;12)(q21;q24),-7,add(21)(q22)[11]  4-5  12 
6  M/11  4.2  46,XY,add(21)(q22)[11]/46,XY[4]  4-5  12 
8 F/12  11.7 
46,XX,t(5;9)(q35;q22), 
-7,ins(8;7)(p11;q11q32),der(11)t(7;11)(q32;p15),add(21)(q22),+mar[5]/ 
45,XX,t(5;9)(q35;q22),-7,add(21)(q22)[4]/46,XX[3] 3-4  12 
9  M/12  69.9 46,XY,add(21)(q22)[8]  4  12 
10  F/12  2.3 46,XX[20]  4  12 
11  F/2  68 47,XX,t(1;19)(q23;p13),+mar[20]  3-4 12 
12  F/5  32.8 53-57,XX,+4,+5,+6,+17,+21,+r(21)(q?)dup(21)(q22.13)inc[12]  4-5  12 
13  M/10  4.2 46,XY,add(4)(q31),add(21)(q22)[21]  5  12 
14  F/9  33.9 47,XX,del(7)(p11.1),add(21)(q22),+mar[6]/46,XX[8]  5  12 
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Reagents 
 
Luria-Bertani (LB) plates. 
  
10g Tryptone (Sigma,UK) 
5g Yeast extract (Sigma,UK) 
10g NaCL2 (Sigma,UK) 
15g Agar (Sigma,UK) 
Make up to 1 litre with distilled water, autoclave, allow to cool to below  
50 ºC, add Chloramphenicol (Sigma,UK) or Kanamycin (Sigma,UK), pour into 
sterile Petri-dishes and store at 4 ºC for up to 1 month. 
 
Luria-Bertani (LB) broth 
10g Tryptone (Sigma, UK) 
5g Yeast extract (Sigma, UK) 
10g NaCL2  (Sigma, UK 
Make up to 1 litre with distilled water and autoclave.  
Store at room temperature for up to 1 month. 
 
Tris EDTA TE buffer pH 7.4 
10ml 1M TrisCL pH 7.4 (Sigma, UK) 
2ml 0.5M EDTA pH8 (Sigma, UK) 
Make up to 1 litre with distilled water and autoclave.  
Store at room temperature for up to 1 month. 
 
Tris-Borate-EDTA buffer (TBE)  Buffer 
 
108gms Tris-Base (Sigma, UK) 
55gms  Boric acid (Sigma, UK) 
9.3gms  Na 2 EDTA (Sigma, UK) 
Make up to 1 litre with distilled water.  
Store at room temperature for up to 1 month. 
 
2x SSC 
50mls 20xSSC (Sigma, UK) 
450mls purified H2O 
 
Block 
1gm dried milk powder (Marvel) in 10mls purified H2O 
 
 
 PCR Primers  
 
RUNX1 (Forward) 5 '-GGCCTCATAAACAACCACAG- 3'   Tm (57.3 ºC) 
RUNX1 (Reverse)  5 '-CATTCAGTGTGATTCGTCCTG- 3'    Tm  (57.9 ºC) 
 
STCH (Forward) 5 '- TTGACTCTCCTGTTGGCCG - 3'           Tm (57.3 ºC) 
STCH (Reverse)  5 '- CCCAACAGAACAATAGGTGG - 3'     Tm  (58.8 ºC) 
 
PRMT2 (Forward) 5 '- GACAAACCACTGCAGATTGG - 3'    Tm (57.3 ºC) 
PRMT2 (Reverse)  5 '-  CTCTTCATCCTGCCACGTG- 3'           Tm  (58.8 ºC) 
 
CYP27C1  (Forward) 5 '- AGTGGCCACCATCCTTTATG - 3'  Tm (57.3 ºC) 
CYP27C1 (Reverse) 5 '- CTGCATACATGGAGGTCTTG - 3'  Tm  (57.3 ºC) 
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Patient 
ID 
Chromosome 21  
morphology 
following review 
Karyotype 
2647 iAMP21 
47,XY,+X,dup(21)(q11q22),+dup(21)(q11q22)[7]/46,XY[2] 
 
2848 iAMP21 
46,XY,add(21)(q11)[7]/46,XY[4] 
 
2879  Loss of 21 
48,XX,+X,der(1)t(1;?13)(p34;q14),der(13)t(1;?;13)(p34;?;q14),+14,-15,+17,der(18)t(18;21)(q22;q21),-21,+mar[11]/46,XX[3] 
 
3137 duplicated  21  46,XX,add(7)(p),add(21)(q)[4]/46,idem,add(3)(q2)[3]/46,XX[3] 
3230 
No slides for 
review 
46,XX,add(21)(q22)[9]/46,XX[2] 
 
3767 iAMP21  46,XX,dup(21)(q?)[2]/46,XX[5] 
2752 iAMP21  46,XX,?add(9)(q34),del(11)(q23),der(18)?t(18;20)(q25;p1?1),der(20)t(11;20)(q?;p?), add(21)(q22)[3] 
2904 iAMP21  46,XX,del(7)(q22q32),add(21)(q22)[16]/46,XX[9] 
5661 iAMP21  47,XX,+X,?del(11)(q?),?add(17?)(q),add(21)(q?),inc[cp10] 
5632 duplicated  21  47,XX,t(14;20)(q32;q1?),add(21)(p1),+add(21)(p1)[9]/46,XX[1] 
4343 duplicated  21 
45,XX,der(1)t(1;4)(p36;?)dup(1)(q32),del(2)(p2?),der(3)t(3;6)(p?;p?),der(4)t(4;5;2),der(5)t(4;5)(q?;q?),der(7)t(7;20)(p22;?), 
der(10)t(10;2)(p;?),der(10)(6;10)(?;q),inv(11)(p15q23),-13,del(16)(q21),der(16)t(16;17)(q13;p13),der(18)t(18;20)(q;?), 
der(20)t(9;20),der(20)t(9;20;?17;14),dup(21)(q21)[cp4] 
5897  Loss of 21  45,XY,t(1;2)(p?22;q3?6),del(4)(q2?5),del(6)(p2?2),-6,?idic(9)(p2),add(14)(q32),+16, add(16)(q2?4),-20,-21,+mar[cp3]/46,XY[7] 
Table A3. 1 Karyotypes of cases identified from G-banding review as being possible iAMP21 patients. 
  
T
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able A3.2. BAC clone name and position for chromosome 21. Clones run from top to 
ottom in centromere to telomere direction. 
 
BAC clone 
Clone 
Position 
Mb  Clone Start 
position 
Clone End 
position 
Chromosome 
21 band  
AF127936 15.1  14988775 15138458  21q21.1 
RP11-15E10 18.7  18595720 18774434  21q21.1 
RP11-375O2 19.3  19211405 19376024  21q21.1 
RP11-49B5 20.3  20224514 20390557  21q21.1 
RP11-64I12 22.1  22059729 22195086  21q21.1 
RP11-97F14 22.9  22783095 22943367  21q21.2 
RP11-80N20 23.8  23885285 24051118  21q21.2 
RP11-13J15 24.1  24047487 24200441  21q21.2 
RP11-88D18 25.5  25400597 25568509  21q21.2 
RP11-15H6 26.7  26666311 26816805  21q21.3 
RP11-90A17 27.7  27718668 27867189  21q21.3 
RP11-79G23 29.3  29260483 29449549  21q21.3 
RP11-30N6 29.7  29766105 29836744  21q21.3 
RP11-191I6 31.4  31453691 31454003  21q22.1 
RP11-147H1 32.3  32372362 32372918  21q22.1 
RP11-79D9 33.2  33204657 33369197  21q22.1 
RP11-79A12 34.7  34660659 34819795  21q22.1 
RUNX1  35.3  35229245 35371851  21q22.1 
AF121782 40.0  40015038 40157799  21q22.2 
RP11-114H1 41.2  41110821 41272864  21q22.2 
RP11-120C17 41.7  41630603 41780323  21q22.3 
RP11-88N2 43.7  43556394  43769964 21q22.3 
21qtel D21S1575  46.9  46144350 46311763  21q22.3 
181Table A3.3 Copy number changes detected by interphase FISH screening along the length 
of chromosome 21 in ten iAMP21 patients and two control patients (6899, 6009).  Probes run 
from top to bottom, centromeric to telomeric direction. Copy number is recorded as the range 
of signals detected at each location. 
 
 
Bac Probe  iAMP21 Patients    
Control 
patients 
   4405  4134  4279  5898  6092  6783  6788  6957 7219 7255     6009  6899 
AF127936  2  2-4  2-3  1-2  2 2-5  2 2 2-5  2-3      2-4 2 
RP11-15E10  2-3  2.6 Fail  1-2 2  2  2-3 2  2-5 1-2     2-4 2 
RP11-375O2  2-3 2-5  2-3  1-2  2 2 2 2 2-6  1-2      2-4 2 
RP11-49B5  2-4  2-5 2-4 1-2 2  2-3 2-3 2  2-5 2-4     2-4 2 
RP11-64I12  2-6  2-5 2-4 2-3 2-4 2-3 2-3 2-3 2-3 2-4     2-4 2 
RP11-97F14  2-6  2-5 2-4 2-3 2-7 2  2-3 2-3 2-3 2-4     2-4 2 
RP11-80N20  2-9  2-8 2-4 2-3 2-6 2-3 2-5 2-5 2-7 2-7     2-4 2 
RP11-13J15  2-8  2-8 2-4 2-3 2-6 2-3 2-5 2-5 2-7 2-8     2-4 2 
RP11-88D18  2-9  2-5 2-5 2-3 2-6 2  2-5 2-5 2-7 2-5     2-4 2 
RP11-15H6  2-11  2-7 2-4 2-3 2-6 2-4 2-5 2-5 2-7 2-9     2-4 2 
RP11-90A17  2-12  2-8 2-6 2-4 2-6 2-4 2-8 2-7 2-9 2-7     2-4 2 
RP11-79G23  2-10  2-6 2-5 2-5 2-5 2-5 2-5 2-5 2-8 2-8     2-4 2 
RP11-30N6  2-9  2-6 2-5 2-5 2-4 2  2-5 2-6 2-7 2-8     2-4 2 
RP11-191I6  2-11  2-5 2-7 2-5 2-7 2  2-5 2-5 2-8 2-9     2-4 2 
RP11-147H1  2-14  2-6 2-6 2-5 2-8 2-6 2-5 2-5 2-7 2-9     2-4 2 
RP11-79D9  2-14  2-7 2-5 2-5 2-7 2-5 2-5 2-7 2-8 2-8     2-4 2 
RP11-79A12  2-7  2-10  2-5 2-5 2-7 2-6 2-6 2-7 2-7 2-8     2-4 2 
RUNX1  2-8  2-7 2-9 2-6 5-8 2-6 2-5 2-9 2-9 2-9     2-4 2 
AF121782  2-11  2-3 2-5 2-5 2-6 2-3 2-6 2-5 2-6 2-8     2-4 2 
RP11-114H1  1-2  1-2 2-6 2-5 2  2-5 2-6 2-5 1-3 2-3     2-4 2 
RP11-120C17  1-2  2-6 2-6 2-5 2  2-5 2-5 2-6 1-3 2-4     2-4 2 
RP11-88N2  1-2  1-2 1-2 1-2 2  2-5 2-5 2-6 1-3 2-4     2-4 2 
21qtel  D21S1575  1-2  1-2 1-2 1-2 2  1-3 2-5 1-2 1-3 2-3     2-4 2 
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Figure A3.1 BAC aCGH profiles of seven iAMP21 patients (5898, 6788, 6957, 6783, 7219, 7255, 4279) and control patient 
  
 
(6899). 
Table A3.4  Copy number changes detected by interphase FISH screening along
P21.Probes run from top to bottom, centromeric to 
elomeric direction. Copy number is recorded as the range of signals detected at e
ocation. 
 the 
length of chromosome 21 in 48 iAM
t ach 
l
 
 BAC Clone and genomic position Mb 
24.1    29.8     32.3     35.5     40.0     43.7     46.9  Patients dup(21) 
RP11-
13J15    
RP11-
30N6    
RP11-
147H1     RUNX1     AF121782    
RP11-
88N2     21qtel 
3131  LM  4-6  3-4  6-7   4-7    4-5    5   3-4 
5754  LM  3   5-8  4-7   4-7    4-6   5-8   1 
5898  LM  3   3-6    3-6   4-6   3-5   1  1 
6020  LM  3   4-5    5-6   5-7   3-5   1  1 
6788  LM  4-5  3-5  4-5   3-5    4-6   4-5  3-5 
6957  LM  3-5  4-5  4-6   4-9    4-6   4-6   1 
7045  LM  4-6  4-8  5-8   5-8    4-8   4-8   1 
7829  LM  FAIL    6-7    FAIL    6-9   6-9   1    1 
3956  LA  5   5-8  5-8  6-10   6-8   5-7   1 
4134  LA  5-8  3-7  4-6   4-7    3-4    3    1 
4178  LA  4-5  6-7  6-8   6-8    7-8    1    1 
4623  LA  2  4   5-9   5-6   6-9   1  1 
6008  LA  5  5   4-6    5-10    5-8   1  1 
6783  LA  3  2   3-6   4-6   3    3-5    1-3 
6937  LA  2   4-5    7-8    7-10    7-9   1  1 
7219  LA  5-7  5-7  5-7   5-9    4-5    1    1 
7255  LA  5-7  3-4  4-14   5-11    5-8    3    2 
8743  LA  3-5  4-6  3-5   3-5    4-5   4-5   1 
2776  R  3  3  3  4-6   6-8    5-8   1 
3743  R  2  2   4-5   4-7   4-5   5  3 
3970  R  FAIL    3-4    FAIL    4-5   6-7   1    1 
4405  R  4-8   6-10  6-10   5-8    5-8    1    1 
4444  R  4-6  4-6  4-6   4-7    6-8   5-8   1 
5607  R  5-7  2-3  5-7   4-6    FAIL   4-7   FAIL 
5674  R  1   4-6    FAIL   6-8   5-8   1  1 
5809  R  3  4   5-8   6-8   5-7   1  1 
7583  R  3  3   4-5   4-6   4    4-5   1 
7650  R  4-5   5   6-8   5-9   5-7   1  1 
3527  SA  3   3-4    4-5   4-5   3   2  2 
4780  SA  2  4   4-5    5    2-3   2  2 
3745  SM  5-8  4-5  6-8   6-8    5   5-7   1 
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Table A3.4 (continued)  Copy number changes detected by interphase FISH screening 
along the length of chromosome 21 in 48 iAMP21.Probes run from top to bottom, 
centromeric to telomeric direction. Copy number is recorded as the range of signals 
detected at each location. 
 
 BAC Clone and genomic position Mb 
24.1    29.8     32.3     35.5     40.0     43.7     46.9  Patients dup(21) 
RP11-
13J15    
RP11-
30N6    
RP11-
147H1     RUNX1     AF121782    
RP11-
88N2     21qtel 
4135  SM  5-6  5-7  5-7   6-9    6-7   4-5   1 
4237  SM  5-6  5-7  5-8   4-9    5-8   5-7   1 
4279  SM  3-4  4-5  4-7   4-9    3-5    1    1 
5655  SM  5  3  1  4-7   4-5   1  1 
6868  SM  FAIL   5-6   FAIL    5-6    FAIL   5-6   FAIL 
4316  n/a  FAIL   3   FAIL   3-5   4-5   3  3 
5858  n/a  3-4  5-7  5-7   4-8    6-7    4    4 
6092  n/a  4-6  3-4  4-8   5-8    3-7    2    2 
6111  n/a  FAIL  FAIL  FAIL   4-11    FAIL   FAIL   1 
6996  n/a  5-9   FAIL   8-10    8-14    8-9    1    1 
7024  n/a  3-4   1   4-5   4-8   6-9   1  1 
7093  n/a  4   5-7    5-7   6-8   5-7   1  1 
7100  n/a  3   3-4    4-5   3-7   3   3  2 
7732  n/a  3    3-5    FAIL    4-7   5-7   4-6    1 
7828  n/a  4-6  5-8  7-9   3-9    5-8    1    1 
8767  n/a  3   4-6  4-6   4-7    5-7    1   1 
8983  n/a  3-9   1   FAIL   4-9  FAIL  1  1 
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Table A3.5 Amplicon size as defined as a continuous area of amplification in iAMP21 
patients. Patients are ordered according to G-banded morphology 
Key : LM=Large metacentric; LA= Large acrocentric; R= Ring; SA= small acrocentric,  
SM= submetacentric;  n/a= Not applicable 
 
 
Patient 
ID 
G-Banded 
morphology 
Amplicon 
size Mb 
3131 LM  >  11.4 
5754 LM  >13.9 
5898 LM  >10.2 
6020 LM  >10.2 
6788 LM  >22.8 
6957 LM  >19.6 
7045 LM  >19.6 
3956 LA  >19.6 
4134 LA  >11.4 
4178 LA  >15.9 
4623 LA  >7.7 
6008 LA  >15.9 
6783 LA  >7.7 
6937 LA  >10.2 
7219 LA  >10.2 
7255 LA  >7.7 
8743 LA  >19.6 
2776 R  >8.2 
3743 R  >11.4 
4405 R  >15.9 
4444 R  >19.6 
5809 R  >7.7 
7583 R  >3.2 
7650 R  >15.9 
3527 SA  >3.2 
4780 SA  >3.2 
3745 SM  >19.6 
4135 SM  >19.6 
4237 SM  >19.6 
4279 SM  >10.2 
5655 SM  >4.5 
5858 n/a  >10.2 
6092 n/a  >7.7 
7024 n/a  >7.7 
7093 n/a  >10.2 
7100 n/a  >3.2 
7828 n/a  >15.9 
8767 n/a  >7.7 
  186 Figure A3.2 FISH with PAN telomeric probes (red) on patient 4623 (a) followed by 
(b) sequential WCP21 (green). WCP21 highlights normal chromosome 21 (small 
chromosome) and dup(21) (large green chromosome). 
 
a b a b a b
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Table A3.6 Karyotypes of patients selected to screen for cryptic abnormalities of chromosome 21. 
 
Patient 
ID 
Age at 
diagnosis  Immnophonotype 
Karyotype 
3209 14  BCP-ALL  46,X,-Y,+5[6]/46,XY[8]                                                                                                                                                            
3335 3  BCP-ALL 46-47,XX,del(1p),?add(9)(p11),del(9)(p11),del(9)(p13),-10,add(11)(p11),-12,del(17)(q21),-18,+3-4mar[cp19]           
3403 7  BCP-ALL  46,XY,del(7)(q22)[7] 46,XY,r(7)[8]/46,XY[5]                                                                                                                        
3836 6  BCP-ALL  47,XX,+X[13]/46,XX[7]                                                                                                                                                           
3854 10  BCP-ALL  46,XX,der(20)t(8;20)(q13;q13)[4]/46,XX[36]                                                                                                                         
3867 1  BCP-ALL 45,X,der(X)t(X;3)(p22;p21),der(3)t(3;9)(q2?;p2?),der(3;9)(q10;q10)[17]/46,XX[3]                                                           
3895 3  BCP-ALL  46,XY,del(7)(q32)[2]/ 46,XY[28]                                                                                                                                            
3939 14  BCP-ALL  46,XY,del(9)(p1?2p2?4)[4]/46,XY[1]                                                                                                                                     
3993 1  BCP-ALL  47,XY,+X,?inv(11)(q13q23)[11]                                                                                                                                              
4021 8  BCP-ALL 45,X,-Y,add(9)(p11)[5]/47,idem,+X,?+Y[1]/46,XY[2]                                                                                                        
4088 9  BCP-ALL  46,XY,del(13)(q14q32)[7]/47,Y,add(X)(p?2),+4,add(9)(p?)[4]                                                                                           
4206 2  BCP-ALL  46,XY,del(9)(p22)[4]/46,XY[20]                                                                                                                                             
4335 12  BCP-ALL  46,XX,del(11)(q13q23)[11]/46,XX[4]                                                                                                                                     
4400 3  BCP-ALL  46,XX,del(12)(p11.2p13),del(13)(q22q32),add(20)(q13)[6]/46,XX[11]                                                                              
4461 12  BCP-ALL  46,XX,t(2;16)(p1?1;p1?1),del(9)(q1?1;q22)[16]/46,XX[13]                                                                                                  
4509 2  BCP-ALL  46,XY,del(9)(p11)[20]                                                                                                                                                               
4521 13  BCP-ALL 46,XY,add(2)(q?1)[5]/46,XY[19]                                                                                                                                            
4557 12  BCP-ALL  47,XY,+12[2]/46,XY[28]                                                                                                                                                          
4730 2  BCP-ALL 45,XY,del(7)(q22),del(7)(q22),-9,add(9)(p12),der(16)t(9;16)(q1?3;q1?3)[8]/46,XY[26]                                                   
4821 1  BCP-ALL 45,XY,t(1;18)(p2?2;q11),-7,der(9)t(7;9)(p1?;p2?),t(14;22)(q11;q1?2)[4] 
 
 
 
 
 
 
 Table A3.6 Karyotypes of patients selected to screen for cryptic abnormalities of chromosome 21 (contd). 
 
Patient 
ID 
Age at 
diagnosis 
Immnophonotype 
Karyotype 
4964 5  BCP-ALL 46,XX,?t(8;20)(q2?3;q1?3.1),del(14)(q11q1?3)[10]                                                                                                                
4970 11  BCP-ALL 46,XX,+8,?dic(8;18)(p11;p11)[7]/47,idem,+?dic(8;18)(p11;p11)[7]/46,XX[1]                                                                  
4972 10  BCP-ALL  46,XX,?dup(14)(?q32?q32)[17]/46,XX[8]                                                                                                                              
4984 5  BCP-ALL  46,XY,i(9)(q10)[8]                                                                                                                                                                     
4990 16  BCP-ALL  46,XX,t(7;17)(q22;p11.2),del(11)(q13q21),t(12;22)(p13q1?3)[5]/46,idem,del(7)(q22q?34)[13]/46,XX[2]                     
5069 4  BCP-ALL 46,XX,der(7)t(7;17)(p22;q21),t(7;15)(q22;q15)[20]/46,XX,t(7;15)(q22;q15),der(12)t(12;17)(p13;q21)[3]/46,XX[7]      
5578 9  BCP-ALL 48,X,t(Y;20)(q?11.2;p?)ins(Y;3)(q?11.2;?q?q),+13,+18[10] 
5630 12  BCP-ALL 46,XX,der(3,13,16)t(3;13)(q1?;q1)t(13;16)(q2;p1)del(3)(p?q?),t(3;8)(q2?;q2?)/46,XX[2]                                                  
5644 2  BCP-ALL  46,XX,del(9)(p1?),der(12)t(11;?;12)[3]/46,XX[8]                                                                                                                  
5666 7  BCP-ALL  45,XX,der(7)t(7;9)(q3?;q3?),-9[6]/46,XX[4]                                                                                                                           
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Table A3.7 Interphase FISH screen of ALL patients with probes adjacent to RUNX1. 
Columns represent probes and rows represent patients. 
. 
Clone 
Position 
Mb 
31.1 34.6  35.5 
(RUNX1) 
38.6 
(ERG) 
39.1 
(ETS2)  46 
Band 21q22.1  21q22.1  21q22 21q22.3  21q22.2 21q22.3 
Patient 
ID 
Copy Number 
3209  2  2 2 2  Fail  Fail 
3335  2  2 2 2  2  Fail 
3403  2  2 2 2  2  2 
3836 Fail Fail  2  2  2  2 
3854  2  2 2 2  2  2 
3867  2  2 2 2  2  2 
3895  2  2 2 2  2  2 
3939  2  2 2 2  Fail  2 
3993  2  2 2 2  2  2 
4021  2  2 2 2  2  2 
4088  2  2 2 2  2  2 
4206  2  2 2 2  2  2 
4335  2  2 2 2  2  2 
4400  2  2 2 2  2  2 
4461  2  2 2 2  2  2 
4509  2  2 2 2  2  2 
4521  2  2 2 2  2  2 
4557  2  2 2 2  2  2 
4730  2  2 2 2  2  2 
4821  2  2 2 2  2  2 
4964  2  2 2 2  2  2 
4970  2  2 2 2  2  2 
4972  2  2 2 2  2  2 
4984  2  2 2 2  2  2 
4990  2  2 2 2  2  2 
5069  2  2 2 2  2  2 
5578  2  2 2 2  2  2 
5630  2  2 2 2  2  2 
5644  2 2 Fail 2 2 2 
5666  2  2 2 2  2  2 
 
 
 
 
 Table A3.8 Interphase FISH screen of i(21)(q10) ALL patients with probes adjacent to 
RUNX1. Columns represent probes and rows represent patients. 
 
Bac clone and genomic position (Mb) 
24.1 29.8 32.3  35.5  40.0  43.7 46.9  Patient 
ID 
dup(21) 
RP11-
13J15 
RP11-
30N6 
RP11-
147H1 
RUNX1  AF121782 
RP11-
88N2 
21qtel 
5612 3  3 3 3  3  3  3 3 
9410 4  4 4 4  4  4  4 4 
9410 5  5 5 5  5  5  5 5 
5586 4  4 4 4  4  4  4 4 
5586 5  5 5 5  5  5  5 5 
5586 6  6 6 6  6  6  6 6 
5003 6  6 6 6  6  6  6 6 
5003 7  7 7 7  7  7  7 7 
 
 
 
 
 
Table A3.9 G-banded karyotypes of i(21) i(21)(q10) ALL patients. 
 
Patient  
ID 
Karyotype 
5003 49,XX,idic(21)(p11),+idic(21)(p11)x2,+mar1,+mar2[cp4] 
5586 56,XX,+X,+X,+4,+6,+10,+14,+17,+18,+21,+21[4]/ 55,idem,-21,-21,+i(21)(q10)[4]/ 
 56,idem,-21,-21,+i(21)(q10),+i(21)(q10)[6]/46,XX[1] 
5612 52-53,XY,+X,+4,+8,+14,+17,+18,idic(21)(p11),inc[cp5]/46,XY[13] 
7015 47,XX,+X,t(2;14)(p1?1;q11),-7,i(21)(q10)x2,+mar[5]/46,XX[5] 
9410 56,XY,+X,+Y,+6,+10,+14,+14,+15,+17,+21,+21,idic(21)(p1)[15] 
4676 47,XY,del(9)?(p11p13),i(21)(q10),+dup(21)(q?21q22)[15]/46,XY[5] 
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Table A3.10 Olignucleotide aCGH data for patients with dup(15;21) der(15;21) 
 
Patient 6783 
Diminished(5)(60.37[q12.1]-80.84[q14.1]), Diminished(9)(21.89[p21.3]-21.99[p21.3]), 
Enhanced(15)(23.23[q11.1]-25.78[q11.1]), Enhanced(15)(28.52[q11.2]-35.23[q13.1]), 
Diminished(15)(36.37[q13.1]-36.57[q13.1]), Diminished(15)(36.84[q13.2]-57.75[q21.1]), 
Amplified(15)(57.75[q21.1]-69.55[q22.31]), Diminished(15)(78.93[q24.1]-79.18[q24.2]), 
Enhanced(15)(79.19[q24.2]-84.29[q25.2]), Diminished(15)(84.29[q25.2]-100.32[q26.3]), 
Diminished(16)(48.09[q12.1]-60.27[q21.1]), Diminished(20), 
Diminished(21)(9.89[p11.2]-13.96[p11.2]), Enhanced(21)(14.48[p11.2]-15.96[p11.1]), 
Diminished(21)(24.28[q21.1]-25.69[q21.1]), Enhanced(21)(25.71[q21.1]-28.14[q21.1]), 
Enhanced(21)(31.19[q21.2]-32.33[q21.3]), Amplified(21)(32.86[q21.3]-39.48[q22.13]), 
Enhanced(21)(39.48[q22.13]-41.57[q22.2]), Amplified(21)(41.57[q22.3]-46.92[q22.3]), 
Diminished(X)(87.78[q21.31]-91.89[q21.31]), Diminished(Y)(2.98[p11.32]-6.50[p11.2]) 
 
Patient 11005 
Diminished(1)(20.59[1q32]-245.3[qter])Enhanced(2)(41.18[p22]-4.15)Diminished(2) 
Diminished(13)(36.99[q13.3]-96.32)Diminished(15)(18.36[q10]-43.36[q21.1]) 
Enhanced(15)(43.36[q21.1]-46.19[q21.1])Amplified(15)(46.19[q21.1]-49.04[q21.2]) 
Enhanced(15)(49.04[q21.2]-51.02[q21.2])Diminished(15)(51.02[q21.2]-60.04[q22.2]) 
Amplified(15)(60.04[q22.2]-69.32[q23.0])Enhanced(15)(69.32[q23.0]-71.06) 
Diminished(15)(71.06[q23]-71.93[q24.1])Enhanced(15)(71.94[71941196]-79.65[q25.1]) 
Diminished(15)(79.71[q25.1]-82.37[q25.2])Enhanced(15)(82.37[q25.2]-85.3[q25.3]) 
Enhanced(15)(85.3[q25.3]-85.97[q26.2])Enhanced(15) 
Diminished(21)(14.4-15.4)Enhanced(21)(1.54[q21.1]-17.67[q21.1]) 
Amplified(21)(17.67[q21.1]-18.4[q21.1])Enhanced(21)(18.41[q21.1]-18.99[q21.1]) 
Amplified(21)(18.0[q21.1]-40.51)Diminished(21) 
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Table A3.11 Q-PCR fold change data from iAMP21 patients for RUNX1 
 
Patient ID  House Ct  Average Ct  std dev  RUNX1  Average Ct  std dev  D Ct  std dev  DD Ct  2^-DDCt  Range  Range  Error  Error 
6996  28.28     >35.00                    
  27.58     >35.00                    
  26.95     26.49                    
   27.6  0.67    26.49    -1.11   -0.25  1.19         
6788  >35.00     26.21                    
  >35.00     26.3                    
  34.26     25.51                    
   34.26      26.01  0.43  -8.25   -7.39  167.73        
7290  26.57     25.46                    
  26.7     25.14                    
  26.7     25.04                    
    26.66 0.08    25.21 0.22  -1.44  0.23 -0.58  1.49  1.8  1.3 0.26  0.22 
7045  26.91     23.16                    
  25.78     23.52                    
  25.6     23.06                    
   26.1  0.71    23.25  0.24  -2.85  0.75 -1.99  3.96  6.7  2.4 2.7  1.61 
4381  25.34     25.36                    
  25.46     24.57                    
  25.4     24.1                    
   25.4  0.06    24.68  0.64  -0.72  0.64 0.14  0.91  1.4  0.6  0.51  0.32 
WT  25.83     25.13                    
  25.66     24.57                    
  25.2     24.4                    
   25.56  0.33    24.7  0.38  -0.86  0.5 0  1  1.4  0.7  0.42  0.29 
 
 
 
 Table A3.11 Q-PCR fold change data from iAMP21 patients for RUNX1 (contd). 
 
Patient ID  House Ct  AverageCt  std dev  RUNX1  AverageCt std  dev 
D 
Ct 
std 
dev 
DD 
Ct 
2^-
DDCt  Range  Range  Error  Error 
11002 28.21     26.72                   
 28.66     26.79                   
 28.6     26.9                   
   28.49  0.24    26.8  0.09  -1.69  0.26 -1.69  3.22  3.9  2.7 0.64  0.53 
4073 27.34     25.87                 
 27.4     25.82                     
 26.96     25.8                    
   27.23  0.24    25.83  0.04  -1.4  0.24 -1.4  2.65  3.1  2.2 0.48  0.41 
WT 25.83      25.13                  
 25.66     24.57                     
 25.2     24.4                     
   25.56  0.33    24.7  0.38  -0.86  0.5 0  1  1.4  0.7  0.42  0.29 
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Table A3.12 Q-PCR fold change data from iAMP21 patients for STCH 
 
Patient ID  House Ct  Average Ct  std dev  STCH  AverageCt std  dev  D Ct  std dev 
DD 
Ct  2^-DDCt   Range     Range Error Error 
6996  22.95     20.96                      
    23.04     21.07                      
    23.06     21.1                      
      23.02 0.06   21.04 0.07  -1.97  0.09 -1.7  3.25  3.5  3  0.22  0.21 
6788  25.92     24.94                      
    26.04     25.08                      
    25.85     25.04                      
     25.94  0.1    25.02  0.07  -0.92  0.12  -0.64 1.56  1.7  1.4 0.14  0.12 
7290  25.75     24.19                      
    25.85     23.97                      
    25.91     24.02                      
      25.84 0.08   24.06 0.12  -1.78  0.14 -1.5  2.83  3.1  2.6  0.29  0.26 
7045  25.17     24.3                      
    25.23     24.35                      
    25.24     24.17                      
      25.21 0.04   24.27 0.09  -0.94  0.1  -0.67 1.59  1.7  1.5 0.11  0.11 
4381  25.34     25.36                      
    25.46     24.57                      
    25.4     24.1                      
     25.4  0.06    24.68  0.64  -0.72  0.64  -0.45 1.37  2.1  0.9 0.76  0.49 
WT  25.23     24.3                      
    25.18     26.19                      
    25.25     24.35                      
      25.22  0.04     24.95  1.08  -0.27 1.08  0  1  2.1  0.5  1.11  0.53 
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Table A3.12 Q-PCR fold change data from iAMP21 patients for STCH (contd). 
 
Patient ID  House Ct  AverageCt  std dev  STCH  AverageCt std  dev D  Ct std  dev DD  Ct 2^-DDCt  Range    Range  Error  Error 
11002 25.58      23.85                     
   25.66      23.72                     
   25.73      23.81                     
      25.66 0.08   23.79 0.07  -1.86  0.1 -1.86  3.64  3.9  3.4  0.26  0.24 
4073  27.29     27.91                      
    27.32     26.16                      
    27.32     26                      
      27.31 0.02   26.69 1.06  -0.62  1.06 -0.62  1.54  3.2  0.7 1.67  0.8 
WT  23.82     22.91                      
    23.75     23.09                      
    23.85     23.18                      
      23.81  0.05     23.06  0.14  -0.75 0.15  0  1  1.1  0.9  0.11 0.1 
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Table A3.13 Q-PCR fold change data from iAMP21 patients for PRMT2 
 
Average  Patient 
ID 
House 
Ct 
Average 
Ct  std dev  PRMT2  Ct 
std 
dev 
D 
Ct 
std 
dev 
DD 
Ct 
2^-
DDCt 
 
Range    Range Error Error 
6996 22.95                             
   23.04                            
   23.06                            
     23.02  0.06                        
6788 25.92      25.95                     
   26.04      26.02                     
   25.85      26                     
     25.94  0.1    25.99  0.04  0.05  0.1 -1.53  2.89  3.1  2.7  0.21  0.2 
7290 25.75      29.1                     
   25.85      28.79                     
   25.91      27.46                     
     25.84  0.08    28.45  0.87  2.61 0.88  1.03  0.49  0.9  0.3  0.41  0.22 
7045 25.17      27.68                     
   25.23      27.83                     
   25.24      27.8                     
     25.21  0.04    27.77  0.08  2.56 0.09  0.97  0.51  0.5  0.5  0.03  0.03 
4381 25.34      28.76                     
   25.46      28.87                     
   25.4      28.83                     
     25.4  0.06    28.82  0.06  3.42 0.08  1.84  0.28  0.3  0.3  0.02  0.02 
WT 25.23      26.72                     
   25.18      26.79                     
   25.25      26.9                     
      25.22  0.04     26.8  0.09 1.58  0.1  0  1  1.1  0.9  0.07  0.07 
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Table A3.13 Q-PCR fold change data from iAMP21 patients for PRMT2 (contd). 
 
Average  Patient 
ID 
House 
Ct 
Average 
Ct std  dev  PRMT2  Ct 
std 
dev 
D 
Ct std  dev 
DD 
Ct 
2^-
DDCt 
 
Range    Range Error Error 
   25.66      25.55                    
   25.73      25.5                    
     25.66  0.08    25.51  0.04 
-
0.15 0.08 
-
0.15 1.11  1.2  1  0.07  0.06 
4073 27.29      27.55                     
   27.32      27.61                     
   27.32      27.33                     
     27.31  0.02    27.5  0.15  0.19 0.15 0.19 0.88  1  0.8  0.1  0.09 
WT 23.82      25.58                     
   23.75      25.66                     
   23.85      25.73                     
      23.81  0.05     25.66  0.08 1.85  0.09  0  1  1.1  0.9  0.07  0.06 
 
 
 
 
 
 
 
 
 
 
 
 
  198 Table A3.14 Q-PCR fold change data from six normal DNA samples for RUNX1 
 
cDNA House 
Average 
Ct 
std 
dev  RUNX1 
Average 
Ct 
std 
dev D  Ct 
std 
dev 
DD 
Ct 
2^-
DDCt 
  
Range    Range  Error  Error 
A1  25.89        25.92                               
A2  25.84        25.92                               
A3  25.87        25.78                               
      25.87  0.03     25.87  0.08  0.01  0.08 0.73  0.6  0.6  0.6  0.04  0.03 
A4  25.92        26.08                               
A5  25.71        26.01                               
A6  25.72        26.04                               
      25.78  0.12     26.04  0.04  0.26  0.12 0.98  0.51  0.6  0.5  0.05  0.04 
A7  23.76        23.39                               
A8  23.67        23.36                               
A9  23.82        23.45                               
      23.75  0.08     23.4  0.05  -0.35  0.09 0.37  0.77  0.8  0.7  0.05  0.05 
A10  25.72        26.01                               
A11  25.93        25.94                               
A12  26.02        25.85                               
      25.89  0.15     25.93  0.08  0.04  0.17 0.76  0.59  0.7  0.5  0.08  0.07 
B1  26.96        27.71                               
B2  27.4        27.62                               
B3  27.23        27.48                               
      27.2  0.12     27.6  0.12  0.41  0.17 1.13  0.46  0.5  0.4  0.06  0.05 
B4  24.88        24.38                               
B5  25.14        24.35                               
B6  25.01        24.49                               
      25.01  0.13     24.41  0.07  -0.6  0.15 0.12  0.92  1  0.8  0.1  0.09 
B10  23.26        22.41                               
B11  23.14        22.55                               
B12  23.59        23.11                               
      23.2  0.08     22.48  0.1  -0.72  0.13 0  1  1.1  0.9  0.09  0.09 
  199 Table A3.15 Q-PCR fold change data from six normal DNA samples for STCH 
 
cDNA House 
Average 
Ct 
std 
dev  STCH 
Average 
Ct 
Std 
dev D  Ct 
std 
dev 
DD 
Ct 
2^-
DDCt Range      Range  Error  Error 
A1  25.89        24.51                               
A2  25.84        24.01                               
A3  25.87        24.57                               
      25.87  0.03     24.54  0.04  -1.33 0.05 -1.42  2.67  2.8  2.6  0.09 0.09 
A4  25.92        23.28                               
A5  25.71        22.76                               
A6  25.72        22.41                               
      25.78  0.12     22.59  0.25  -3.2 0.27  -3.29 9.77  11.8  8.1 2.05  1.69 
A7  23.76        22.51                               
A8  23.67        22.71                               
A9  23.82        22.63                               
      23.75  0.08     22.62  0.1  -1.13 0.13 -1.22  2.33  2.5  2.1  0.21 0.2 
A10  25.72        24.58                               
A11  25.93        24.58                               
A12  26.02        24.48                               
      25.89  0.15     24.55  0.06  -1.34 0.16 -1.43  2.7  3  2.4  0.33 0.29 
B1  26.96        26.02                               
B2  27.4        25.83                               
B3  27.23        25.78                               
      27.32  0.12     25.88  0.13  -1.44 0.17 -1.53  2.88  3.3  2.6  0.37 0.33 
B4  24.88        23.76                               
B5  25.14        23.76                               
B6  25.01        23.73                               
      25.01  0.13     23.75  0.02  -1.26 0.13 -1.35  2.55  2.8  2.3  0.24 0.22 
B10  23.26        23.29                               
B11  23.14        23.3                               
B12  23.59        23.28                               
      23.2  0.08     23.29  0.01  0.09 0.09  0  1  1.1  0.9  0.06  0.06 
  200 Table A3.16 Q-PCR fold change data from six normal DNA samples for PRMT2 
 
cDNA House 
Average 
Ct 
std 
dev  PRMT2 
Average 
Ct 
std 
dev D  Ct 
std 
dev DD  Ct 
2^-
DDCt 
  
Range    Range  Error  Error 
A1  25.89        28.6                               
A2  25.84        28.39                               
A3  25.87        28.68                               
      25.87  0.03     28.56  0.15  2.69 0.15 0.81  0.57  0.6  0.5 0.06  0.06 
A4  25.92        27                               
A5  25.71        27.02                               
A6  25.72        27                               
      25.78  0.12     27.01  0.01  1.22  0.12 -0.66  1.58  1.7  1.5 0.14  0.12 
A7  23.76        24.38                               
A8  23.67        24.36                               
A9  23.82        24.48                               
      23.75  0.08     24.41  0.06  0.66  0.1 -1.22 2.33  2.5  2.2 0.17  0.16 
A10  25.72        27.06                               
A11  25.93        27.08                               
A12  26.02        27.03                               
      25.89  0.15     27.06  0.03  1.17  0.16 -0.71  1.64  1.8  1.5 0.19  0.17 
B1  26.96        27.01                               
B2  27.4        26.94                               
B3  27.23        27.01                               
      27.32  0.12     26.99  0.04  -0.33 0.13 -2.21  4.62  5  4.2 0.42  0.39 
B4  24.88        25.41                               
B5  25.14        25.47                               
B6  25.01        25.47                               
      25.01  0.13     25.45  0.03  0.44 0.13 -1.44  2.71  3  2.5 0.27  0.24 
B10  23.26        25.11                               
B11  23.14        24.97                               
B12  23.59        25.16                               
      23.2  0.08     25.08  0.1  1.88 0.13  0  1  1.1  0.9 0.09  0.09 
  201 Figure A3.3 Comparison of ‘Ct’ ratios between STCH and PRMT2 using RUNX1 as 
the calibrator. 
PRMT2 
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values) 
Gene vs RUNX1 
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d Losses of telomeric regions detected by MLPA. 
Code: 21= gain of a single chrom
chromosome 21 abnormality not known. 
 
 
osome 21, Ho =Hypodiploid karyotype,  HeH= Hyperdiplio, Nor =Normal,  NK = 
 
 
Table A3.17 Gains an 
T
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able A3.18 Gains and Losses of telomeric regions detected by MLPA and G-
anding. +21= gain of a single chromosome 21. Ho =Hypodiploid karyotype  b
 
 
HeH= Hyperdipliod Nor =Normal 
Patient 
ID 
Gains/Losses detected by 
MLPA 
Code Karyotype 
3043 +21p,+PRSS7, 
+RUNX1,+21q 
+21 47,XY,+21/46,XY[5] 
4073 +21p,+PRSS7,+RUNX1, 
+Xp 
+21 47,XX,+21c[10]/48,idem,+X  [10] 
4184 +21p,+PRSS7,+RUNX1, 
+21q,+Xp,+Xq 
Ho 25,XY,+21[9]/50,XY,+X,+Y,+21,+21 
[3]/46,XY[2] 
4318 +21p,+PRSS7,+RUNX1, 
+21q 
+21 47,XY,del(9)(p22p24),+21c[20] 
7290 +4p,+4q,+6p,+6q,+8p,+8q, 
+10p,+10q, 
+14p,+14q,+17p,+17q,+18q, 
+21px2,+PRSS7 x2,+RUNX1 
x2,+21qx2, +X/Yp,+X/Yq 
HeH 57,XX,+X,+4,+6,+8,+10,+14,+17,+18,+
21,+21,+21[18]/56,idem,dup(1)(q1q4
),-21[2] 
7558 -2p, 
+4p,+4q,+6p,+6q,+8p,+8q, 
+10p,+10q ,-11q, 
+14p,+14q,-16q, 
+17p,+17q,+19q,+21px3, 
+PRSS7 x4,+RUNX1 
x4,+21qx3, +X/Yp,+X/Yq 
HeH 
i(21) 
50-
53,XY,+X,+4,+6,+?17,+i(21)(q10),+i(2
1)(q10),inc[cp5]/46,XY[4] 
9525 -13q,-16q,19q+,-20p,-20q, 
+21px2,+PRSS7x2, 
+RUNX1x2,+21qx2, 
+X/Yp,+X/Yq 
+21 47,XY,+X,-13,-
16,+21,+21[10]/46,XY[5] 
10958 No  change  Nor  46,XY[20] 
11102 +4p,+4q,+9p,+9q,+10p,+10q
, 
+14p,+14q,+17p,+17q,+18q, 
+21p,+PRSS7,+RUNX1,+21
q, +X/Yp,+X/Yq 
HeH 53~55,XY,+X,+4,+9,+10,+18,+21c,+21
,+2~3mar[cp12] 
12025 +1q,+4p,+4q,+6p,+6q, 
+9p,+9q,+10p,+10q,+14p,+1
4q,+17p,+18p,+18qx2 
+21px2,+PRSS7,+RUNX1,+
21qx2, +X/Yp,+X/Yq 
HeH 56~59,XX,+X,+4,+6,+8,+9,+10,+14,+1
5,+17,+18,+19,+21,+21,+mar[8]/46,X
X[2] 
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We have previously identiﬁed a unique subtype of acute lympho-
blastic leukemia (ALL) associated with a poor outcome and char-
acterized by intrachromosomal ampliﬁcation of chromosome 21
including the RUNX1 gene (iAMP21). In this study, array-based
comparative genomic hybridization (aCGH) (n  10) detected a
common region of ampliﬁcation (CRA) between 33.192 and 39.796
Mb and a common region of deletion (CRD) between 43.7 and 47
Mb in 100% and 70% of iAMP21 patients, respectively. High-
resolutiongenotypicanalysis(n3)identiﬁedallelicimbalancesin
the CRA. Supervised gene expression analysis showed a distinct
signature for eight patients with iAMP21, with 10% of overex-
pressed genes located within the CRA. The mean expression of
these genes was signiﬁcantly higher in iAMP21 when compared to
other ALL samples (n  45). Although genomic copy number
correlated with overall gene expression levels within areas of loss
or gain, there was considerable individual variation. A unique
subset of differentially expressed genes, outside the CRA and CRD,
were identiﬁed when gene expression signatures of iAMP21 were
compared to ALL samples with ETV6-RUNX1 fusion (n  21) or high
hyperdiploidy with additional chromosomes 21 (n  23). From this
analysis, LGMN was shown to be overexpressed in patients with
iAMP21 (P  0.0012). Genomic and expression data has further
characterized this ALL subtype, demonstrating high levels of 21q
instability in these patients leading to proposals for mechanisms
underlying this clinical phenotype and plausible alternative
treatments.
array CGH  expression proﬁling  RUNX1  iAMP21  genomic instability
W
e have recently defined a recurrent chromosomal abnormal-
ity at an incidence of 1.5% in childhood B-lineage acute
lymphoblastic leukemia (ALL) involving intrachromosomal dupli-
cation of chromosome 21 and amplification of the RUNX1 (AML1)
gene (iAMP21) (1). These patients have a median age of 9 years,
a low presenting white blood cell count, and a poor prognosis (2).
Thus, on the current U.K. ALL treatment protocol, ALL 2003,
these children are classified as high-risk and receive more intensive
treatment. iAMP21 was identified on routine screening of child-
hood ALL patients for the ETV6-RUNX1 (TEL-AML1) fusion by
fluorescenceinsituhybridization(FISH).Althoughnegativeforthe
fusion, leukemic cells showed multiple RUNX1 signals, seen as
clusters in interphase and in tandem duplication on the long arm of
an abnormal chromosome 21 in metaphase. This abnormality
cannot be defined by conventional cytogenetic analysis because the
abnormal chromosome 21 adopts a range of different morpholog-
ical forms. FISH with probes directed to the RUNX1 gene is
currently the only detection method, which explains its prior
description as ‘‘amplification of RUNX1.’’ However, there are
several reasons why FISH detection, based solely on RUNX1 copy
number, may be inappropriate. First, interpretation may be mis-
leading, particularly in patients with a hidden high hyperdiploid
clone comprising several copies of chromosome 21 (3). Second,
because the observed increase in RUNX1 copy number was seren-
dipitous, it may not be the causative mechanism. In view of the
high-risk associated with iAMP21, it is important to fully charac-
terize this abnormality to provide accurate diagnosis, particularly
for ALL patients without any other high-risk clinical features.
Similar chromosome 21 amplifications have been reported in
patients with acute myeloid leukemia (AML) and myelodysplastic
syndrome (4–9). The most recent AML study, using BAC array-
based comparative genomic hybridization (BAC aCGH), identified
two common regions of amplification on 21q in 12 patients. These
were at 25–30 Mb and 38.7–39.1 Mb. Oligonucleotide expression
analysis revealed that most significantly overexpressed genes were
located within these amplicons, implying that the changes in gene
expression were entirely related to alterations in copy number (5).
Similar gene expression analyses from children with high hyper-
diploid ALL (10) and Down syndrome (11) have suggested that
additionalcopiesofchromosome21leadtooverexpressionofgenes
on chromosome 21. By using a variety of classical and innovative
molecular techniques, we have been able to characterize the
iAMP21 in patients with ALL and, in so doing, provide a plausible
alternative therapeutic approach.
Results and Discussion
In this study, we have validated the existence of the chromosomal
abnormality iAMP21 in childhood ALL and characterized the
rearrangement using whole genome analyses. Genome-wide BAC
aCGH showed genomic imbalances in all 10 patients with iAMP21
analyzed. Patterns of imbalance corresponding to over- and under-
representation of specific regions of chromosome 21 were unique
toeachpatient(Table1).AlthoughallBACclonesonchromosome
21 showed gain in at least one patient, these gains most frequently
involved clones between genomic positions 22.1 and 27.8 Mb
(clones RP11-64I12 to RP11-90A12). The size of the most highly
amplified region varied considerably between patients, from 3–8.6
to 24.0–24.1 Mb for patients 6783 and 6788, respectively. However,
a common region of amplification (CRA) of 8.6 Mb, between
clones RP11-191I6 and RP5-206A10 (genomic positions 31.5 and
40.1 Mb, respectively), was identified in all 10 patients, which was
accompanied by deletions of 21q in seven patients. With the
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Sexception of one within the centromeric region (from 15.1–20.3 Mb
inpatient5898),alldeletionsincludedacommonregionofdeletion
(CRD) of 4 Mb close to the telomere. In three patients with
iAMP21, imbalances of 21q were the sole genomic changes at 1-Mb
resolution. Among the other patients, no recurrent changes involv-
ing chromosomes other than 21 were identified. (Table 3, which is
published as supporting information on the PNAS web site). To
prove the validity of aCGH, the presence of an entire additional
copy of chromosome 21 was verified in seven patients with high
hyperdiploidy and additional copies of chromosome 21 (HD  21)
(example,patient6009)(Table1).Furthermore,nochangesincopy
number were observed among 50 patients with apparently normal
copies of chromosome 21 (example, patient 6899) (Table 1). FISH
analysis confirmed the variation in copy number along 21q in the
cases analyzed by BAC aCGH (Table 1 and Fig. 1 A and B). FISH
identified the same CRA and CRD. The high concordance be-
tween the two procedures indicated the accuracy of BAC aCGH in
the determination of copy number changes, whereas FISH analysis
providedprecisequantification.Betweenthreeandeightadditional
copies of the clones within the CRA were demonstrated by FISH,
indicating a 2.5–5 fold gain. FISH data on copy number changes in
an additional three patients with iAMP21 provided further confir-
mation of the BAC aCGH results (data not included). Using
tiling-path Oligo aCGH (Fig. 1C), the extent of the CRA was
refined to a region of 6.527–6.604 Mb in size (between genomic
positions 33.192 and 39.796 Mb) in five patients, whereas the CRD
was refined to 3.541 Mb. High-resolution genotype array analysis of
single-nucleotide polymorphisms (SNP analysis) was performed on
three patients for whom both diagnostic and remission samples
were available, permitting comparison of germ-line and tumor
genotypes (examples are shown in Fig. 3, which is published as
supporting information on the PNAS web site). These analyses
identified the same regions of genomic gain and loss of heterozy-
gosity within the CRA and CRD.
Combining the results from these genomic analyses has high-
lighted regions of variable gain along 21q in patients with iAMP21
and identified a CRA covering a large genomic region of 6 Mb,
containing the RUNX1 gene. This CRA was found to be telomeric
of the first of the two amplified regions described for AML (25–30
Mb) but overlapping with the second (38.7–39.1 Mb) (5). The
majority of patients showed a 3.5-Mb CRD, telomeric of the CRA.
The SNP data suggested that the amplification was derived from a
Table 1. BAC aCGH and FISH results for 10 ALL patients with iAMP21
Gains (green) and losses (red) of 21q material detected by BAC aCGH. Yellow regions correspond to those areas exhibiting ﬂuorescent ratios within standard
deviation limits (SDL). Ratio values were unavailable on several samples due to a lack of material, and on certain DNA clones due to poor ratio measurements.
WhereFISHwascarriedout,resultsareshownnumericallyasdeviationsfromanormalcopynumberof2.Theasterisksindicatecasesstudiedforgeneexpression
by oligonucleotide array. The # indicates those cases used for further genomic proﬁling with Oligo aCGH array analysis. Cases 6899 and 6009 are ALL patients
with an apparently normal and high hyperdiploid (tetrasomy 21) karyotype, respectively.
8168  www.pnas.orgcgidoi10.1073pnas.0602360103 Strefford et al.single chromosome. Overall, the results indicated the highly vari-
able nature of this abnormality, reflecting considerable instability
of chromosome 21, thus making it difficult to determine the
causative event.
Global gene expression profiling, using the Affymetrix U133A
oligonucleotidearraycontaining22,283probessets,wasperformed
on eight patients with aCGH results. The CRA was represented on
thisAffymetrixGeneChipby96probesetsintotal,including40well
characterized genes and six ORFs. The genes located within the
CRAandCRDareindicatedinTables4and5,whicharepublished
as supporting information on the PNAS web site. From a total of
768 probe sets within the CRA, 321 (42%) were present (or
marginal)andup-regulated(Fig.4,whichispublishedassupporting
information on the PNAS web site). Of the 46 sequences from the
genes and ORF, 13 were up-regulated in at least 75% of patients.
The CRD was represented on the GeneChip by 83 probe sets,
containing 33 genes, three ORFs, and three ESTs. From a total of
664 probe sets, 462 (70%) were absent. An absent flag was carried
in 22 of these 39 gene sequences in at least 75% of patients. When
compared to all children with ALL (n  89) from our previously
reported analysis (12), 14 (10%) of the top 150 genes significantly
overexpressed in patients with iAMP21 were located within the
CRA, for which there was a strong correlation with the Taqman
data (Table 6, which is published as supporting information on the
PNAS web site). As shown in Table 4, 51 (53%) of the 96 probe sets
within the CRA had a 1.5-fold increase in expression. This obser-
vation suggested that overexpression of these genes corresponded
to the gain of genomic material. However, it was noted that 47% of
the probe sets from the CRA were not overexpressed. To examine
the effect of the gain of chromosomal material more closely, we
calculated the mean and median expression of the genes within the
CRA in the eight iAMP21 and six patients with other subtypes of
ALL (Fig. 2A). The mean expression levels of the genes contained
within the CRA was higher in patients with iAMP21 (t test, P 
0.00903) and those with HD  21 (t test, P  2.02e-7) compared
with the other subtypes. These observations support previous
reports demonstrating that large-scale genomic alteration does
resultinchangesinexpressionofgeneswithintheseregions(13,14),
but we could not correlate all gene expression changes with
alterationatthegenomiccopylevel.Therewasnolinearcorrelation
between the degree of amplification and expression; this may have
arisen from heterogeneity of amplification within the region or
other regulatory mechanisms influencing gene expression, such as
epigenetics and biofeedback regulation. We have recently reported
partial acquired isodisomy in patients with AML (15), whereas
others have reported disomy of chromosome 21 in cases of Down
syndrome and ALL (16). Thus, it is plausible that this type of
mechanism may contribute to variations in expression.
LiketheAMLstudy(5),ourworkshoweddifferentialexpression
of genes located outside the CRA, leading to expression variation
Fig. 1. Genomic analysis of DNA and cell suspension
from patient 5989. (A) BAC aCGH results: chromosome
21 is positioned horizontally, with the centromeric to
telomeric positions running from left to right, respec-
tively. Dye swap experiments 1 and 2 are shown by the
blue and red lines, respectively. Double deviation of
both these experiments from a normal value of 1.00
demonstrates loss or gain of DNA material. Deviation
of the red and blue line 1.00 shows loss or gain of
copy number, respectively. (B) Examples of the FISH
conﬁrmation of aCGH data: each numbered FISH
probe corresponds to the same highlighted clone in A.
(C)OligoaCGHdataforthispatient.Chromosome21is
positionedasinA.Thescatterplotdemonstratesmean
logintensityratiosat5,000-bpintervalsalongchromo-
some 21. Segmentation analysis is shown as red hori-
zontal lines.
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cancer pathogenesis. However, these genes were not consistent
between patients. When the expression profiles from patients with
iAMP21 were compared to the original cohort of 89 pediatric ALL
patients (12) in an unsupervised analysis, the patients with iAMP21
did not cluster together (data not shown). Due to correlation
between gene expression and loss or gain of chromosomal material,
a supervised cluster analysis was carried out to take into consid-
eration that expression profiles were influenced by ALL samples
with rearrangements and gains of chromosome 21. The global gene
expressionprofilingoftheeightiAMP21patientswascompared:to
the full cohort (n  89); to a subgroup of patients with the
ETV6-RUNX1 fusion (n  21); and to a subgroup of patients with
HD21(n23).Whenthegenelistwascompiledinthismanner,
patients with iAMP21 exhibited a distinctive expression pattern
(Fig. 4). Using SAM, with a cutoff level for false discovery rate
(FDR) of 10%, the three comparisons yielded 4,174, 4,768, and
5,147 probe sets, respectively. The top 150 probe sets (FDR 
5.3%) were used for comparison against other ALL samples, and
thetop100forcomparisonsagainstpatientswiththeETV6-RUNX1
fusion (FDR  0.54%) and HD  21 (FDR  0.81%). The gene
lists with full annotation are presented in the supplemental data
(Tables 7–9, which are published as supporting information on the
PNAS web site). Comparison of all three lists identified 11 genes
thatwereuniquelyoverexpressediniAMP21patients,ofwhichonly
two, C21orf66 and ATP50, were within the CRA. One of the other
overexpressed genes was legumain (LGMN). As shown in Fig. 2B,
LGMN expression was significantly elevated in those with iAMP21
when compared to other subtypes of ALL (t statistics  4.38; df 
7;P0.0012).Usingasimilarapproach,12genesoutsidetheCRD
were shown to be expressed at significantly lower levels (Table 2).
Unlike the AML report, in which a control cohort of normal
karyotype AML patients was used, our report benefited from
comparisons with patient groups who had either gained an entire
chromosome 21 as part of a high hyperdiploid karyotype or in
association with an ETV6-RUNX1 fusion. By using these subgroups
for comparison, it was possible to identify a unique subset of over-
andunderexpressedgenesinpatientswithiAMP21relativetothose
withwithout other chromosome 21 aberrations. This finding dem-
onstrated that comparative information on the loss or gain of
chromosomal material is essential when interpreting expression
data. Curiously, RUNX1 expression in ETV6-RUNX1 positive and
iAMP21patientswascomparable,whichmaybeduetotheinability
of the global gene expression profiling platform used in this study
to distinguish between wild-type RUNX1 and ETV6-RUNX1 fusion
transcripts. Additional copies of the ETV6-RUNX1 fusion and
RUNX1 are common findings in patients with the translocation,
t(12;21)(p13;q22)(3),whichmaycontributetotheelevatedRUNX1
expression levels in ETV6-RUNX1-positive patients. These obser-
vations suggest that there are common processes leading to dupli-
cation and translocation, further strengthening the hypothesis that
genomic instability of a region on 21q creates a cascade of events
leading to or sustaining leukemogenesis.
Although the processes that lead to ALL appear to affect a
commongenomicregionofchromosome21,thereisdisparityinthe
outcome to treatment. HD  21 and ETV6-RUNX1 have an
excellent survival rate on current chemotherapy protocols, whereas
iAMP21 patients have a poor outcome. Recently, two papers have
correlatedgeneexpressionpatternswithinvitrochemosensitivityof
blast cells and both demonstrated that these patterns were predic-
tiveofoutcomeinchildhoodALL(17,18).Althoughtheexpression
patterns in our patients did not accurately reflect those associated
with poor clinical outcome and chemo-resistance (including As-
paraginase), there were a number of similarities including over-
(IGHM, CD44, IGFBP7, RPS9, and MAFF) and underexpression
(TCF4, F8A, and TAF5) of a number of genes. Of these, MAFF
overexpression is known to correlate with steroid resistance and
F8A down-regulation with insensitivity to asparaginase. We have
shown that the gene LGMN is overexpressed in ALL samples with
iAMP21. LGMN is a lysosomal cysteine protease that specifically
cleaves after the asparagine residue and participates in antigen
processing(19).CancercellsexpressingLGMNhavebeenshownto
invade extracellular spaces. Overexpression in a number of aggres-
sive cancers correlates with invasiveness, dissemination, and poor
outcome (20, 21). We hypothesize that lymphoblasts expressing
LGMN may enter extravascular spaces. These cells survive because
of suboptimal cytotoxic levels, which may lead to subsequent
relapse.
We conclude that the CRA on chromosome 21 represents the
only detectable recurrent finding in patients with iAMP21. Expres-
sion profiling did not show significant overexpression of RUNX1 in
these patients, suggesting that it is unlikely to be the target gene.
Overall, the increase of gene expression within the CRA was a
result of the genomic copy number gain within this region, sug-
gesting that these genes may be important in leukemogenesis.
However, no single causative gene was identified. Outside the
CRA, overexpression of LGMN was demonstrated. We hypothe-
size that this gene may contribute to the poor clinical outcome and
treatmentresponseobservediniAMP21patients.Inadditiontothe
6.5–6.6 Mb CRA, there was associated genomic imbalance in
patients with iAMP21, in particular deletions affecting the subte-
lomeric region (CRD) of chromosome 21. These data have pro-
Fig.2. BoxplotdiagramsillustratingLGMNexpression(A)andexpressionof
thosegeneswithintheCRA(B),comparedtootherALLsubtypes.Onthexaxis
are shown seven ALL subtypes, BCR-ABL, E2A-PBX1, T-ALL, HD  21, ETV6-
RUNX1,iAMP21,andothers.Theyaxisrepresentstherelativegeneexpression
level of either LGMN or all those genes within the CRA. Each box plot shows
the distribution of expression levels from 25th to 75th percentile. The median
is shown as a line across the box, whereas the  is the calculated mean
expressionlevelfortheparticularsubtype.Thedottedlineindicatestheinner
fence, and a value outside the outer fence is shown as an asterisk.
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diagnostic test. The expansion of this innovative study may uncover
other molecular and cellular mechanisms underlying this clinical
phenotype, demonstrating a pivotal role of chromosome 21 insta-
bility in the initiation of acute leukemia.
Materials and Methods
Patients. In this study, 14 patients with iAMP21, defined in accor-
dance with published cytogenetic and FISH criteria (1), with DNA
andor RNA available were identified among those registered to
the U.K. ALL treatment trials: ALL9799, MRD PILOT, or
ALL2003 for children aged 1–18 years, or UKALLXII for adults
aged 15–55 years. Genome and expression studies were applied to
these patient samples as indicated in Table 3. Each center obtained
informed consent from patients or their parents.
Cytogenetic Analysis. Diagnostic bone marrow andor peripheral
blood samples from all patients in this study were analyzed by
standard cytogenetic methods in the U.K. regional cytogenetics
laboratories.RUNX1copynumberwasdeterminedbyusingtheLSI
TELAML1 ES Dual Color Translocation FISH probe (Abbott
Diagnostics, Maidenhead, U.K.). This information is provided in
Table 3.
BAC aCGH and FISH Confirmation. For 10 patients, genomic copy
number variation was assessed by using a commercially available
BAC aCGH system (Spectral Genomics, Genosystems). The arrays
comprised 2,621 genomic clones positioned at 1-Mb intervals
throughout the genome. Of these, 26 were located along 21q from
position 15.1 Mb (centromeric) to 46.9 Mb (telomeric). The posi-
tions of genes and BAC clones were determined by using the
National Center for Biotechnology Information (NCBI) Map-
Viewer for Homo Sapiens, Build 35, version 1 (www.ncbi.nlm.nih.
govmapview).
Pooled DNA extracted from peripheral blood of 10 healthy
donors, sex matched to the test sample, was used as the reference
(Promega) and processed according to the manufacturer’s in-
structions. On the basis of control experiments, a normal range
of 0.8–1.2 was used for the analysis of patients with iAMP21, a
rangebroaderthanonecalculatedonthebasisof2 SDforeach
clone calculated, in the normal-versus-normal hybridizations. In
an attempt to improve sensitivity, fluorescence ratio outside the
limit of 2 SD (standard deviation limits, SDL), but within
standardcutoffvaluesofbetween0.8and1.2,werealsorecorded
for comparisons with FISH confirmatory data.
Forninepatients,DNAcopynumberchangesdetectedbyaCGH
were validated by using FISH probes from the same BAC clones as
spotted on the array (Genosystems) (Table 1). Where possible, 200
interphase nuclei per probe were analyzed by two independent
analysts, and images were recorded by using MACPROBE software
(Applied Imaging, Newcastle, U.K.) (further details of aCGH and
FISH analysis are given in Supporting Text, which is published as
supporting information on the PNAS web site).
Genomic Oligonucleotide Arrays. Five patients (all analyzed with
BAC aCGH of the same sample) were analyzed with high-density
oligonucleotide-based CGH (Oligo aCGH) arrays (NimbleGen
Systems, Madison, WI), designed with probes tiled through chro-
mosome21.Sequences(NCBIbuild35.1)wererepeat-masked,and
oligonucleotides were selected at a minimal spacing distance of 60
bpfromboththeforwardandreversestrands,resultingin190,000
features along the length of the chromosome. The arrays were
synthesized as described (22), and standard labeling, hybridization,
and image capture was performed in the NimbleGen Systems
Service Laboratory, in a similar manner to that described by Selzer
et al. (23). Data were extracted from scanned images by using
NIMBLESCAN extraction software (NimbleGen Systems), which al-
lows automated grid alignment, extraction, and generation of data
files. Segmentation analysis of data sets indicated deletion and
amplification breakpoints. Corrections for optical noise, back-
ground adjustments, and normalization were performed by using
BIOCONDUCTOR as described (24). After a loss correction for probe
GC content, the log2 ratios were averaged in windows ranging from
Table 2. Signiﬁcant differentially expressed genes in patients with iAMP21 (n  8)
Gene
Probe
identiﬁer Gene name
Chromosomal
location UniGene cluster
Up-regulated
LGMN 201212at Legumain 14q32.1 Hs.18069
C1orf54
(FLJ23221)
219506at Chromosome 1 open reading frame 54 1q21.2 Hs.91283
STK17B 205214at Serinethreonine kinase 17b (apoptosis-inducing) 2q32.3 Hs.88297
BHLHB2 201170sat Basic helix-loop-helix domain containing, Class B, 2 3p26 Hs.171825
ARPC5L 220966xat Actin related protein 23 complex, subunit 5-like 9q33.3 Hs.132499
TBCD 211052sat Tubulin-speciﬁc chaperone d 17q25.3 Hs.464391
LSM7 204559sat LSM7 homolog, U6 small nuclear RNA associated (S. cerevisiae) 19p13.3 Hs.512610
GADD45B 209304xat Growth arrest and DNA-damage-inducible, beta 19p13.3 Hs.110571
C20orf111 209020at Chromosome 20 open reading frame 111 20q13.11 Hs.75798
C21orf66 221158at Chromosome 21 open reading frame 66 21q21.3 Hs.473635
ATP5O 200818at ATP synthase, H transporting, mitochondrial F1 complex, O
subunit (oligomycin sensitivity conferring protein)
21q22.1-q22 Hs.409140
Down-regulated
NIPBL 207108sat Nipped-B homolog (Drosophila) 5p13.2 Hs.481927
BAT2 208132xat HLA-B associated transcript 2 6p21.3 Hs.436093
CDYL 203100sat Chromodomain protein, Y-like 6p25.1 Hs.269092
GFOD1 219821sat Glucose-fructose-oxidoreductase domain containing 1 6pter-p22.1 Hs.484686
KIAA0265 209256sat KIAA0265 protein 7q32.2 Hs.520710
CAMSAP1 212710at Calmodulin regulated spectrin-associated protein 1 9q34.3 Hs.522493
PELI2 219132at Pellino homolog 2 (Drosophila) 14q21 Hs.105103
KIAA0100 201729sat KIAA0100 gene product 17q11.2 Hs.151761
SS18 216684sat Synovial sarcoma translocation, Chromosome 18 18q11.2 Hs.404263
FEM1B 212367at Fem-1 homolog b (C. elegans) 15q22 Hs.362733
RNF146 221430sat Ring ﬁnger protein 146 6q22.1-q22.3 Hs.267120
MBD1 208595sat Methyl-CpG binding domain protein 1 18q21 Hs.405610
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details are provided Supporting Text.
GeneChip Human Mapping 10K Array. The GeneChip mapping assay
protocol (Affymetrix) was used to produce the 10,000 SNP array
results for three iAMP21 patients as described (26, 27). The
protocolwasadaptedsuchthatthepurificationofPCRproductwas
performed by using the Ultrafree-MC filtration column (Millipore,
Billerica, MA). Signal intensity data were analyzed by the Gene-
Chip DNA analysis software (GDAS), which uses a model algorithm
to generate SNP calls. Signal values are normalized across each
array to the median value, and copy number ratios and changes in
SNP calls between leukemia and germ-line remission bone marrow
were annotated by using a program written in visual basic. Noise
was reduced by zeroing negative signal values, and using mean
signal values in a running window of five SNPs.
Global Expression Profiling. RNA Extraction and probe preparation.
Global expression profiling was carried out on bone marrow
aspirates from eight patients (seven with aCGH results). RNA was
extracted with TRIzol (Invitrogen) followed by a second ethanol
precipitation, before quality assessment using the Agilent 2100
Bioanalyser (Agilent Technologies, Waldbronn, Germany). Fluo-
rescently labeled cRNA probes were synthesized and hybridized to
Affymetrix HG-U133A oligonucleotide arrays according to the
manufacturer’s instructions. The arrays were scanned on a Gene-
Array scanner (Agilent Technologies), and the intensities of the
fluorescence signals were captured and analyzed with Affymetrix
MAS 5.0 software. No scaling was applied. Further detailed descrip-
tions of the procedure and the raw Affymetrix files are given in
Supporting Text.
Gene expression analysis. GENESPRING 6.0 (Silicon Genetics, Red-
woodCity,CA)wasusedforrawdatanormalization.First,thedata
were normalized to the median per sample, using all genes not
marked absent. Each gene was then divided by the median of its
measurements in all samples (i.e., across all arrays). If the median
of the raw values was 10, then each measurement for that gene
was divided by 10. Signal intensities were log transformed for
statistical analysis. Genes called absent in all samples were removed
to exclude those with minimal variation across the experiments.
Probe sets passing the filter were used to find statistically significant
differentially expressed genes between the subgroups studied.
Significance Analysis of Microarrays (SAM) was applied to the
normalizedandlog-transformeddata.Weuseddefaultsettingsand
selected the significant genes based on the d-score with a maximum
FDR of 5.3%. These were compared with a data set of 89 children
with ALL, of whom 21 had an ETV6-RUNX1 fusion, 23 had high
hyperdiploidy comprising at least one additional copy of chromo-
some 21 (HD  21) and 45 had no abnormality of chromosome 21.
For 80 patients, including one patient with a iAMP21, the gene
expression pattern has been reported (12).
Both unsupervised and supervised analyses were used and the
results visualized in a two-way hierarchical cluster. Normalized
gene expression values were used to obtain the mean and median
expression values of genes within the defined amplicon. Signifi-
cance in the differences of expression between the different sub-
groups was tested by using a t test.
Quantitative RT-PCR. Real-Time quantitative RT-PCR (qRT-PCR)
was carried out to assess the expression of genes situated within the
amplicon (SOD1, OLIG2, IFNAR2, IL10RB, ITSN1, CRYZL1,
RUNX1, TTC3, ERG and ETS2) for six patients, using the Taqman
Gene Expression Assays (Applied Biosystems) according to the
manufacturer’s instructions. Appropriate positive and negative
control RNA samples were tested in parallel. The comparative Ct
method was used for quantitation of relative gene expression. The
average Ct value of the endogenous control gene, GAPDH, was
subtracted from the average experimental gene Ct value to give the
Ctvalue. Differences between control and test were carried out by
using Ct. Concordance between the qRT-PCR and global ex-
pression profile was demonstrated after calculation of the correla-
tion coefficients between the level of expression as quantified by
both qRT-PCR and Affymetrix expression arrays.
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21 (iAMP21) May Arise from a Breakage–Fusion–
Bridge Cycle
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Intrachromosomal ampliﬁcation of chromosome 21 (iAMP21), involving ampliﬁcation of the RUNX1 gene and duplication of
chromosome 21, dup(21q), deﬁnes a new cytogenetic subgroup in B-lineage acute lymphoblastic leukemia (ALL) with a poor
prognosis. Characterization of this abnormality has become vital to ensure that the most accurate detection method is used.
We have previously deﬁned common regions of ampliﬁcation and deletion of chromosome 21 in these patients, although the
level and extent of ampliﬁcation within the amplicon was highly variable. This study, using interphase ﬂuorescence in situ
hybridization (FISH) with chromosome 21 locus speciﬁc probes, substantiated these ﬁndings in a large series of patients and
conﬁrmed that the amplicon always included RUNX1. Thus, FISH with probes directed to the RUNX1 gene remains the most
reliable detection method. Metaphase FISH, supported by G- and multiple color chromosomal banding (mBAND) revealed the
patient speciﬁc morphology and genetic proﬁle of the dup(21q) chromosomes, as well as the complexity of the intrachromoso-
mal changes giving rise to them. These ﬁndings suggested that iAMP21 had arisen from a breakage–fusion–bridge cycle: a
mechanism previously described in tumors, which we report for the ﬁrst time in ALL. V V C 2007 Wiley-Liss, Inc.
INTRODUCTION
Acquired chromosomal abnormalities are impor-
tant disease-speciﬁc markers in hematological malig-
nancies. They have contributed signiﬁcantly toward
the understanding of the mechanisms leading to leu-
kemogenesis. Probably, the most important feature
is the independent prognostic signiﬁcance attributed
to a number of them, which form the basis of risk
stratiﬁcation for treatment. Chromosome 21 is often
gained in acute myeloid leukemia (AML) (United
Kingdom Cancer Cytogenetics Group, 1992) and
acute lymphoblastic leukemia (ALL), in which it is
the hallmark of the good-risk high hyperdiploid
group (Moorman et al., 2003). One gene, RUNX1
(AML1) at 21q22, is frequently involved in chromo-
somal rearrangements of different, lineage-speciﬁc
subtypes of leukemia. For example, the transloca-
tion, t(8;21)(q22;q22), gives rise to the RUNX1-
RUNX1T1 fusion in AML of favorable risk;
t(12;21)(p13;q22) results in the RUNX1-ETV6 fusion
in childhood ALL; while t(3;21)(q26;q22) produces
the RUNX1-MDS1 fusion in myelodysplastic syn-
drome (MDS) and the blastic phase of chronic mye-
loid leukemia (Miyoshi et al., 1991; Nucifora and
Rowley, 1995; Romana et al., 1995).
In addition to rearrangements of the gene,
ampliﬁcation involving RUNX1 has been reported
in both myeloid and lymphoid leukemia. Although
rarely described in AML and MDS (Hilgenfeld
et al., 2001; Andersen et al., 2005), there are a num-
ber of reports in ALL (Niini et al., 2000; Busson-Le
Coniat et al., 2001; Dal Cin et al., 2001; Mikhail
et al., 2002; Morel et al., 2002; Penther et al., 2002;
Harewood et al., 2003; Robinson et al., 2003; Sou-
lier et al., 2003), from which it has been deﬁned as
a rare cytogenetic subgroup (Robinson et al., 2003;
Soulier et al., 2003). In these ALL studies, addi-
tional copies of the RUNX1 gene were found while
screening for the presence of the ETV6-RUNX1
fusion by ﬂuorescence in situ hybridization (FISH)
(Harrison et al., 2005). Although negative for the
fusion, multiple copies of RUNX1 were found to
be arranged in a ladder-like fashion on a single
duplicated chromosome 21, dup(21q) (Harewood
et al., 2003). The size and morphology of the
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GENES, CHROMOSOMES & CANCER 46:318–326 (2007)dup(21q) was highly variable between patients
(Harewood et al., 2003); therefore, it could not be
reliably classiﬁed by cytogenetics alone. Array-
based comparative genomic hybridization (aCGH)
deﬁned a common region of ampliﬁcation (CRA)
(genomic position, 33.2–39.8 Mb) and deletion
(CRD) (genomic position, 43.7–47 Mb, including
subtelomeric sequences) on chromosome 21 (Stref-
ford et al., 2006). This study also demonstrated
that, although the CRA always contained RUNX1,
the amplicon showed considerable variation in
extent and level of ampliﬁcation between patients,
as observed in earlier FISH investigations (Le
Coniat et al., 1995; Busson-Le Coniat et al., 2001).
Thus, the abnormality was renamed to more accu-
rately reﬂect these features, as intrachromosomal
ampliﬁcation of chromosome 21 (iAMP21) (Stref-
ford et al., 2006). It occurs at an incidence of
approximately 2% in childhood ALL, with a higher
frequency in older children (Harewood et al., 2003;
Soulier et al., 2003). All patients have a common/
precursor-B immunophenotype, generally with a
low presenting WBC count and, most signiﬁcantly,
an adverse outcome (Robinson et al., 2003; Moor-
man et al., 2006). In view of these ﬁndings, it has
been recommended in the United Kingdom that
childhood patients are treated as high-risk on cur-
rent protocols. Thus, characterization of this abnor-
mality has become vital to ensure that the most
accurate detection method is applied.
Our recent studies have contributed toward an
improved deﬁnition. In addition to depicting the
genomic features, we have described the gene
expression proﬁles. In eight iAMP21 patients,
RUNX1 was not differentially over expressed when
compared to other ALL patients in the cohort
described by Van Delft et al. (2005). No putative
genes were highlighted within the CRA that might
be driving leukemia pathogenesis in these patients
(Strefford et al., 2006). Although point mutations
in the Runt domain coding exons of RUNX1 have
been detected in AML and MDS (Osato et al.,
1999; Roumier et al., 2003; Cameron and Neil,
2004; Mikhail et al., 2006), sequence analysis did
not detect such mutations in iAMP21 patients
(Busson-Le Coniat et al., 2001; Penther et al.,
2002). Therefore, whether RUNX1, or any other
gene within the CRA, is the target of this chromo-
somal subgroup has yet to be established.
To increase further our understanding of this ab-
normality, a combinatorial approach based upon
the original aCGH study, using FISH, conven-
tional cytogenetics, and multiple color chromo-
somal banding (mBAND), has been performed in a
large group of iAMP21 patients. Comparison of
amplicon size, level of ampliﬁcation, FISH signal
distribution in metaphase, and chromosomal mor-
phology have revealed unexpected ﬁndings, point-
ing to a potentially distinct mechanism giving rise
to the formation of iAMP21.
MATERIALS AND METHODS
Patients
A total of 46 ALL patients with iAMP21 entered
to one of the United Kingdom treatment trials
(ALL97 or ALL2003 for children aged 1–18 years
and UKALLXII for adults aged 15–55 years) were
included in this study. All patients with meta-
phases were identiﬁed as iAMP21 by FISH and
conventional cytogenetics, according to our previ-
ous description: patients with three or more extra
copies of RUNX1 on a single abnormal chromo-
some 21 (Harewood et al., 2003). Patients with no
metaphases available were classiﬁed according to
the deﬁnition: within interphase cells, RUNX1 sig-
nals were present as a group, gathered closely to-
gether in a cluster, characteristic of ampliﬁcation
on a single chromosome; while a single signal,
assumed to represent the normal chromosome 21,
was usually located apart.
Cytogenetics
Conventional cytogenetic analysis was under-
taken by the United Kingdom regional cytogenet-
ics laboratories on diagnostic bone marrow and/or
peripheral blood samples. Chromosomal abnormal-
ities were further characterized by FISH where
possible. Karyotypes of the iAMP21 patients were
reviewed by the Leukemia Research Cytogenetic
Group (Harrison et al., 2001) and described accord-
ing to the International System of Human Cytoge-
netic Nomenclature (ISCN, 2005). The abnormal
chromosome 21 was classiﬁed according to mor-
phology (Harewood et al., 2003).
FISH
FISH was performed on the same ﬁxed cell sus-
pensions as used for cytogenetic analysis. Initial
FISH screening, to identify iAMP21 patients, was
carried out using the LSI
1 TEL/AML1 ES Dual
Color Translocation probe (Abbott Diagnostics,
United Kingdom). RUNX1 copy number was deter-
mined from the number of signals in 200 inter-
phase cells.
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chromosome 21 locus-speciﬁc probes generated
from the same BAC clones as found on the aCGH
BAC array (Genosystems, France), as described pre-
viously (Strefford et al., 2006), together with a 21q
subtelomeric probe (Tel21q) (QBiogene, United
Kingdom). The genomic positions of the BAC clones
were determined using the National Center for Bio-
technology Information (NCBI) MapViewer for
Homo Sapiens, Build 35, version 1 (www.ncbi.nlm.
nih.gov/mapview). They were selected to represent
those regions ﬂanking the CRA, which had been pre-
viously shown to be either gained or lost by aCGH
(Strefford et al., 2006). These probes, including
RUNX1, were denoted A to G (A: RP11-13J15;
B: RP11-30N6; C: RP11-147H1; D: RUNX1;E :
AF121782; F: RP11-88N2; G: Tel21q). Their
genomic positions and chromosomal localization are
provided in Figure 1. Dual probe, dual color experi-
ments were carried out, with the same probe combi-
nations used in all patients. These probes were la-
beled with either Spectrum Green or Spectrum Red
(Abbott Diagnostics), as indicated in Figure 1, and
hybridized according to standard methodologies.
T h ec o p yn u m b e rf o re a c hp r o b ew a sd e t e r m i n e db y
scoring 100 abnormal interphase cells. The clustering
of signals in interphase resulted in their close apposi-
tion, often making accurate enumeration difﬁcult. If
a variation in copy number was observed between
cells of the same patient, it was recorded as a range.
Our previous study (Harewoodetal.,2003) identiﬁed
that the additional signals were usually present on
the dup(21q), thus it was assumed that ﬁve or more
clustered signals (gain of three or more) seen in inter-
phase represented ampliﬁcation on dup(21q), while
three or four signals (gain of one or two) represented
a gain or a high level gain, respectively. The close
association of the signals in interphase differentiated
this abnormality from gain of signals resulting from
multiple copies of chromosome 21 as seen, for exam-
ple, in high hyperdiploidy. The presence of a single
signal indicated a deletion.
In samples with available metaphases, the num-
bers and positions of signals from each probe were
mapped to dup(21q) in relation to each other. A
peptide nucleic acid (PNA) probe, which hybrid-
izes to the telomeric TTAGGG repeats (Telomere
PNA FISH Kit/CY3, Dako Cytomation, Den-
mark), was used to demonstrate the presence of a
telomere on dup(21q). Although it did not identify
the chromosomal origin of the telomeric sequen-
ces, it hybridized distal to Tel21q. Whole chromo-
some paint (wcp) 21 (QBiogene) was applied
sequentially to metaphases hybridized with the
latter two probes to conﬁrm their location to
dup(21q). These sequential studies were carried
out on ﬁve patients (3131, 3956, 4623, 6937, and
6788). The same ﬁve patients were studied further
with a chromosome 21 mBAND paint (Xcyte 21,
MetaSystems, Germany) using different classiﬁers,
as previously described (Chudoba et al., 2004).
RESULTS
Conventional Cytogenetics
Karyotypes of the 37 patients with a successful
cytogenetic result are provided in Table 1. In six
patients, dup(21q) was the sole chromosomal
change. The chromosome number ranged from 45
to 47, with subpopulations of two patients having 48
and 51 chromosomes. Conventional and molecular
cytogenetic analysis showed no established chromo-
somal abnormalities, previously deﬁned as charac-
teristic of certain diagnostic/prognostic subgroups.
Apart from the gain of an X chromosome in seven
patients, the other associated abnormalities were
nonrecurrent. The dup(21q) were classiﬁed accord-
ing to their morphology, as previously described
(Harewood et al., 2003): large metacentric (LM),
large acrocentric (LA), ring (R), small acrocentric
(SA), submetacentric (SM), and normal (N) chromo-
Figure 1. Metaphase FISH, G- and mBAND of ﬁve cases of iAMP21.
The chromosomal band locations and genomic positions of the seven
locus-speciﬁc probes, A–G, are shown in the chromosome 21 idiogram.
The red and green boxes indicate the labeling of the probes with Spec-
trum Red and Spectrum Green, repectively. Metaphase FISH results of
the seven probes, mBAND and G-banding of dup(21q) (columns) from
ﬁve patients (3131, 6788, 4623, 6937, and 3956) (rows). In patient
6937, the mBAND classiﬁer assigned the centromeric region brown
and the telomeric region green; the opposite of the other four patients.
The variable number, size, and intensity of signals are shown. The rela-
tive positions of the signals can be deduced by comparison between col-
umns and the differences between patients by comparison of rows.
[Color ﬁgure can be viewed in the online issue, which is available at
www.interscience.wiley.com.]
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Case 5898, which showed variation from cell to cell,
the morphology of the dup(21q) was consistent in
all metaphases from the same patient.
Interphase FISH
Interphase FISH results from the 46 iAMP21
patients are shown in Table 2. Results from two or
more probes were available for all patients. The
number of signals for each probe varied between
patients. In all cases the amplicon included the
RUNX1 gene (probe D), for which the copy num-
ber ranged from 4 to 14 signals. The extent of the
ampliﬁed region was variable, resulting in a unique
pattern of imbalance for each patient. On the basis
of our aCGH study (Strefford et al., 2006), if ampli-
ﬁcation of two consecutively positioned probes was
observed, it was assumed that the area between
them was also ampliﬁed. In the majority of
patients, the amplicon extended proximally and
distally, to include probes C and E, spanning a
region of 10 Mb. In one patient (6788), the entire
length of 21q, including probes A to G, was ampli-
ﬁed, while in ﬁve patients (3131, 7255, 5607, 5655,
TABLE 1. Karyotypes of 35 iAMP21 Patients
Patient no.
Morphology
of dup(21q) Karyotype
3,131
a LM 46,XY,t(1;16)(q23;p13),ider(21)(q10)dup(21)(q?)[3]/51,idem,+X,+3,+10,+14,+21 [3]
5,754
a LM 46,XY,ider(21)(q10)dup(21)(q?)[6]
5,898
b,c LM 47,XY,+X,del(16)(q13),i(17)(q10),ider(21)(q10)dup(21)(q?)[3]/47,idem,add(7)(p1?)[3]
6,020
c LM 46,XY,del(7)(q22q36),ider(21)(q10)dup(21)(q?)[cp3]
6,788
c LM 46,XY,add(13)(q?),ider(21)(q10)dup(21)(q?)[2]/48,idem,+8,+14[5]
6,957
c LM 46,XX,ider(21)(q10)dup(21)(q?)[13]
7,045 LM 47,XX,+X,del(9)(p?),10,del(11)(q13),ider(21)(q10)dup(21)(q?),+mar[cp11]
7,829 LM 48,XY,+X,inv(1)(p13q?32),ider(21)(q10)dup(21)(q?),+mar[11]
3,956
a LA 45,XY,dic(8;16)(p1?;p1?),del(13)(q1?4),dup(21)(q?)[6]/46,idem,der(Y)t(Y;13)(q1?;q1?4),
+dic(8;16)(p1?;p1?),del(13)(q1?4)[2]
4,134
a LA 46,XY,dup(21)(q?)[13]
4,178
a LA 46,XX,del(7)(q22),t(14;22)(q32;q11),dup(21)(q?)[10]
4,623
a LA 46,XX,dup(21)(q?)[11]
6,008 LA 46,XY,t(2;8)(p12;q24),del(9)(p2?1),del(13)(q1?),dup(21)(q?)[9]
6,937 LA 46,XX,dup(21)(q?)[10]
7,219
c LA 46,XY,dup(21)(q?),inc[3]
7,255
c LA 45,XX,21,+mar1,inc[2]
8,743 LA 46,XX,t(7;9;17)(q22;p1?;p1?),del(11)(q23q2?5),dup(21)(?)[7]
2,776
a R 47,XX,+X,der(21)r(21)(q?)dup(21)(q?)[3]
3,743
a R 45,XX,add(8)(p?),11,der(15)t(11;15)(?;q24),der(21)r(21)(q?)dup(21)(q?)[2]
3,970
a R 47,XX,add(7)(q2),+10,der(21)r(21)(q?)dup(21)(q?)[7]/47,idem,del(12)(p13)[4]
4,405
a R 45,Y,t(X;15)(q2?1;q2?4),dic(12;17)(p1?;p1?),der(21)r(21)(q?)dup(21)(q?)[4]
4,444
a R 46,XY,der(21)r(21)(q?)dup(21)(q?)[3]
5,607
a R 46,XY,t(8;11)(p1?;q21),del(11)(q2?1),der(21)r(21)(q?)dup(21)(q?)[8]
5,674
b R 47,XY,+X,dup(21)(q?)[7]
5,809 R 45,XY,add(1)(p36),2,add(4)(q35),7,del(12)(p12),del(16)(q2?),
19,der(21)r(21)(q?)dup(21)(q?),+4mar,inc[cp6]
7,583 R 47,XY,+X,der(21)r(21)(q?)dup(21)(q?)[4]
7,650 R 47,XY,+9,der(21)r(21)(q?)dup(21)(q?)
3,527
a SA 45,XX,7,del(12)(p12),dup(21)(q?)[5]
4,780
b SA 45,XY,11,del(12)(p1?2),der(20)t(11;20)(q?;q?),dup(21)(q?)[21]
7,45
a SM 46,XY,dup(21)(q?)[4]/46,idem,del(5)(q?),der(15)t(5;15)(q?;q?)[3]
4,135
a SM 46,XX,t(12;16)(q24;p11),del(15)(q24q26),t(17;20)(p1?3;q11),dup(21)(q?)[6]
4,237
a SM 46,XX,dup(21)(q?)[3]/46,idem,del(16)(q1?)[7]
4,279
a,c SM 46–47,XY,dup(21)(q?),inc[12]
5,655
b SM 46,XX,del(1)(q4?),del(6)(q1?5),del(7)(q2?2q3?1),dup(21)(q?)[3]/46,idem,add(6)(q2?)[12]
6,868 SM 47,XY,+X,5,9,add(20)(q),+21,dup(21)(q?),+mar,inc[7]
4,316 N 46,XX[24]
7,828 N 46,XY[20]
LM, large metacentric; LA, large acrocentric; R, ring; SA, small acrocentric; SM, sub-metacentric; N, normal. The normal population has been omitted
from the abnormal karyotypes.
aPreviously reported in Harewood et al. (2003).
bPreviously reported in Robinson et al. (2003).
cPreviously reported in Strefford et al. (2006).
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Results for each patient are given in rows. The chromosomal morphology of the dup(21q) is indicated in column 2: LM, large metacentric; LA,
large acrocentric; R, ring; SA, small acrocentric; SM, small metacentric; N, normal; F, failed cytogenetics. The results are grouped according to the
morphology of the dup(21 q). The boxes relate to the results from individual probe hybridizations for each patient (columns A–G). The number
inside the boxes indicates the copy number for each probe; FAIL, FISH failed to produce a result. [Color table can be viewed in the online issue,
which is available at www.interscience.wiley.com.]
Genes, Chromosomes & Cancer DOI 10.1002/gcc
322 ROBINSON ET AL.and 6092), the level of ampliﬁcation was variable
within the amplicon. In two patients (6996 and
5858), interphase FISH showed two clusters of sig-
nals, with a single signal apart, indicating that, in
addition to the normal chromosome 21, two copies
of dup(21q) were present. Unfortunately, no meta-
phases were available to conﬁrm these ﬁndings.
Deletions of probe G, covering the subtelomeric
region, were observed in 34/44 (77%) patients. In
20 (59%) of them, the deletion extended proxi-
mally to include probe F, deﬁning a deleted region
of up to 3.5 Mb. Probe G was gained in six
patients (3131, 6788, 3743, 4316, 5858, and 5809)
and showed a normal copy number in ﬁve (7255,
3527, 4780, 6092, and 7100). In three patients
(5674, 5655, and 7024), deletions were observed at
sites proximal to RUNX1.
Comparison of dup(21q) and Amplicon Size
Comparison of the dup(21q) morphology with
the FISH data (Table 2) provided the opportunity
to determine the relationship between the level
and extent of ampliﬁcation and the size and form
of the abnormal chromosome. The two patients
(3527 and 4780) with the smallest dup(21q) chro-
mosomes were the only ones to have SA morphol-
ogy. They had the smallest ampliﬁed regions, cov-
ering probes C and D only, with the lowest level of
gain indicated by three additional signals. They
showed no deletion of the subtelomeric region by
FISH. In the remaining 33 cases, dup(21q) was
larger, which corresponded to an increased ampli-
con size by FISH. However, the different patterns
of imbalance did not correlate with a particular
morphological type. In view of the level and extent
of the ampliﬁed regions in the two cases with nor-
mal chromosomes 21 and the lack of abnormal
metaphases seen by FISH, it is likely that the
abnormal population was nondividing.
Metaphase FISH Analysis
In ﬁve cases (3131, 6788, 4623, 6937, and 3956),
metaphase FISH was successful with the seven
locus-speciﬁc probes. The signals were located to
the normal and dup(21q) chromosome, as shown in
Figure 1. There was a high level of heterogeneity
in number, size, and intensity of signals between
probes on the dup(21q) chromosomes, with consid-
erable variation between patients. Signals fre-
quently appeared larger and brighter, suggesting
ampliﬁcation of the regions spanned by the probes.
Most signiﬁcantly, signals were often in unex-
pected locations in relation to each other, indicat-
ing that a series of complex intrachromosomal rear-
rangements had occurred. For example, patient
3131 showed four signals for probe A and two for
probe B. The orientation of these probes relative
to each other provided evidence of an inversion in
each arm. The multiple signals of probes C, D, and
E were distributed in a ladder-like fashion along
dup(21q), consistent with a high level of chromo-
somal breakage within these regions. The subtelo-
meric signals (probe G) were located to the center
of each chromosome arm. As the signals for probe
F appeared to be located distal to the subtelomeric
ones, this provided additional evidence of an inver-
sion. In Case 6788, the signals were distributed
unevenly between the two arms. Patients 4623 and
6937 showed loss of signals for probes F and G,
while 3956 showed loss of the probe G signal only,
indicating variability in the extent of the subtelo-
meric deletion. Signals from the probe localized to
the highly ampliﬁed region (D) were distributed
along the length of the dup(21q), indicating multi-
ple breaks and inversions. The mBAND and G-
Figure 2. High resolution mBAND image of a normal chromosome
21 (a) compared to the dup(21q) from patient 6937 (b). The duplicated
and inverted regions are clearly shown. [Color ﬁgure can be viewed in
the online issue, which is available at www.interscience.wiley.com.]
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rearrangements giving rise to dup(21q), as well as
the variability between patients, even when classi-
ﬁed into the same morphological group (LM,
patients 3131 and 6788; LA, patients 4623, 6937,
and 3956). Figure 2 shows a higher resolution
mBAND image from patient 6937, which indicates
the duplicated and inverted segments in compari-
son to the normal chromosome 21. Although the or-
igin of the telomere was unknown, pantelomeric
probes indicated the presence of telomeric sequen-
ces on the dup(21q) chromosomes of three patients
with loss of their subtelomeres (3956, 4623, and
6937).
DISCUSSION
This study reports detailed analysis of a large
group of ALL patients with iAMP21 by FISH and
conventional cytogenetics, from which a clearer
understanding of the mechanisms giving rise to the
dup(21q) have emerged. This approach provided
conclusive evidence that the abnormality is highly
complex, with each patient having a unique
dup(21q) genomic proﬁle. This was further sup-
ported by the range of morphological forms
observed at the chromosomal level. It demon-
strated that the amplicon was usually large, with
considerable variability in the level of ampliﬁca-
tion, both within the amplicon and between
patients. FISH conﬁrmed that the highly ampliﬁed
region of 21q always included the RUNX1 gene,
which corresponded to the CRA indicated in our
previous study. In 77% of patients, an accompany-
ing deletion of variable size around the subtelo-
meric region was present, corresponding to the pre-
viously identiﬁed CRD (Strefford et al., 2006).
The distribution of signals from the individual
locus-speciﬁc probes observed in metaphase indi-
cated that the dup(21q) was formed as a result of
multiple breaks and reunions, leading to complex
intrachromosomal rearrangements, including dele-
tions, duplications, inversions, and ampliﬁcations.
The complexity of the rearrangements was high-
lighted by the variable mBAND and G-banding
patterns. There was some evidence from inter-
phase FISH that the dup(21q) chromosome may
be duplicated in some patients, but it was not pos-
sible to conﬁrm this in metaphase.
From solid tumor studies, there is increasing evi-
dence that gene ampliﬁcation may arise from a
breakage–fusion–bridge (BFB) cycle. This mecha-
nism, ﬁrst described by McClintock (1941), pro-
posed that, following an initiating event, a double-
stranded DNA break (DSB) occurs (Fig. 3a),
resulting in the formation of a chromosome with
two broken sister chromatids (Fig. 3b). Subsequent
to replication, the chromatids fuse to form a dicen-
tric chromosome (Fig. 3c). Mitotic segregation of
the centromeres to opposite poles at anaphase
results in breakage at a site close to the original
one, leading to generation of a chromosome with
an inverted repeat (Fig. 3c). Following multiple
cycles of BFB it is possible to produce a chromo-
some with accumulated additional copies of intra-
chromosomal regions organized as inverted repeats
(palindromic ampliﬁcation) (Fig. 3d). It is likely
that the dup(21q), with the characteristic ladder-
like distribution of RUNX1 signals, has arisen
through a BFB mechanism. As the size of the CRA
is relatively large, it is probable that other regions
are coampliﬁed along with RUNX1, supported by
the spatial distribution of signals.
Loss of a telomere has been proposed as an ini-
tiating event of the BFB cycle (Gisselsson et al.,
2001; Lo et al., 2002; Murnane and Sabatier, 2004;
Sabatier et al., 2005). In this study, we have shown
deletion of the subtelomeric region in the majority
of cases, indicative of telomeric disruption. These
deletions were always located adjacent to the
amplicon. This observation is consistent with the
loss of chromosomal material from the region close
to the point of chromosomal breakage, followed by
ampliﬁcation of sequences centromeric to the
breakpoint. In those cases with no subtelomeric
loss, it is possible that a deletion may have
occurred within the region distal to that covered by
the subtelomeric probe. In one patient (6788),
Figure 3. Diagrammatic representation of BFB cycle. (a) DSB
occurs, leading to loss of the telomere; (b) Two broken sister chroma-
tids form a dicentric chromosome; (c) Breakage leads to a chromosome
with an inverted repeat; (d) Multiple BFB cycles produce a series of
inverted repeats.
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observed, consistent with breakage in the adjacent
distally located region, in a manner similar to that
reported for mouse embryonic stem cells (Lo et al.,
2002). Further support comes from the dup(21q) of
patient (3131), in whom the subtelomeric signal
was found in an unexpected location, indicating
that a break must have occurred within a region
distal to this probe. In ﬁve patients with no subte-
lomeric deletion and three with gain of probe G, it
was not possible to conﬁrm the location of these
signals in metaphase. Thus, it cannot be ruled out
that an additional copy(ies) of a chromosome 21
intact telomeric region was present, as observed in
two patients (3131 and 3745) with subpopulations
including an extra copy of chromosome 21 seen by
conventional cytogenetics.
Although loss or dysfunction of the telomeric
region may prove to be the initiating event, the
complexity of the dup(21q) indicated that break-
age must also have occurred in other regions of the
chromosome. Previous studies have indicated that
ampliﬁcation of genes may result from breakage
within locations in close proximity to fragile sites
(Ciullo et al., 2002). Although there are no reports
of fragile sites located to chromosome 21, Hattori
et al. (2000) reported duplicated sequences on
chromosome 21, which may be susceptible to DSB
(Kolomietz et al., 2002).
T h eB F Bc y c l eu s u a l l ye n d sw h e nt h eu n s t a b l e
chromosome acquires a new telomere. Acquisition
of a new telomere may result from a number of
mechanisms including: nonreciprocal translocations,
breakage induced replication, direct addition by
telomerase, the formation of a dicentric or ring chro-
mosome (Murnane and Sabatier, 2004). Thus, the
loss of one telomere may directly affect the stability
of the whole genome (Hattori et al., 2000; Ciullo
et al., 2002; Gisselsson, 2005; Sabatier et al., 2005). It
is likely that the more efﬁcient the cell is at telomere
acquisition the less complex the karyotype and the
lower the level of ampliﬁcation. It was of note that
the level of ampliﬁcation in the iAMP21 patients
was relatively low (5–14 copies), raising the possibil-
ity that stabilization of this abnormality occurs early,
thus inhibiting high level ampliﬁcation.
Firm evidence to support this hypothesis of a
B F Bc y c l eg i v i n gr i s et oi A M P 2 1w o u l db ec o n v i n c -
ingly supported by the observation of anaphase
bridges in bone marrow smears or biopsies. Although
no such material was available for these patients, it
is unlikely that bridges would have been seen
because, apart from a single case, all dup(21q) chro-
mosomes were identical between cells of the same
patient. This implicates that the cycle may have ter-
minated and the chromosome become stable by the
time the diagnostic sample had been taken.
In this study, we have used a FISH approach in
an attempt to deﬁne further the mechanism giving
rise to iAMP21. A high level of chromosomal insta-
bility and subsequent karyotype complexity of the
dup(21q) chromosome has indicated that it has
arisen from a BFB cycle. The initiating event giv-
ing rise to this mechanism remains, as yet, unre-
solved. This study has conﬁrmed that RUNX1 is
always located within the amplicon. Therefore,
FISH with probes directed to the RUNX1 gene
remains the most reliable detection method for
this high-risk abnormality: iAMP21.
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